deoxycytidine has been researched along with Colorectal Neoplasms in 847 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (1.77) | 18.2507 |
| 2000's | 400 (47.23) | 29.6817 |
| 2010's | 420 (49.59) | 24.3611 |
| 2020's | 12 (1.42) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, L; Li, H; Li, S; Tong, R; Yu, D; Zhang, Q | 1 |
| Doki, Y; Eguchi, H; Hasegawa, J; Ikenaga, M; Imasato, M; Kagawa, Y; Kato, A; Kato, T; Kudo, T; Miyoshi, N; Mizushima, T; Mori, M; Murata, K; Nakata, K; Ohtsuru, T; Sakai, D; Satoh, T; Takahashi, H; Tei, M; Uemura, M; Yamamoto, H | 1 |
| Gong, P; Sun, L; Zhang, L; Zhang, X; Zhao, Y | 1 |
| Begg, W; Kibudde, S | 1 |
| Banciu, M; Berindan-Neagoe, I; Jurj, A; Rus, L; Sesarman, A; Stiufiuc, R; Tefas, LR; Toma, I; Tomuta, I | 1 |
| Berres, ML; Gonzalez-Carmona, M; Kehmann, L; Keitel, V; Luedde, T; Modest, DP; Mohr, R; Roderburg, C; Strassburg, C; Trautwein, C; Venerito, M; Wree, A | 1 |
| Chen, D; Shen, W; Tan, X; Xu, T | 1 |
| Chen, M; Dai, XY; Ding, KF; Fu, DL; He, JJ; Huang, XF; Jiang, K; Kong, XX; Li, GH; Li, J; Li, JS; Li, XL; Lu, M; Song, YM; Sun, LF; Tian, Y; Wang, JW; Xu, D; Xu, JY; Yan, M; Ying, XJ; Yuan, Y; Zhou, JJ | 1 |
| Allen, PJ; Balachandran, VP; Boerner, T; Boucher, TM; Cercek, A; Chapman, WC; Chou, JF; D'Angelica, MI; DeMatteo, RP; Diaz, LA; Do, RKG; Drebin, JA; Fields, RC; Gönen, M; Harding, JJ; Hauser, HF; Hawkins, WG; Jarnagin, WR; Kemeny, NE; Kingham, TP; Lim, KH; Lowery, MA; Majella Doyle, MB; Reidy-Lagunes, D; Saltz, L; Sanchez-Vega, F; Schultz, N; Strasberg, SM; Tan, BR; Vachharajani, N; Varghese, AM | 1 |
| Bi, M; Hong, S; Li, S; Song, Y; Yan, Z | 1 |
| Li, Q; Liao, W; Wang, X; Wu, Q; Zhang, M; Zhang, P | 1 |
| Ali, A; Daily, KC; Dang, LH; George, TJ; Iqbal, A; Ivey, AM; Lee, JH; Ramnaraign, BH; Read, TE; Tan, SA; Terracina, KP; Wang, Y | 1 |
| Akce, M; Alese, O; Bryson, E; Davis, C; Draper, A; El-Rayes, B; Goyal, S; Hall, K; Patel, U; Sakach, E; Shaib, W; Szabo, S; Watson, M; Wu, C | 1 |
| Ahn, JB; Bai, L; Cho, SH; Fang, WJ; Han, SW; Hong, YS; Iwasa, S; Kim, TW; Kotaka, M; Lee, KW; Matsuoka, H; Morita, S; Muro, K; Nakamura, M; Nishina, T; Park, YS; Sakamoto, J; Yamada, Y; Yuan, XL; Yuan, Y; Zhang, DS | 1 |
| Ando, Y; Hayashi, T; Ikeda, Y; Ito, K; Kawada, K; Kumazawa, S; Maeda, K; Matsuoka, H; Murai, S; Ohta, H; Shiouchi, H; Yamada, S; Yasuda, K | 1 |
| Aisu, N; Goto, S; Hamada, Y; Hasegawa, S; Ishii, F; Kamigaki, T; Kato, D; Kodama, S; Kojima, D; Mera, T; Naito, K; Nimura, S; Tanaka, T; Yamauchi, Y; Yasumoto, K; Yoshida, Y | 1 |
| Hama, T; Inoue, A; Kawakami, K; Kobayashi, K; Machida, Y; Suenaga, M; Sugisaki, T; Suzuki, K; Yamaguchi, K; Yamaguchi, T; Yokokawa, T | 1 |
| Chalchal, H; Payette, E; Sarker, S | 1 |
| Baratelli, C; Brizzi, MP; Di Maio, M; Scagliotti, GV; Sonetto, C; Tampellini, M; Zichi, C | 1 |
| Chen, D; Gao, G; Hu, J; Li, L; Liu, B; Qian, X; Shen, L; Yang, M; Zhang, X | 1 |
| Aprile, G; Bergamo, F; Cardellino, GG; Cremolini, C; de Braud, F; Falcone, A; Fassan, M; Fontanini, G; Lonardi, S; Marmorino, F; Mazzaferro, V; Mennitto, A; Milione, M; Morano, F; Morelli, L; Pellegrinelli, A; Pietrantonio, F; Prisciandaro, M; Rossini, D; Schirripa, M; Urbani, L; Zucchelli, G | 1 |
| Albrecht, MH; Gruber-Rouh, T; Hammerstingl, R; Lahrsow, M; Thompson, ZM; Vogl, TJ | 1 |
| Bi, F; Cao, D; Chen, Y; Gou, H; Li, Z; Peng, Y; Yang, Y; Zhang, X | 1 |
| Álvarez-Gallego, R; Cubillo, A; de Vicente, E; Garralda, E; Hidalgo, M; Martin, M; Muñoz, C; Muñoz, M; Perea, S; Pond, G; Quijano, Y; Rodríguez-Pascual, J; Sánchez, G; Toledo, RA; Ugidos, L; Vega, E | 1 |
| Liang, F; Liu, F; Song, W; Wang, L; Wu, Y; Xu, Y | 1 |
| Esna-Ashari, O; Fathi-Azarbayjani, A; Kheradmand, F; Malekinejad, H; Mohammadian, M; Rasmi, Y; Zeynali-Moghaddam, S | 1 |
| Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Freiberg-Richter, J; Giessen-Jung, C; Graeven, U; Heinemann, V; Held, S; Jung, A; Kirchner, T; Modest, DP; Peuser, B; Peveling Genannt Reddemann, C; Schenk, M; Schuch, G; Schwaner, I; Stahler, A; Stintzing, S; Uhlig, J; Vehling-Kaiser, U | 1 |
| Ahn, JB; Han, SW; Kang, WK; Kim, ST; Kim, TW; Kim, Y; Lee, J; Lim, HY; Park, JO; Park, YS | 1 |
| Akagi, J; Baba, H | 1 |
| Junghanss, C; Maletzki, C; Nassar, I; Stenzel, J; Wiegele, L | 1 |
| Chen, K; Duan, W; Ge, XX; Gong, FR; Shou, LM; Tao, M; Wang, WJ; Wu, J; Wu, MY; Xu, MD; Zhi, Q; Zhu, W | 1 |
| Barrett, AM; Chen, A; Doroshow, JH; Dull, AB; Hollingshead, MG; Kinders, RJ; Kummar, S; Lawrence, SM; Parchment, RE; Wilsker, DF | 1 |
| Birnbaum, A; Cohen, RB; Denlinger, CS; Giles, J; He, AR; Hwang, J; Lewis, N; Moser, B; Mynderse, M; Niland, M; Plimack, ER; Sama, A; Sato, T; Walgren, R; Wallin, J; Zhang, W | 1 |
| Barreda-Hernández, D; Fernández-Carballido, AM; Sánchez-Gundín, J; Torres-Suárez, AI | 1 |
| Fujita, KI; Ishida, H; Ishikawa, F; Kubota, Y; Ohkuma, R; Sasaki, Y; Sekido, M; Shibanuma, M; Takahashi, T; Tsunoda, T | 1 |
| Bae, JM; Bang, D; Cha, Y; Han, H; Han, SW; Jang, H; Jeong, SY; Kang, GH; Kim, H; Kim, HP; Kim, TY; Lee, DW; Lyu, J; Park, KJ; Won, JK | 1 |
| Goto, S; Ibe, H; Kamigaki, T; Makita, K; Matsuda, E; Naitoh, K; Oguma, E; Okada, S; Takimoto, R | 1 |
| Gelderblom, H; Guchelaar, HJ; Punt, CJ; van Huis-Tanja, LH | 1 |
| Adams, LM; Botbyl, J; Brady, J; Chau, I; Corrie, P; Digumarti, R; Laubscher, KH; Mallath, M; Midgley, RS | 1 |
| Bemelmans, MH; Dejong, CH; Dello, SA; Driessen, A; Jansen, RL; Olde Damink, SW; van Bijnen, AA; van den Broek, MA; Vreuls, CP; Winstanley, A | 1 |
| Arnold, D; Dietrich, G; Freier, W; Geißler, M; Graeven, U; Hegewisch-Becker, S; Hinke, A; Kubicka, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schmoll, HJ; Tannapfel, A | 1 |
| Burge, M; Clarke, S; Cordwell, C; Gibbs, P; Reece, W; Tebbutt, N | 1 |
| Andersen, CL; Brünner, N; Christensen, LL; Hansen, F; Hansen, TF; Hansen, TP; Jensen, BV; Jensen, NF; Lindebjerg, J; Pfeiffer, P; Qvortrup, C; Rasmussen, MH; Rømer, MU; Stenvang, J; Tarpgaard, LS; Ørntoft, TF | 1 |
| Koopman, M; Mol, L; Ottevanger, PB; Punt, CJ; van Gils, CW | 1 |
| Bernard, A; Facy, O; Ghiringhelli, F; Ladoire, S; Lokiec, F; Magnin, G; Mordant, P; Pagès, PB | 1 |
| Burton, A; Craven, O; Hughes, CA; Molassiotis, A; Saunders, MP | 1 |
| Boxberger, F; Dörje, F; Harich, HD; Hohenberger, W; Koch, S; Neurath, MF; Siebler, J; Wein, A | 1 |
| Arnheim, K | 1 |
| Cassidy, J; Hochster, H | 1 |
| Bae, KS; Chang, HM; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG; Sym, SJ | 1 |
| Amara, A; Bulusu, A; Honeycutt, W; Hurwitz, HI; Liu, Y; Nixon, AB; Pang, H; Starr, MD; Wong, NS | 1 |
| Jiao, SC; Li, JY; Wen, XY; Wu, LL; Zhang, GQ; Zhao, H | 1 |
| Aksu, G; Bilici, A; Cabuk, D; Gumus, M; Kaya, S; Oven Ustaalioglu, BB; Seker, M; Temiz, S; Uygun, K; Yildiz, R | 1 |
| de Gramont, A; Green, E; Haller, DG; McCleary, NJ; Meyerhardt, JA; O'Connell, M; Saltz, LB; Sargent, DJ; Twelves, CJ; Van Cutsem, E; Yothers, G | 1 |
| Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW | 1 |
| Biasco, G; Brandi, G; de Rosa, F; Derenzini, E; Di Girolamo, S; Ercolani, G; Falcone, A; Grazi, GL; Loupakis, F; Masi, G; Pantaleo, MA; Pietrabissa, A; Pinna, AD | 1 |
| Alvarez Suarez, S; Blanco Codeidido, M; García Alfonso, P; López Martín, P; Martin, M; Mondejar Solis, R; Muñoz Martin, A; Tapia Rico, G | 1 |
| Boers-Sonderen, MJ; Desar, IM; Koopman, M; Punt, CJ; van Herpen, CM | 1 |
| Jensen, SA | 1 |
| Buta, M; de Campos-Lobato, LF; de Sousa, JB; Dietz, DW; Fazio, VW; Kalady, MF; Lavery, IC; Stocchi, L | 1 |
| Hansen, TF; Jakobsen, A; Nielsen, BS; Sørensen, FB | 1 |
| Field, KM; Gibbs, P; McKendrick, JJ; Shapiro, JD; Wong, HL | 1 |
| Boisen, MK; Dehlendorff, C; Hansen, J; Hansen, TF; Holländer, NH; Jensen, BB; Jensen, BV; Johansen, JS; Keldsen, N; Larsen, JS; Nielsen, SE; Pfeiffer, P; Tarpgaard, LS; Østerlind, K | 1 |
| Ahuja, N; Azad, NS; Danilova, L; Delmas, A; Herman, JG; Pelosof, L; Yerram, SR | 1 |
| Andersen, RF; Christensen, Rd; Hansen, TF; Jakobsen, A; Johnsson, A; Sørensen, FB | 1 |
| Hardingham, JE; Lee, CK; Murone, C; Price, TJ; Simes, RJ; Tebbutt, NC; Townsend, AR; Weickhardt, A; Wilson, K; Wrin, JW | 1 |
| Foubert, F; Matysiak-Budnik, T; Touchefeu, Y | 1 |
| Arnold, D; Hacker, UT; Hallek, M; Hinke, A; Hochhaus, A; Hoehler, T; Hofheinz, R; Kanzler, S; Moehler, MH; Schimanski, C; Seufferlein, T; Siebler, J; von Wichert, G | 1 |
| Abad, A; Aranda, E; Benavides, M; Gallen, M; Gómez, A; López, MR; Massutí, B; Rivera, F; Rubio, ED; Sastre, J; Vidaurreta, M | 1 |
| Albain, KS; Blanke, CD; Coleman, D; Ely, B; Gold, PJ; Gotay, C; Lenz, HJ; Louie, SG; Raghavan, D; Shields, AF | 1 |
| Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K | 1 |
| Alonso, MÁ; Jorge, M; Mendez, JC; Montes, AF; Pellón, ML; Quintero, G; Ramos, M; Reboredo, M; Romero, C; Salgado, M; Valladares-Ayerbes, M; Varela, S | 1 |
| Andre, N; Cunningham, D; Jonker, D; Lang, I; Lorusso, V; Marcuello, E; Ocvirk, J; Osborne, S; Saunders, MP; Shin, DB; Waterkamp, D | 1 |
| Alvarez, E; Campos, B; Candamio, S; Casal, J; Gallardo, E; Grande, C; Mel, JR; París Bouzas, L; Quintero, G; Villanueva, MJ | 1 |
| Hutchinson, L | 1 |
| Arnold, D; Behringer, D; Hegewisch-Becker, S; Kettner, E; Kirsch, A; Kretzschmar, A; Pflüger, KH; Stein, A; Wolff, T; Zimber, J | 1 |
| Aprile, G; Bearz, A; Berretta, M; Borsatti, E; Canzonieri, V; Ferrari, L; Fiorica, F; Fisichella, R; Foltran, L; Lestuzzi, C; Lleshi, A; Lutrino, S; Nasti, G; Talamini, R; Tirelli, U; Urbani, M | 1 |
| Ahuja, A; Chan, AT; Chan, C; Chan, SL; Dattatray, RD; Ho, WM; Hui, EP; King, AD; Lau, W; Ma, BB; Mo, F; Poon, A; To, KF; Wong, SC | 1 |
| Baba, H; Chika, N; Fukuchi, M; Hatano, S; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Matsuzawa, T; Mochiki, E; Okada, N; Tajima, Y; Yokoyama, M | 1 |
| Giessen, C; Graeven, U; Hegewisch-Becker, S; Heinemann, V; Laubender, RP; Modest, DP; Porschen, R; Reinacher-Schick, A; Schmiegel, W; Schulz, C; Stintzing, S | 1 |
| Barry, ST; Hoff, PM; Jürgensmeier, JM; Morgan, SR; Pommier, AJ; Robertson, JD; Spencer, SK | 1 |
| Arimoto, A; Iwamoto, S; Kanazawa, A; Kataoka, K; Kato, T; Nakajima, A | 1 |
| Arrowood, C; Blobe, GC; Brady, JC; Cohn, A; Haley, S; Hsu, SD; Hurwitz, HI; McCall, S; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Rushing, C; Starodub, A; Strickler, JH; Uronis, HE; Zafar, SY | 1 |
| Carter, HE; Howard, K; John Simes, R; Price, TJ; Schofield, DJ; Tebbutt, NC; Zalcberg, JR; Zannino, D | 1 |
| Buyukberber, S; Buyukunal, E; Camci, C; Cevik, D; Dane, F; Kilickap, S; Ozdener, F; Sencan, O; Uslu, R; Yalcin, S; Yilmaz, U; Zengin, N | 1 |
| Abad, A; Carmona, FJ; Cassingena, A; Elez, E; Esteller, M; Martínez-Balibrea, E; Martinez-Cardús, A; Moutinho, C; Musulen, E; Navarro-Pérez, V; Salazar, R; Santos, C; Sartore-Bianchi, A; Siena, S; Tabernero, J | 1 |
| Anota, A; Auquier, P; Bascoul-Mollevi, C; Bonnetain, F; Borg, C; Chibaudel, B; Fiteni, F; Hamidou, Z; Paget-Bailly, S; Westeel, V | 1 |
| Ferry, D; Fournier, M; Gebski, V; Gordon, S; Karapetis, CS; Price, TJ; Ransom, D; Simes, RJ; Tebbutt, N; Wilson, K; Yip, D | 1 |
| Endo, A; Nakashima, R; Takahashi, N; Tanabe, K; Yoshida, Y | 1 |
| Bestoso, E; Bianco, MT; Botta, C; Caraglia, M; Ciliberto, D; Conca, R; Correale, P; Cusi, MG; Fioravanti, A; Guglielmo, A; Guidelli, GM; Licchetta, A; Mantovani, G; Martino, E; Mini, E; Misso, G; Pastina, P; Pirtoli, L; Ridolfi, R; Rotundo, MS; Tagliaferri, P; Tassone, P | 1 |
| Cai, S; Li, W; Sun, M; Yu, Q; Zhang, W; Zhang, Z; Zhao, J; Zhu, D | 1 |
| Jiang, W; Li, Y; Liu, J; Ma, D; Yang, D | 1 |
| Borg, C; Cléau, D; Curtit, E; Demarchi, M; Dobi, E; Fratte, S; Guiu, B; Heyd, B; Jary, M; Kim, S; Lakkis, Z; Lamfichekh, N; Monnien, F; Nerich, V; Nguyen, T | 1 |
| Chiu, J; Chu, KW; Epstein, RJ; Leung, R; Poon, J; Tang, V; Wong, H; Yau, T | 1 |
| Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Mihara, K; Mori, T; Nagashima, A; Ohkubo, Y; Yamamuro, W | 1 |
| Akiba, T; Enomoto, H; Kawahara, H; Tomoda, M; Watanabe, K; Yanaga, K | 1 |
| Bhardwaj, TR; Malhotra, M; Rawal, RK; Sharma, AK; Sharma, R | 1 |
| Berthou, J; Bichard, D; Borg, C; Facy, O; Ghiringhelli, F; Heyd, B; Ladoire, S; Lakkis, Z; Limat, S; Lorgis, V; Nerich, V; Orry, D; Ortega-Deballon, P; Rat, P; Vincent, J | 1 |
| Aalbers, A; Boot, H; Hompes, D; Prevoo, W; van Tinteren, H; van Velthuysen, ML; Verwaal, V; Vogel, W | 1 |
| Benzon, EV; Brünner, N; Christensen, IJ; Engelmann, BE; Gerds, TA; Hansson, SH; Holländer, NH; Højgaard, L; Kjær, A; Kristensen, MH; Löfgren, J; Loft, A; Markova, E; Nielsen, HJ; Sloth, C | 1 |
| Guo, Y; Shen, X; Shi, M; Yang, C; Yang, L; Zhang, J | 1 |
| Chan, D; Dichmann, R; Hecht, JR; Hu, EH; Liem, AK; Naeim, A; Patel, R; Tchekmedyian, NS; Wainberg, ZA; Wang, HJ; Ward, PR | 1 |
| Andersen, RF; Jakobsen, A; Pallisgaard, N; Ploen, J; Spindler, KL | 1 |
| Andrade, AC; Barrios, CH; Chinen, RN; Correa, M; Coutinho, AK; del Giglio, A; Dutra, C; Forones, NM; Hoff, PM; Passos, VQ; Portella, Mdo S; Saragiotto, DF; van Eyll, B | 1 |
| Berk, V; Bozkurt, O; Duran, AO; Inanc, M; Karaca, H; Ozaslan, E; Ozkan, M | 1 |
| Cartwright, T; Cassidy, J; Chu, E; Haller, D; Lee, S; McKenna, E; Saif, MW; Schmoll, HJ; Sun, W; Twelves, C | 1 |
| Cavicchiolo, T; Chappell, B; Gill, S; Herbertson, RA; Hopkins, W; Lee, FT; Lee, ST; Murphy, R; O'Keefe, GJ; Poon, A; Saunder, T; Scott, AM; Scott, FE; Tebbutt, NC | 1 |
| Diasio, RB; Lee, AM | 1 |
| Afzal, S; Boige, V; Braun, M; Church, D; Domingo, E; Enghusen, H; Etienne-Grimaldi, MC; Garcia-Foncillas, J; Garmo, H; Glimelius, B; Gonzalez-Neira, A; Green, E; Gusella, M; Jensen, SA; Johnstone, E; Jones, A; Julier, P; Kerr, D; Kleibl, Z; Lacas, B; Laurent-Puig, P; Lecomte, T; Love, S; Martin, M; Martinez-Balibrea, E; McLeod, H; Midgley, R; Milano, G; Morel, A; Nicholson, G; Palles, C; Pignon, JP; Ribelles, N; Rosmarin, D; Sargent, D; Schwab, M; Scudder, C; Seymour, M; Sharma, R; Thompson, L; Tomlinson, I; Wadelius, M; Wang, H; Zanger, UM | 1 |
| Alba, E; Alonso, R; de la Torre-Montero, JC; Dolan, ME; González-Neira, A; Lopez-Fernandez, LA; Martín, M; Pita, G; Wheeler, HE | 1 |
| Aksun, S; Alacacioglu, A; Bayoglu, IV; Coban, E; Demir, L; Dirican, A; Kucukzeybek, Y; Sutcu, R; Tarhan, MO; Varol, U | 1 |
| Jennings, BA; Willis, G | 1 |
| Carracedo, A; Castells, A; Castellvi-Bel, S; Domingo, E; Fernández-Rozadilla, C; Freeman-Mills, L; Gonzalez-Neira, A; Howarth, K; Johnstone, E; Jones, A; Julier, P; Kaur, K; Kerr, D; Kerr, R; Love, S; Martin, M; Pagnamenta, A; Palles, C; Pita, G; Rosmarin, D; Ruiz-Ponte, C; Scudder, C; Taylor, J; Tomlinson, I; Wang, H | 1 |
| Bortlicek, Z; Buchler, T; Dusek, L; Finek, J; Majek, O; Melichar, B; Pavlik, T; Prausova, J; Slavicek, L; Tomasek, J; Vyzula, R | 1 |
| Ahn, JB; Baek, SJ; Baik, SH; Cho, MS; Chung, M; Hur, H; Kim, CW; Kim, MS; Kim, NK; Min, BS; Shin, SJ | 1 |
| Bates, RC; He, S; Proia, DA; Sang, J; Sequeira, M; Smith, DL | 1 |
| Amemori, K; Koike, C; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamada, T; Yamagiwa, K | 1 |
| Bowers, M; Bridgewater, J; Butler, R; Cunningham, D; Dixon, E; Falk, S; Finch-Jones, M; Garden, OJ; Hickish, T; Hornbuckle, J; Iveson, T; Little, L; Maughan, T; O'Reilly, D; Peterson, M; Primrose, J; Pugh, S; Rees, M; Siriwardena, A; Stanton, L; Valle, J | 1 |
| Abal, M; Barbazán, J; Candamio, S; Cano, A; Casares de Cal, Mde L; Díaz-López, A; Gómez-Tato, A; López-López, R; Muinelo-Romay, L; Vieito, M | 1 |
| Boukovinas, I; Christophylakis, C; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Karampeazis, A; Matikas, A; Polyzos, A; Souglakos, J; Vamvakas, L | 1 |
| Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A | 1 |
| Chu, E; Lee, JJ | 2 |
| Brooks, C; Gibson, O; Grainger, L; Larsen, M; Love, SB; Shanyinde, M; Shearwood, V; Tarassenko, L; Waters, R; Weaver, A; Young, AM | 1 |
| Han, GH; Huang, JX | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Daher Abdi, Z; Lavau-Denes, S; Leobon, S; Marquet, P; Martin, J; Prémaud, A; Rousseau, A; Sauvage, FL; Tubiana-Mathieu, N; Urien, S | 1 |
| Gao, RJ; Li, L; Li, Y; Liu, XJ; Qin, Y; Shao, RG; Zhen, YS | 1 |
| Aisu, N; Hirata, K; Hoshino, S; Mogi, A; Naito, M; Tamura, K; Tanaka, T; Tanimura, S; Yamashita, Y; Yoshida, Y | 1 |
| Alacacioglu, A; Barutca, S; Degirmenci, M; Dirican, A; Karabulut, B; Oktay, E; Uslu, R; Varol, U; Yildiz, I | 1 |
| Alonso, V; Alonso-Espinaco, V; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Gallego, R; Garcia-Albeniz, X; Horndler, C; Jares, P; Lozano, JJ; Marmol, M; Maurel, J; Ortego, J; Rosell, R | 1 |
| Marshall, JL | 2 |
| Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ | 1 |
| Abrahamova, J; Benesova, V; Bortlicek, Z; Buchler, T; Dusek, L; Kiss, I; Kohoutek, M; Melichar, B; Obermannova, R; Pavlik, T; Usiakova, Z; Vyzula, R | 1 |
| Aparicio, J; Bohn, U; Bosch, C; Carmona, A; Casado, E; Escudero, P; Feliu, J; García-Girón, C; Jorge, M; Martínez-Marín, V; Maurel, J; Pérez-Carrión, R; Safont, MJ; Salud, A; Serra, O; Vera, R | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY | 1 |
| Czejka, M; Dittrich, C; Gintersdorfer, S; Kitzmueller, M; Lichtneckert, M; Neudorfer, C; Poxhofer, M; Schreiber, V | 1 |
| Buchner, P; Czejka, M; Farkouh, A; Georgopoulos, A; Gruenberger, B; Scheithauer, W; Schueller, J | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, IV; Can, A; Coban, E; Demir, L; Dirican, A; Erten, C; Koyuncu, B; Kucukzeybek, Y; Somali, I; Tarhan, MO; Varol, U; Yildiz, Y | 1 |
| Chan, D; Dichmann, R; Hecht, JR; Hu, EH; Liem, AK; Naeim, A; Patel, R; Tchekmedyian, NS; Wainberg, ZA; Wang, HJ; Ward, P | 1 |
| Andreoli, SC; de Andrade, RV; de Carvalho, GP; Garicochea, B; Gasparini, NJ; Pogue, RE | 1 |
| Altaf, R; Kristensen, B; Lund Brixen, A; Nielsen, SE | 1 |
| Basdanis, G; Dermitzakis, EV; Eleftheraki, A; Fountzilas, G; Georgiadis, G; Kimiskidis, VK; Konstantis, A; Lazaridis, G; Tsiptsios, I | 1 |
| Blackmon, SH; Correa, AM; Eng, C; Kee, B; Subbiah, IM; Swisher, SG; Vaporciyan, AA | 1 |
| Carter, GC; Johnson, BH; Landsman-Blumberg, PB; Li, L; Nicol, SJ; Sedgley, R; Shankaran, V | 1 |
| Cao, J; Huang, XE; Qian, ZY; Shi, L; Wu, XY; Xu, X | 1 |
| Chen, HC; Chen, HH; Chen, WT; Chou, YH; Fang, CY; Hsu, HH; Huang, CC; Lee, HC; Lin, BW; Lin, JK; Lin, PC; Tan, EC; Ting, WC; Yang, MC; Yeh, CH | 1 |
| Gu, Y; Guo, R; He, X; Liu, L; Liu, P; Lu, K; Shu, Y; Yin, Y; Zhang, J; Zhang, Q; Zhu, L | 1 |
| Hirai, K; Igarashi, T; Miyamae, Y; Ogawa, H; Sunose, Y; Takahashi, K; Takahashi, N; Takeyoshi, I; Tanaka, K; Tsukagoshi, H; Yoshinari, D | 1 |
| Danno, K; Fujitani, K; Fukui, A; Iwase, K; Kawada, J; Kubota, M; Matsuda, C; Miyazaki, S; Takagi, M; Tanaka, Y | 1 |
| Ali, R; Chan, ML; Chia, WK; Deng, YH; Ho, GF; Jian, X; Mehta, S; Segelov, E; Sharma, A; Soon, SS; Tan, CS; Toh, HC; Wee, HL | 1 |
| Adams, J; Deva, S; Findlay, MP; Hinder, VA; Isaacs, R; Jackson, CG; O'Donnell, A; Perez, DJ; Robinson, BA; Sharples, K; Thompson, PI | 1 |
| Goto, A; Hamamoto, Y; Morita, S; Nakajima, T; Nakayama, N; Nishina, T; Sakamoto, J; Shimada, K; Ura, T; Yamada, Y; Yamaguchi, T; Yamazaki, K | 1 |
| Boisen, MK; Dehlendorff, C; Hansen, TF; Holländer, NH; Høgdall, EV; Jensen, BB; Jensen, BV; Johansen, JS; Keldsen, N; Larsen, JS; Linnemann, D; Nielsen, BS; Nielsen, SE; Osterlind, K; Pfeiffer, P; Qvortrup, C; Tarpgaard, LS | 1 |
| Goldberg, RM; Nordlinger, B; Poston, GJ | 1 |
| Aisu, N; Hirata, K; Hoshino, S; Kojima, D; Mogi, A; Tanimura, S; Yamada, T; Yamashita, Y; Yoshida, Y | 1 |
| Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ | 1 |
| Brunner, S; Camenisch Gross, U; Cathomas, R; Freyholdt, T; Mey, U; von Moos, R | 1 |
| Amaraneni, A; Chandana, SR; Itawi, EA; Seth, A | 1 |
| Bensch, F; Reyners, AK; Schröder, CP; van Rooijen, JM | 1 |
| Akinwande, O; Hayes, D; Martin, RC; Miller, A; O'Hara, R; Tomalty, D | 1 |
| Chen, Z; Guo, W; Li, J; Li, W; Liu, T; Shen, L; Xu, J; Zhang, W; Zhu, X | 1 |
| Cao, J; Ding, HH; Ji, ZY; Jiang, T; Jin, JH; Song, WF; Wang, JJ; Wang, LW; Wu, WD | 1 |
| Babacan, NA; Doğan, M; Kaçan, T; Kiliçkap, S; Koç, S; Seker, MM; Uysal, IO; Yüce, S | 1 |
| Furuhata, T; Hayashi, T; Hirakawa, M; Hirata, K; Iyama, S; Kato, J; Kawano, Y; Kobune, M; Miyanishi, K; Mizuguchi, T; Murase, K; Ohnuma, H; Okagawa, Y; Okita, K; Osuga, T; Sato, T; Sato, Y; Takada, K; Takahashi, M; Takimoto, R | 1 |
| Alberti, P; Argyriou, AA; Bergamo, F; Briani, C; Bruna, J; Cacciavillani, M; Campagnolo, M; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Frigeni, B; Izquierdo, C; Kalofonos, HP; Velasco, R | 1 |
| Carlsen, AL; Hansen, TF; Heegaard, NH; Jakobsen, A; Sørensen, FB | 1 |
| Aparicio, J; Bohn, U; Bosch, C; Carmona, A; Casado, E; Custodio, AB; Escudero, P; Feliu, J; García-Girón, C; Jorge, M; Losa, F; Maurel, J; Pérez-Carrión, R; Safont, MJ; Salud, A | 1 |
| Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY | 1 |
| Aitini, E; Bajetta, E; Barni, S; Bertolini, A; Ciarlo, A; Di Bartolomeo, M; Dotti, KF; Iacovelli, R; Maggi, C; Perrone, F; Pietrantonio, F; Verusio, C | 1 |
| Anderson, EM; Chang, DT; Jayachandran, P; Koong, AC; Kozak, MM; Limaye, M; Longacre, T; Pai, J; Pai, RK; Shaffer, JL; von Eyben, R; Vossler, SR | 1 |
| Bruhn, MA; Cunningham, D; Gebski, V; Hardingham, JE; Lee, CK; Mann, KP; Price, TJ; Robinson, B; Simes, J; Tebbutt, NC; Townsend, AR; Van Hazel, G; Weickhardt, A; Wilson, K; Wrin, JW | 1 |
| Higashino, K; Noura, S; Ohue, M; Sakai, D; Shingai, T; Sugimoto, N; Takeuchi, Y; Yagi, T; Yamamoto, S; Yano, M; Yoshinami, T | 1 |
| Barni, S; Cabiddu, M; Coinu, A; Ghilardi, M; Petrelli, F; Zaniboni, A | 1 |
| Braun, HJ; Cats, A; Creemers, GJ; de Jongh, FE; Derleyn, VA; Erdkamp, FL; Erjavec, Z; Haasjes, JG; Honkoop, AH; Jansen, RL; Koopman, M; Loosveld, OJ; May, A; Mol, L; Nieboer, P; Punt, CJ; Simkens, LH; ten Tije, AJ; Tol, J; van der Hoeven, JJ; van der Torren, AM; van Tinteren, H; Wals, J | 1 |
| Bencsikova, B; Bortlicek, Z; Dusek, L; Halamkova, J; Kiss, I; Melichar, B; Ostrizkova, L; Pavlik, T; Valik, D; Vyzula, R; Zdrazilova-Dubska, L | 1 |
| Andreĭtseva, OI; Gritsiuta, AI; Kalinin, DV; Kharazov, AF; Vishnevskiĭ, AV; Zhavoronkova, OI | 1 |
| Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ide, Y; Kudo, T; Miyake, Y; Mizushima, T; Mori, M; Morita, S; Nakata, K; Nezu, R; Nishimura, J; Ohno, Y; Sakai, D; Satoh, T; Sekimoto, M; Takemasa, I; Takemoto, H; Uemura, M; Yamamoto, H; Yasui, M | 1 |
| Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC | 1 |
| Ayez, N; Eggermont, AM; Grünhagen, DJ; Rothbarth, J; van der Stok, EP; van Meerten, E; Verhoef, C | 1 |
| Aoyama, T; Kataoka, M; Kono, T; Matsuda, C; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Oshiro, M; Sakamoto, J | 1 |
| Bai, L; Han, C; Jiao, S; Li, J; Su, D; Wang, Y; Zhang, T | 1 |
| Aieta, M; Angelini, V; Antonuzzo, L; Azzarello, D; Bertolini, A; Corsi, DC; Di Costanzo, F; Di Fabio, F; Giommoni, E; Latiano, T; Mogavero, S; Pastina, I; Pastorelli, D; Pavese, I; Pazzagli, M | 1 |
| Asadi, K; Chionh, F; Lee, CK; Mariadason, JM; Murone, C; Nagtegaal, ID; Parry, MM; Price, TJ; Punt, CJ; Scott, AM; Simes, J; Tebbutt, NC; Weickhardt, AJ; Williams, DS; Wilson, K | 1 |
| Endo, I; Ichikawa, Y; Kunisaki, C; Osada, S; Ota, M; Shoichi, F; Suwa, H; Tanaka, K; Tatsumi, K; Watanabe, J; Watanabe, K | 1 |
| Figoni, W; Ikenishi, M; Konishi, Y; Kuroda, A; Matsuda, T; Matsuyama, K; Nakao, M; Nakatsuka, E; Ohtori, T; Satoh, H; Sawada, Y; Takeuchi, M; Tsukazaki, H; Ueda, M | 1 |
| Akagi, Y; Baba, H; Emi, Y; Kimura, M; Kusumoto, T; Maehara, Y; Ogata, Y; Oki, E; Sadanaga, N; Saeki, H; Shimokawa, M; Shirouzu, K; Tanaka, T; Touyama, T | 1 |
| Fukunaga, M; Hasegawa, J; Hazama, S; Kono, E; Kotaka, M; Maeda, H; Mishima, H; Nagata, N; Oba, K; Sakamoto, J; Soda, H; Takahashi, T | 1 |
| Bando, H; Fujii, A; Fukunaga, M; Hata, T; Honda, M; Ishibashi, K; Kobayashi, M; Matsuda, C; Mishima, H; Munemoto, Y; Nagata, N; Oba, K; Oshiro, M; Tanaka, C; Tokunaga, Y | 1 |
| Dai, GH; Mao, H; Shi, Y; Sun, DC; Wang, ZK | 1 |
| Fahimi, A; Payandeh, M; Sadeghi, M; Shahriari-Ahmadi, A | 1 |
| Dasari, A; Donehower, RC; He, P; Hidalgo, M; Jimeno, A; Jin, R; Laheru, D; Messersmith, WA; Purcell, WT; Rudek, MA; Taylor, GE; Walker, R | 1 |
| Cai, G; Cai, S; Hu, J; Xu, Y | 1 |
| Cohen, SA; Fountzilas, G; Gkakou, C; Gourgioti, G; Grady, WM; Kalogeras, KT; Karavasilis, V; Kotoula, V; Papaxoinis, G; Pectasides, D; Pentheroudakis, G; Raptou, G; Wirtz, R; Wu, C; Yu, M | 1 |
| André, T; Bonnet, I; Bouché, O; Boucher, E; Chibaudel, B; Dauba, J; Faroux, R; Garcia, ML; Guering-Meyer, V; Hug de Larauze, M; Lapeyre-Prost, A; Lièvre, A; Malka, D; Obled, S; Taieb, J; Ychou, M | 1 |
| Aftimos, P; Awada, A; Bahleda, R; Bourbouloux, E; Campone, M; Frenel, JS; Gombos, A; Soria, JC; Varga, A | 1 |
| Sugihara, K; Tsuji, Y | 1 |
| Chan, KW; Chen, H; Li, Y; Liu, G; Luo, L; McMahon, MT; van Zijl, PC; Vogelstein, B; Xu, J; Yadav, NN; Zhou, S | 1 |
| Cheng, Y; Guo, Y; Ma, L; Xiong, BH; Zhang, T | 1 |
| Hu, XH; Jia, J; Li, YH; Lin, DR; Lin, YC; Luo, HY; Ma, D; Peng, JW; Wang, FH; Wang, W; Wang, ZQ; Xu, RH; Yuan, X; Zhang, DS | 1 |
| Attene, F; Borrego-Estella, V; Hörndler, C; Moro, SS; Paliogiannis, P; Pulighe, F; Scognamillo, F; Serrablo, A | 1 |
| Chiang, JM; Hsieh, TY; Hsu, CK; Lai, MW; Liang, KH; Lim, SN; Lin, WR; Tsou, YK; Yeh, CT | 1 |
| Cremolini, C; Falcone, A; Masi, G; Moretto, R | 1 |
| Luo, HY; Xu, RH | 1 |
| Ciftci, R; Iner-Koksal, U; Kaytan-Saglam, E; Namal, E; Okyar, A; Ordu, C; Pala-Kara, Z; Pilancı, KN; Saglam, S; Yucel, S | 1 |
| Aisu, N; Daibo, K; Goto, S; Hasegawa, S; Kamigaki, T; Mera, T; Naito, K; Naito, M; Tanaka, T; Yamada, T; Yamashita, Y; Yasumoto, K; Yoshida, Y | 1 |
| Chen, Y; Cui, Y; Liang, L; Liu, T; Wang, Y; Wang, Z; Yu, Y; Zhou, Y; Zhuang, R | 1 |
| Li, C; Liu, F; Wang, Z; Wu, Y; Xu, Y; Yang, L; Zhao, J; Zheng, H | 1 |
| Hazama, S; Iida, M; Inoue, Y; Kanekiyo, S; Nagano, H; Sakamoto, K; Suzuki, N; Takeda, S; Tokuhisa, Y; Tokumitsu, Y; Tomochika, S; Tsunedomi, R; Ueno, T; Yoshino, S | 1 |
| Banaszkiewicz, Z; Gackowski, D; Modrzejewska, M; Olinski, R; Starczak, M; Szpila, A; Zarakowska, E | 1 |
| Cassidy, J | 6 |
| Pantano, F; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B | 1 |
| Amarantidis, K; Ardavanis, A; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Polyzos, A; Souglakos, J; Tsousis, S; Vamvakas, L; Vardakis, N; Varthalitis, I; Ziras, N | 1 |
| Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL | 1 |
| Besnard, T; Etienne-Grimaldi, MC; François, E; Milano, G; Renée, N | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T | 1 |
| Anthoney, DA; Bradley, C; Brown, JM; Brown, S; Crawford, SM; Hennig, IM; Jackson, DP; Melcher, AM; Naik, JD; Seymour, MT; Szubert, A | 1 |
| Bennouna, J; Douillard, JY; Senellart, H | 1 |
| Abubakr, Y; Childs, BH; Cohn, AL; Fehrenbacher, L; Hainsworth, JD; Hart, LL; Hedrick, E; Hochster, HS; Ramanathan, RK; Saif, MW; Schwartzberg, L; Wong, L | 1 |
| Chu, E | 2 |
| Chu, E; Gibson, TB; Grothey, E | 1 |
| Bernhardt, G; Cerwenka, H; Kornprat, P; Mischinger, HJ; Schöllnast, H; Werkgartner, G | 1 |
| Grouls, V | 1 |
| Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S | 1 |
| Abbas, R; Boni, J; Bukowski, R; Croghan, G; Donehower, R; Erlichman, C; Hidalgo, M; Jimeno, A; Laheru, D; Martins, P; Messersmith, W; Pelley, R; Rudek, M; Zacharchuk, C | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Koopman, M; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T | 1 |
| Alabiso, O; Amoroso, D; D'Alonzo, L; Donati, S; Fornasiero, A; Forti, L; Iacono, C; Lalli, A; Lopatriello, S; Lucenti, A; Negrini, C; Smergo, A | 1 |
| Röcken, C | 1 |
| Bodoky, G; Garay, C; Habboubi, N; Haller, DG; Koralewski, PM; Miller, WH; Olivatto, LO; Rothenberg, ML; Wong, AO | 1 |
| Booth, C | 1 |
| Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E | 1 |
| Curzen, NP; Ferchow, L; Hobson, A; Scott, PA | 1 |
| Bisegna, R; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F | 1 |
| Galmarini, CM; Kohli, E; Mitin, A; Vinogradov, SV; Warren, G; Zeman, A | 1 |
| Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P | 1 |
| Boonnuch, W; Chinswangwatanakul, V; Lohsiriwat, D; Mahamadsolaeh, P; Veerasarn, V | 1 |
| Campbell, ML; Landry, CS; Martin, RC; McMasters, KM; Scoggins, CR; Slomiany, BA; Woodall, CE | 1 |
| Arkenau, HT; Arnold, D; Cassidy, J; Diaz-Rubio, E; Douillard, JY; Grothey, A; Hinke, A; Hochster, H; Martoni, A; Porschen, R; Schmiegel, W; Schmoll, HJ | 1 |
| Dobrova, NV; Lichinitser, MR; Semenov, NN; Vakhabova, JV | 1 |
| Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S | 1 |
| Cassidy, J; Dartois, C; Freyer, G; Girard, P; Hénin, E; Hoff, PM; Sirzen, F; Tod, M; Twelves, C; VanCutsem, E; You, B; Zuideveld, KP | 1 |
| Fakih, MG; Khushalani, N; Mashtare, T; Puthillath, A; Romano, K; Ross, ME; Steinbrenner, L; Wilding, G; Wisniewski, M | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T | 1 |
| Balzer, JO; Eichler, K; Gruber, T; Hammerstingl, R; Vogl, TJ; Zangos, S | 1 |
| Danenberg, KD; Danenberg, PV; Grem, JL; Uchida, K | 1 |
| Anderson, H; Berglund, K; Byström, P; Ekelund, M; Fernebro, E; Glimelius, B; Gunnlaugsson, A; Holm, T; Johnsson, A; Kjellén, E; Påhlman, L | 1 |
| Abad, A; Aranda, E; Carrato, A; Chaves, M; Díaz-Rubio, E; García, T; Gómez-España, A; González-Flores, E; Losa, F; Maestu, I; Massutí, B; Queralt, B; Reina, JJ; Rivera, F; Sanchez-Rovira, P; Sastre, J; Tabernero, J | 1 |
| Davies, JM; Goldberg, RM | 1 |
| Dugan, U; Heimbrook, D; Higgins, B; Kohles, J; Kolinsky, K; Packman, K; Shen, BQ; Zhang, YE; Zioncheck, TF | 1 |
| Buffart, TE; Carvalho, B; Eijk, PP; Koopman, M; Meijer, GA; Peters, GJ; Postma, C; Punt, CJ; van Krieken, JH; Ylstra, B | 1 |
| Biasco, G; Brandi, G; Di Cicilia, R; Maleddu, A; Nannini, M; Nobili, E; Pantaleo, MA | 1 |
| Abdelfattah, M; Adami, B; Flieger, D; Galle, PR; Godderz, W; Hoehler, T; Kanzler, S; Majer, K; Moehler, M; Schimanski, CC; Siebler, J; Sprinzl, MF; Teufel, A | 1 |
| Adams, RA; Fisher, D; Kaplan, RS; Kay, E; Kenny, S; Madi, A; Maughan, TS; Meade, AM | 1 |
| Antonini, NF; Hoogerbrugge, N; Koopman, M; Kortman, GA; Ligtenberg, MJ; Mekenkamp, L; Punt, CJ; van Krieken, JH | 1 |
| Hofer, S; Krähenbühl, S; Ludwig, C; Rätz Bravo, AE | 1 |
| Chu, E; Schulman, KL; Song, X; Zelt, S | 1 |
| Antonini, NF; Cats, A; Creemers, GJ; Dalesio, O; Dijkstra, JR; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Richel, DJ; Rodenburg, CJ; Schrama, JG; Sinnige, HA; Tol, J; van Groeningen, CJ; van Krieken, JH; Vink-Börger, ME; Voest, EE; Vos, AH | 1 |
| Mayer, RJ | 3 |
| Dorfmeister, M; Eipeldauer, S; Gruenberger, B; Gruenberger, T; Hacker, S; Herberger, B; Klinger, M; Koelblinger, C; Tamandl, D | 1 |
| Grossbard, M; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Wasserman, C | 1 |
| Fountzilas, G; Fragoulakis, V; Maniadakis, N; Pectasides, D | 1 |
| Bae, SH; Chae, YS; Choi, GS; Jeon, SW; Jun, SH; Kang, BM; Kim, JG; Kum, Y; Lim, KH; Moon, JH; Park, IJ; Ryoo, HM; Sohn, SK | 1 |
| Cao, Y; Gao, F; Liao, C; Liu, L; Mo, Z; Tan, A | 1 |
| Gruenberger, B; Gruenberger, T; Herberger, B; Kaczirek, K; Tamandl, D | 1 |
| Aprile, G; Mazzer, M; Moroso, S; Puglisi, F | 1 |
| Dugan, U; Heimbrook, D; Higgins, B; Kolinsky, K; Packman, K; Zhang, YE | 1 |
| Des Guetz, G; Morere, JF; Nicolas, P; Schischmanoff, O; Uzzan, B | 1 |
| Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X | 1 |
| Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E | 1 |
| Haller, DG; Teitelbaum, UR | 1 |
| Berry, S; Bridgewater, J; Canon, JL; Cunningham, D; DiBartolomeo, M; Georgoulias, V; Kretzschmar, A; Mazier, MA; Michael, M; Peeters, M; Rivera, F; Van Cutsem, E | 1 |
| Amoroso, D; Andreuccetti, M; Antonuzzo, A; Brunetti, IM; Bursi, S; Chiara, S; Cupini, S; Di Donato, S; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Petrini, I; Ricci, S; Vasile, E | 1 |
| Goff, LW; Mernaugh, RL; Pohlmann, PR | 1 |
| Di Maio, M; Falcone, A; Loupakis, F | 1 |
| Copur, MS; Norvell, M; Obermiller, A | 1 |
| Casado-Jiménez, M; Feito-Rodriguez, M; Feltes, RA; Floristan, U; Ramírez-Marín, P; Sendagorta, E; Vidaurrázaga, C | 1 |
| Koopman, M; Ligtenberg, MJ; Nagtegaal, I; Punt, CJ; Van Krieken, JH; van Tinteren, H; Venderbosch, S | 1 |
| Bilek, M; Bouskova, K; Fidlerova, J; Kleibl, Z; Kleiblova, P; Kormunda, S; Novotny, J; Sevcik, J | 1 |
| Gao, P; Ma, B; Tian, JH; Yang, KH; Zhao, G | 1 |
| Fukuda, T; Shiroiwa, T; Tsutani, K | 3 |
| Kocák, I; Kocáková, I; Nemecek, R; Rehák, Z; Standara, M; Svoboda, M | 1 |
| Aebi, S; Amstutz, U; Farese, S; Largiadèr, CR | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Nortier, JW; Punt, CJ | 1 |
| Johnstone, E; Kerr, D; Midgley, R; Swanton, C; Tomlinson, I; Walther, A | 1 |
| Fujimoto-Ouchi, K; Mori, K; Yamashita, Y; Yanagisawa, M; Yorozu, K | 1 |
| Landherr, L; Nagykálnai, T | 2 |
| Saltz, L | 1 |
| Bai, CM; Chen, SC; Cheng, YJ; Jia, N; Shao, YJ; Zhou, JF | 1 |
| Bjerregaard, B; Fokstuen, T; Glimelius, B; Jensen, BV; Keldsen, N; Larsen, FO; Mejer, J; Nielsen, SE; Pfeiffer, P; Qvortrup, C | 1 |
| Aggarwal, BB; Anand, P; Deorukhkar, A; Diagaradjane, P; Gelovani, J; Guha, S; Harikumar, KB; Krishnan, S; Kunnumakkara, AB; Kuzhuvelil, HB | 1 |
| Chen, XQ; He, YJ; Li, YH; Pan, ZZ; Qiu, MZ; Ruan, DY; Teng, KY; Wan, DS; Xu, RH | 1 |
| Koopman, M; Mol, L; Ottevanger, PB; Punt, CJA | 1 |
| Bruno, R; Claret, L; Fagerberg, J; Girard, P; Hoff, PM; Jorga, K; Van Cutsem, E; Zuideveld, KP | 1 |
| Schmidt, C | 1 |
| Hoimes, C; Merl, M; Pham, T; Saif, MW | 1 |
| Bodnar, L; Stec, R; Szczylik, C | 1 |
| Brearley, SG; Craven, O; Molassiotis, A; Saunders, M; Swindell, R | 1 |
| Bordonaro, R; Caputo, G; Cordio, S; Manzione, L; Novello, G; Reggiardo, G; Rosati, G | 1 |
| Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Watanabe, M; Yasuda, N | 1 |
| Bendell, JC; Cartwright, T; Chu, E; Shi, N; Wei, W | 1 |
| Garcia-Alfonso, P; Gonzalez-Flores, E; Mendez-Ureña, M; Muñoz-Martin, A; Perez-Manga, G; Quiben-Pereira, R | 1 |
| Cathomas, R; Köberle, D; Mayer, G; Mey, U; Räss, A; Ruhstaller, T; von Moos, R | 1 |
| Cai, J; Ji, X; Li, Q; Tucker, S; Wan, F; Wang, D; Zhao, R; Zhong, B; Zhu, J | 1 |
| Koopman, M; Punt, CJ | 2 |
| Chen, XQ; He, YJ; Li, YH; Luo, HY; Qiu, MZ; Shi, YX; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH | 1 |
| Rajebi, MR; Saif, MW; Shahrokni, A | 1 |
| Heymanns, J; Kleboth, K; Köppler, H; Thomalla, J; Weide, R | 1 |
| Ahmad, A; Gounaris, I | 1 |
| Andersen, RF; Jakobsen, A; Jensen, LH; Ploen, J; Spindler, KG | 1 |
| Cats, A; Creemers, GJ; Koopman, M; Miller, MC; Nagtegaal, ID; Punt, CJ; Terstappen, LW; Tibbe, A; Tol, J; Vos, AH | 1 |
| Brearley, S; Craven, O; Farrell, C; Luker, K; Molassiotis, A; Saunders, M; Swindell, R; Todd, C; Wardley, A | 1 |
| Adenis, A; Bennouna, J; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Llédo, G; Rebischung, C; Ychou, M | 1 |
| Chang, DK; Cho, YB; Chun, HK; Kang, WK; Kim, DS; Kim, HC; Kim, JY; Kim, ST; Kim, YH; Lee, J; Lee, WY; Lim, HY; Park, JO; Park, SH; Park, YS; Rhee, PL; Yun, H; Yun, SH | 1 |
| Dohn, LH; Jensen, BV; Larsen, FO | 1 |
| Bargagli, G; Bellan, C; Conca, R; Fiaschi, AI; Francini, E; Francini, G; Lazzi, S; Lorenzi, B; Martellucci, I; Pascucci, A; Petrioli, R | 1 |
| Heller, G; Panageas, KS; Schrag, D; Sima, CS | 1 |
| An, X; Feng, F; He, YJ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH; Zhao, Y | 1 |
| Alberts, SR; Bolton, JS; Dentchev, T; Lai, LL; Mahoney, MR; Molina, R; Nagorney, DM; O'Connell, MJ; Roh, MS; Schwarz, RE; Smyrk, TC; Wagman, L; Weiland, TL | 1 |
| Baeksgaard, L; Jensen, SA; Petersen, LN; Reiter, L; Sørensen, JB | 1 |
| Kopper, L; Tímár, J | 1 |
| Ashley, S; Brown, G; Chau, I; Cunningham, D; Gillbanks, A; Karanjia, N; Mudan, SS; Norman, AR; Watkins, DJ | 1 |
| Bae, SH; Chae, YS; Choi, GS; Jun, SH; Kang, BW; Kim, JG; Kim, NS; Moon, JH; Park, JH; Park, JY; Ryoo, HM; Sohn, SK | 1 |
| Sun, W | 1 |
| Andersen, RF; Brandslund, I; Garm Spindler, KL; Hansen, TF; Jakobsen, A; Lindebjerg, J | 1 |
| Adenis, A; Bennouna, J; Boer, K; Douillard, JY; Escudero, P; Kim, TY; Lang, I; Morris, CD; Pover, GM; Valladares-Ayerbes, M | 1 |
| Majumdar, AP; Patel, BB | 1 |
| Dorfmeister, M; Eipeldauer, S; Gruenberger, B; Gruenberger, T; Hacker, S; Herberger, B; Kaczirek, K; Klinger, M; Tamandl, D | 1 |
| Ferrari, G; Gemignani, F; Macaluso, C | 1 |
| Frieling, T; Graeven, U; Hegewisch-Becker, S; Lehnert, L; Reinacher-Schick, A; Schmiegel, W; Trarbach, T; Vanhoefer, U | 1 |
| Bandres, E; Bitarte, N; Chopitea, A; Gacía-Foncillas, J; Patiño-Garcia, A; Ponz-Sarvise, M; Ramirez, N; Rodríguez, J; Viudez, A; Zarate, R | 1 |
| Bontemps, H; Coursier, S; Emptoz, J; Guillermet, A; Martelet, S; Villier, C | 1 |
| Boehm, KA; Cartwright, T; McCollum, D | 1 |
| Best, JH; Garrison, LP | 1 |
| Uña Cidón, E | 1 |
| Fang, F; Li, DC; Lu, GC | 1 |
| Liao, WJ; Luo, RC; Shen, P; Shi, M; Wu, Wy | 1 |
| Bolaños, M; Bosch, C; Castro-Carpeño, J; Escudero, P; Feliu, J; García-Girón, C; Gil, M; González-Barón, M; Llombart, A; López, R; Losa, F; Madroñal, C; Safont, MJ; Salud, A | 1 |
| Emiliani, A; Losanno, T; Manna, G; Seminara, P | 1 |
| Bianchessi, C; Bollina, R; Carteni, G; Cozzi, C; De Portu, S; Grimaldi, AM; Mantovani, LG; Ravaioli, A; Tamburini, E; Testa, TE | 1 |
| Boku, N; Doi, T; Hamamoto, Y; Kato, K; Koizumi, W; Komatsu, Y; Mizunuma, N; Muro, K; Sato, A; Takiuchi, H; Yamaguchi, K | 2 |
| Adenis, A; Bennouna, J; Bergougnoux, L; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Lledo, G; Rebischung, C; Ychou, M | 1 |
| Czejka, M; Farkouh, A; Gruenberger, B; Scheithauer, W; Schueller, J | 1 |
| Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D | 1 |
| Goldberg, RM | 1 |
| Cathomas, R; Köberle, D; Lanz, D; Popescu, R; Roth, A; Ruhstaller, T; Simcock, M; Uhlmann, C; von Moos, R; Widmer, L | 1 |
| Braun, M; Jaehde, U; Ko, YD; Kuhn, W; Mey, UJ; Ringsdorf, S; Schmidt-Wolf, I; Schwindt, PF; Simons, S | 1 |
| Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM | 1 |
| Azman, N; Haron, M; Kamil, M; Khalid, I; Yosuff, N | 1 |
| Eickhoff, JC; Holen, KD; Jumonville, A; Loconte, NK; Lubner, SJ; Mulkerin, DL; Schelman, W; Seo, S; Thomas, JP | 1 |
| Berglund, A; Brünner, N; Christensen, IJ; Frederiksen, C; Glimelius, B; Jensen, BV; Keldsen, N; Nielsen, HJ; Nielsen, SE; Pfeiffer, P; Qvortrup, C | 1 |
| Allen, J; Bentley, D; Gollins, S; Lloyd, A; Morris, J; Saunders, MP; Soe, W; Swindell, R; Taylor, MB; Valle, J; Waddell, T | 1 |
| Matouskova, E; Mladkova, J; Sanda, M; Selicharova, I | 1 |
| Bergin, P; Damianovich, D; Findlay, M; Hanning, F; Hill, A; McKeage, MJ; Thompson, P | 1 |
| Matsuoka, M; Mishima, H; Muro, K; Oba, K; Oriuchi, N; Sakamoto, J; Satoh, T | 1 |
| Chiba, M; Fujimoto, H; Igawa, A; Iizawa, H; Ikeda, E; Inoue, K; Ishiyama, K; Kobayashi, Y; Matsuda, M; Mori, N; Saito, T; Sato, T; Sugawara, M; Suto, T; Suzuki, Y; Watanabe, T; Yabuki, H | 1 |
| Eipeldauer, S; Gruenberger, B; Gruenberger, T; Herberger, B; Kaczirek, K; Klinger, M; Tamandl, D | 1 |
| Andretta, V; Bennicelli, E; Bordignon, C; Caprioni, F; Comandini, D; Fornarini, G; Guglielmi, A; Lambiase, A; Mammoliti, S; Mazzola, G; Pessino, A; Sciallero, S; Sobrero, AF | 1 |
| Khattak, A; Price, TJ; Townsend, AR | 1 |
| Ai, B; Ding, L; Li, L; Wu, JY; Wu, XN; Zhao, YB; Zhou, MZ | 1 |
| Midgley, RS; Yanagisawa, Y | 1 |
| Chalermchai, T; Sriuranpong, V; Suwanrusme, H; Tantiphlachiva, K; Voravud, N | 1 |
| Cartwright, T; Chu, E; McKenna, EF; Schulman, KL | 1 |
| Aliberti, C; Chiriatti, A; Fiorentini, G; Licitra, S; Montagnani, F | 1 |
| Bagli, L; Drudi, F; Fantini, M; Gianni, L; Nicoletti, S; Possenti, C; Ravaioli, A; Sintini, M; Tamburini, E; Tassinari, D | 1 |
| Fan, J; Ling, W; Ma, Y; Wang, H | 1 |
| Bergman, AM; Dalesio, O; Rinkes, IH; Schouten, SB; Snoeren, N; Tollenaar, RA; van der Sijp, JR; van Hillegersberg, R; Verheul, HM; Voest, EE | 1 |
| Abajo, A; Bandres, E; Bitarte, N; Boni, V; Chopitea, A; Garcia-Foncillas, J; Ponz, M; Rodriguez, J; Zarate, R | 1 |
| Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M | 1 |
| Gelderblom, H; Guchelaar, HJ; Pander, J; Punt, CJA; van der Straaten, T; Wessels, JAM | 1 |
| Boban, M; Hrabar, A; Omrčen, T; Vrdoljak, E | 1 |
| Baird, R; Barbachano, Y; Biondo, A; Chau, I; Chhaya, V; Cunningham, D; Karpathakis, A; McLachlan, J; Rahman, S | 1 |
| Imholz, AL; Knijn, N; Koopman, M; Mol, L; Punt, CJ; Teerenstra, S; Tol, J; Valster, FA; Vincent, AD; Werter, MJ | 1 |
| Cennamo, V; Fuccio, L | 1 |
| Chen, G; Lu, SX; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX | 1 |
| Chay, WY; Choo, SP; Gao, F; Koo, WH; Lo, YL; Ng, HC; Ong, SY; Tan, SH | 1 |
| Gill, JF; Hentschel, P; Higby, DJ; Khan, MQ; Leichman, CG; Madajewicz, S; Malik, SK; Nicol, SJ; Ritch, PS; Waterhouse, DM; Zhao, L | 1 |
| Azzariti, A; Cinieri, S; Colucci, G; De Vita, F; Lorusso, V; Maiello, E; Millaku, A; Numico, G; Petriella, D; Pisconti, S; Russo, A; Santini, D; Silvestris, N; Tommasi, S | 1 |
| Alvarez, S; Barrueco, N; Cortejoso, L; García, MI; García-Alfonso, P; Gonzalez-Haba, E; Jiménez, JL; López-Fernández, LA; López-Lillo, C; Martín, ML; Muñóz-Fernández, MA; Sanjurjo, M | 1 |
| Guillén-Ponce, C; Molina-Garrido, MJ | 1 |
| Czejka, M; Ettlinger, D; Farkouh, A; Georgopoulos, A; Scheithauer, W; Schueller, J | 1 |
| Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ | 1 |
| Bandres, E; Bitarte, N; Boni, V; Chopitea, A; Garcia-Foncillas, J; Hernández, A; Ponz-Sarvisé, M; Rodriguez, J; Zarate, R | 1 |
| Ng, S; O'bichere, A; Platell, C; Tebbutt, N | 1 |
| Berti, P; Daniele, S; Frezza, AM; Picardi, A; Tonini, G; Vespasiani, U; Vincenzi, B | 1 |
| Fridlyand, J; Fyfe, G; Kaiser, LD | 1 |
| Aklilu, M; Ashton, J; Bendell, JC; Blobe, GC; Cushman, S; Fernando, NH; Hurwitz, HI; Morse, MA; Nixon, AB; Pang, H; Wong, NS | 1 |
| Barbachano, Y; Brown, G; Chau, I; Chua, YJ; Compton, S; Cunningham, D; Hickish, T; Khan, A; Mudan, S; Saffery, C; Strimpakos, AS; Thomas, J; Valle, J; Wong, R; Wotherspoon, A | 1 |
| Abenhardt, W; Decker, T; Dietzfelbinger, H; Haberl, C; Hass, HG; Heinemann, V; Jung, A; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schalhorn, A; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF; Zellmann, K | 1 |
| Furushima, K; Ishihara, T; Katou, Y; Tanai, C; Tanaka, Y; Usui, K | 1 |
| Cassidy, J; Lindsay, CR | 1 |
| Rather, A; Shah, A; Shah, NR | 1 |
| Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J | 1 |
| Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW | 1 |
| Bennouna, J; Conroy, T; Dominguez, S; Douillard, JY; Ducreux, M; Faroux, R; Florentin, V; Hebbar, M; Lledo, G; Perrocheau, G; Ychou, M | 1 |
| Boot, H; de Hingh, IH; Klaver, YL; Verwaal, VJ | 1 |
| Cabebe, EC; Fisher, GA; Sikic, BI | 1 |
| Abt, M; Burns, I; Chen, E; Goldstein, D; Major, P; McKendrick, J; Rittweger, K; Robinson, B; Zhi, J | 1 |
| Backshall, A; Clarke, SJ; Keun, HC; Sharma, R | 1 |
| Cassidy, J; Cunningham, D; Gilberg, F; Hoff, P; Kang, Y; Saini, JP; Saltz, L; Twelves, C; Van Cutsem, E | 1 |
| Beijnen, JH; Burylo, AM; Cats, A; de Boer, A; Deenen, MJ; Doodeman, VD; Guchelaar, HJ; Punt, CJ; Schellens, JH; Smits, PH; Tol, J; Vincent, A | 1 |
| Crucitti, P; Falcone, A; Frezza, AM; Galluzzo, S; Graziano, F; Loupakis, F; Muda, AO; Perrone, G; Rabitti, C; Rizzo, S; Russo, A; Ruzzo, AM; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
| De Bruijn, MT; Hinrichs, J; Kranenburg, O; Punt, CJ; Raats, DA; Rinkes, IH; Teerenstra, S; Tol, J | 1 |
| Barni, S; Cabiddu, M; Petrelli, F | 1 |
| Fukui, E; Kawahara, K; Sakurai, M; Ueda, R; Yamada, R | 1 |
| Brewster, AE; Langley, RE; Maughan, TS; Middleton, G; O'Mahony, MS; Parmar, M; Seymour, MT; Shepherd, SF; Thompson, LC; Wasan, HS | 1 |
| Schmoll, HJ | 1 |
| Ahn, JB; Hong, YS; Kim, SH; Kim, SY; Kim, TW; Lee, KH; Lee, SH; Park, SH; Park, YS; Shin, SJ | 1 |
| Arkenau, HT; Baraniskin, A; Graeven, U; Meier, D; Munding, J; Porschen, R; Reinacher-Schick, A; Schmiegel, W; Schulmann, K; Tannapfel, A | 1 |
| Alberti, D; Bowen, CJ; Dar, MM; Dennie, TW; Fleming, RA; Holen, KD; Loconte, N; Mulkerin, D; Oliver, K | 1 |
| Girard, P; Paule, I; Tod, M | 1 |
| Boc, M; Ocvirk, J; Rebersek, M | 1 |
| Cunningham, D; Hewish, M | 1 |
| Adams, RA; Bridgewater, J; Cheadle, JP; Claes, B; Fisher, D; Harris, R; Idziaszczyk, S; James, MD; Jasani, B; Kaplan, R; Kay, E; Kennedy, MJ; Kenny, SL; Lambrechts, D; Madi, A; Maughan, TS; Meade, AM; Mitchell, JK; Seymour, MT; Smith, CG; Wilson, RH | 1 |
| Chua, A; Cummins, MM; Hardingham, JE; Lee, CK; Murone, C; Price, TJ; Shivasami, A; Tebbutt, NC; Townsend, AR; Weickhardt, A; Wrin, JW | 1 |
| Ross, JS | 1 |
| Cassidy, J; Clarke, S; Díaz-Rubio, E; Figer, A; Gilberg, F; Koski, S; Rittweger, K; Saltz, L; Scheithauer, W; Wong, R | 1 |
| Chau, J; Chua, DT; Lee, AW; Lee, V; McGhee, SM; Ng, WT; Tse, VC | 1 |
| Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K | 1 |
| Holt, K | 1 |
| Almeida da Cruz, L; Ferrari, CL; Hoff, PM; Riechelmann, RS | 1 |
| Giaccone, G; Giovannetti, E; Hanauske, AR; Leon, LG; Peters, GJ; Smid, K; van Houte, BP | 1 |
| Absenger, G; Benhaim, L; Bohanes, P; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; Labonte, MJ; Lenz, HJ; Ning, Y; Paez, D; Singh, H; Wilson, PM; Winder, T; Yang, D; Zhang, W | 1 |
| Bennouna, J; Borg, C; Bouché, O; Delord, JP; Douillard, JY; Faroux, R; François, E; Goldwasser, F; Husseini, F; Kraemer, S; Senellart, H; Trillet-Lenoir, V; Ychou, M | 1 |
| Derleyn, VA; Koopman, M; Mol, L; Muller, EW; Punt, CJ; Simkens, LH; Teerenstra, S; Ten Bokkel Huinink, D; Veldhuis, GJ | 1 |
| Freyer, G; Girard, P; Hénin, E; Paule, I; Tod, M; You, B | 1 |
| Eropkin, PV; Kashnikov, VN; Panina, MV; Rybakov, EG | 1 |
| Krotova, OA; Polysalov, VN; Rutkin, IO; Tlostanova, MS | 1 |
| Adenis, A; Boige, V; Boucher, E; Chauffert, B; Conroy, T; Cvitkovic, F; Ducreux, M; Farace, F; François, E; Galais, MP; Guichard, P; Jacques, N; Malka, D; Pierga, JY; Vimond, N | 1 |
| Dennie, T; Holen, KD; Mohammed, TA | 1 |
| Bendell, JC; Blobe, GC; Fernando, NH; Honeycutt, W; Hurwitz, HI; Morse, MA; Pang, H; Wong, NS | 1 |
| Balaban, EP; Crandall, TL; Kane, P; Lembersky, BC; Pinkerton, RA; Potter, DM; Rajasenan, KK; Ramanathan, RK; Schmotzer, A; Sehgal, R; Zeh, H | 1 |
| Aubele, P; Bangerter, M; Denzlinger, C; Freiberg-Richter, J; Giessen, C; Heinemann, V; Hinke, A; Kullmann, F; Mayerle, J; Modest, DP; Moosmann, N; Schulz, C; Sieber, M; Stintzing, S; Teschendorf, C; Vehling-Kaiser, U; von Weikersthal, LF | 1 |
| Hotchkiss, S; Kaley, K; Penney, R; Saif, MW; Strimpakos, AS; Syrigos, KN | 1 |
| Yusuf, SW | 1 |
| Gelderblom, H; Opdam, FL; Swen, JJ; Wessels, JA | 1 |
| Largiadèr, CR; van Kuilenburg, AB | 1 |
| Peeters, M; Price, T | 1 |
| Boisen, MK; Fromm, AL; Jensen, BV; Larsen, FO | 1 |
| Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX | 1 |
| Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ | 1 |
| Ackland, SP; Broad, A; Cassidy, J; Ganju, V; Price, TJ; Robinson, BA; Simes, RJ; Tebbutt, NC; Van Hazel, GA; Wilson, K; Zannino, D | 1 |
| Chen, G; Chen, R; Ding, KF; Li, J; Song, YM; Yan, M; Ying, XJ; Zhou, JJ | 1 |
| Arnold, D; Stein, A | 1 |
| Bollag, G; Bradley, WD; Heimbrook, D; Higgins, B; Kolinsky, K; Kopetz, S; Lee, RJ; Lestini, B; Packman, K; Schostack, K; Simcox, ME; Su, F; Yang, H | 1 |
| Ciccolini, J; Dahan, L; Evrard, A; Iliadis, A; Lacarelle, B; Mbatchi, L; Mercier, C; Norguet, E; Ouafik, L; Ries, P; Seitz, JF; Tibbitts, J | 1 |
| Bellot, GL; Koh, D; Tan, WH; Tay, LL; Wang, X | 1 |
| Amano, R; Fuyuhiro, Y; Hirakawa, K; Ishikawa, T; Kashiwagi, S; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Nagahara, H; Nakata, B; Noda, E; Ohira, M; Tanaka, H; Yamada, N; Yashiro, M | 1 |
| Kato, K | 1 |
| Abad, A; Antón, A; Aranda, E; Arrivi, A; Benavides, M; Cervantes, A; Díaz-Rubio, E; Dueñas, R; Escudero, P; Fernández-Martos, C; Gallén, M; Gómez-España, A; González, E; Lacasta, A; Llanos, M; López-Ladrón, A; Losa, F; Marcuello, E; Martínez de Prado, P; Massutí, B; Rivera, F; Safont, MJ; Sastre, J; Tabernero, JM; Valladares, M | 1 |
| Bargagli, G; Conca, R; Francini, E; Francini, G; Licchetta, A; Marzocca, G; Miano, ST; Pascucci, A; Petrioli, R; Roviello, G | 1 |
| Boukovinas, I; Christophyllakis, Ch; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, Ch; Makrantonakis, P; Polyzos, A; Souglakos, J; Vamvakas, L; Xynogalos, S; Ziras, N | 1 |
| Biondani, P; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Marchianò, A; Pellegrinelli, A; Pietrantonio, F | 1 |
| Burtness, B; Cohen, SJ; Denlinger, CS; Dotan, E; Lee, J; Meropol, NJ; Mintzer, D; Ruth, K; Sylvester, J; Tuttle, H; Zhu, F | 1 |
| Bhattacharya, D; Easthall, C; Small, M; Watson, S; Willoughby, KA | 1 |
| Chen, E; Feld, R; Knox, J; Krzyzanowska, MK; Liu, G; MacKay, H; Moore, MJ; Petronis, J; Renouf, DJ; Wang, L; Welch, S | 1 |
| Aranda, E; Benavides, M; Díaz-Rubio, E; Grávalos, C; Hidalgo, M; Manzano, JL; Marcuello, E; Massuti, B; Rivera, F; Sastre, J; Valladares-Ayerbes, M | 1 |
| Jennings, BA; Kwok, CS; Loke, YK; Matthews, V; Wawruch, P; Willis, G | 1 |
| Assy, N; Basher, W; Chetver, L; Shnaider, J; Zidan, J | 1 |
| Hansen, TF; Jakobsen, A; Lindebjerg, J; Sørensen, FB | 1 |
| Chen, XF; Guo, RH; Li, J; Røe, OD; Shu, YQ; Wang, R; Wu, T; Yin, YM; Zhu, LJ | 1 |
| Brodowicz, T; Giessen, C; Heinemann, V; Knittelfelder, R; Laubender, RP; Modest, DP; Reinacher-Schick, A; Schmiegel, W; Stintzing, S; Tannapfel, A; Vrbanec, D; Zielinski, CC | 1 |
| Brittain, EH; Fay, MP; Follmann, DA | 1 |
| Conibear, J; Raouf, S; Tarver, K | 1 |
| Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG | 1 |
| Maughan, T | 1 |
| Burns, WI; Dowling, AJ; Liew, D; McLachlan, SA; Newnham, GM; Ng, SL; Snyder, RD | 1 |
| Bo, X; Dexiang, Z; Haifu, W; Haohao, L; Jia, F; Jianmin, X; Lechi, Y; Li, L; Li, R; Qinghai, Y; Shenyong, Z; Tianshu, L; Xiangou, P; Xinyu, Q; Ye, W; Yunshi, Z | 1 |
| Barbachano, Y; Chau, I; Cunningham, D; Dewdney, A | 1 |
| Abbruzzese, A; Apollinari, S; Bestoso, E; Botta, C; Caraglia, M; Correale, P; Cusi, MG; Misso, G; Pastina, P; Sperlongano, P; Tagliaferri, P; Tassone, P | 1 |
| Berk, V; Elmalı, F; Er, O; Inanç, M; Karaca, H; Ozkan, M; Saraymen, R | 1 |
| Iwai, M; Kimura, M; Yasuda, T; Yoshimura, T | 1 |
| Cartwright, T; Hu, S; Hurwitz, H; Kwok, A; McKenna, E; Mitchell, EP; Patt, YZ | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Cetin, B; Coskun, U; Isıkdogan, A; Kaplan, MA; Ozkan, M; Ozturk, SC | 1 |
| Abad, A; Aranda, E; Arrivi, A; Benavides, M; Díaz-Rubio, E; Fernández-Martos, C; Gallén, M; Gómez-España, A; González, E; Maestro, ML; Marcuello, E; Massuti, B; Rivera, F; Sastre, J; Tabernero, JM; Valladares, M; Vidaurreta, M | 1 |
| Giessen, C; Heinemann, V; Jung, A; Kapaun, C; Kirchner, T; Laubender, RP; Modest, DP; Moosmann, N; Neumann, J; Stintzing, S; Wollenberg, A | 1 |
| Chen, X; Choo, SP; Chowbay, B; Farid, M; Koo, WH; Ong, SY; Ramasamy, S; Tan, SH; Toh, HC | 1 |
| Alì, G; Calabrese, R; Lenzi, P; Moretti, P; Orsucci, D; Petrozzi, L; Pizzanelli, C; Ricci, G; Siciliano, G | 1 |
| Arnold, D; Dellas, K; Dunst, J; Reese, T; Richter, M | 1 |
| de Lima Lopes, G; Haaland, BA; Ku, GY | 1 |
| Bafaloukos, D; Economopoulos, T; Eleftheraki, AG; Fountzilas, G; Kalogeras, KT; Klouvas, G; Koutras, A; Makatsoris, T; Nikitas, N; Papakostas, P; Papandreou, CN; Papaxoinis, G; Pectasides, D; Pentheroudakis, G; Samantas, E; Sgouros, J; Syrigos, KN; Timotheadou, E; Varthalitis, I; Xanthakis, I | 1 |
| Kobunai, T; Nakagawa, F; Nukatsuka, M; Saito, H; Sakamoto, K; Shiraishi, K; Takechi, T; Uchida, J | 1 |
| Baek, JY; Hong, YS; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Kim, TY; Lee, J; Lee, JL; Lee, KW; Park, JO; Park, SH; Park, YS | 1 |
| Begent, R; Gafson, AR; Goodkin, O | 1 |
| Doornebal, J; Koopman, M; Lemmens, W; Punt, CJ; Teerenstra, S; Venderbosch, S | 1 |
| Ahmad, A; Armstrong, G; Blesing, C; Bond, S; Bulusu, R; Corrie, PG; Daniel, F; Hardy, R; Hill, M; Lao-Sirieix, S; McAdam, K; Moody, AM; Osborne, M; Parashar, D; Wilson, CB; Wilson, G | 1 |
| Aggarwal, BB; Baladandayuthapani, V; Deorukhkar, A; Diagaradjane, P; Guha, S; Kannappan, R; Krishnan, S; Prasad, S; Reuter, S; Sung, B; Wei, C; Yadav, VR | 1 |
| Aguilella-Vizcaíno, MJ; Calleja-Hernández, MÁ; Cortés-Funes Castro, H; Cortijo-Cascajares, S; García-Escobar, I; Herreros-de-Tejada, A; Nacle-López, I | 1 |
| Baranger, B; Bollet, MA; Cacheux, W; Farkhondeh, F; Mariani, P; Servois, V; Zefkili, S | 1 |
| Alberti, P; Argyriou, AA; Briani, C; Bruna, J; Cacciavillani, M; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Kalofonos, HP; Lonardi, S; Santos, C; Velasco, R | 1 |
| Ahn, JB; Hong, YS; Jung, KH; Kim, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, JL; Park, YS; Shim, BY; Zang, DY | 1 |
| Adams, RA; Fisher, D; Kaplan, R; Kenny, SL; Madi, A; Maughan, TS; Meade, AM; Nichols, LL; Seymour, MT; Wasan, H; Wilson, RH | 1 |
| Carlsson, G; Holmberg, C; Pettersson, K; Sporrong, SK | 1 |
| Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM | 1 |
| Brodowicz, T; Heinemann, V; Jung, A; Kirchner, T; Knittelfelder, R; Kurteva, G; Laubender, RP; Modest, DP; Neumann, J; Ocvirk, J; Papai, Z; Stintzing, S; Zielinski, CC | 1 |
| Esaki, S; Goshima, F; Kimura, H; Murakami, S; Nishiyama, Y | 1 |
| Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B | 1 |
| Flatmark, K; Fleten, KG; Furre, T; Hektoen, HH; Kristian, A; Ree, AH; Saelen, MG | 1 |
| Asghar, U; Barbachano, Y; Chau, I; Constantinidou, A; Cunningham, D; Khan, A; Mudan, S; Rao, S; Shurmahi, F | 1 |
| Burkholder, I; Gencer, D; Heinemann, V; Hochhaus, A; Hofheinz, RD; Laubender, RP; Stintzing, S; von Weikersthal, LF | 1 |
| Grothey, A | 1 |
| Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ | 1 |
| de Braud, F; Díaz-Rubio, E; Pietrantonio, F | 1 |
| Chachad, S; Malhotra, G; Naidu, R; Purandare, S | 1 |
| Aprile, G; Avallone, A; Bilancia, D; Butera, A; Reggiardo, G; Rosati, G | 1 |
| Cool, M; Deboever, G; Hiltrop, N; Lambrecht, G | 1 |
| Hezel, A; McCleary, NJ; Meyerhardt, JA; Odejide, O; Ryan, D; Szymonifka, J | 1 |
| Alberti, P; Argyriou, AA; Bergamo, F; Briani, C; Bruna, J; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Kalofonos, HP; Lonardi, S; Lucchetta, M; Velasco, R | 1 |
| Ahn, JB; Hong, YS; Im, SA; Jung, KH; Kang, YK; Kim, JH; Kim, KP; Kim, TW; Kim, TY; Lee, JL; Lee, SS; Park, YS; Shin, SJ | 1 |
| Belliere, A; Chevrier, R; Chollet, P; Dillies, AF; Durando, X; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Thivat, E; Van Praagh, I | 1 |
| Guduru, SR; Gunuganti, AR; Lee, L; McKenna, E; Reyes, C; Satram-Hoang, S; Yu, S | 1 |
| Albiol, M; Alsina, M; Codina-Barreras, A; Figueras, J; Guardeño, R; Hernandez-Yagüe, X; Lopez-Ben, S; Queralt, B; Soriano, J | 1 |
| Aranda, E; Arrivi, A; Bando, I; Benavides, M; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Gómez-España, A; González, E; Manzano, JL; Marcuello, E; Martínez de Prado, P; Massutí, B; Montagut, C; Reboredo, M; Rivera, F; Safont, MJ; Sastre, J | 1 |
| Chen, JX; Shen, XH | 1 |
| Pox, C; Reinacher-Schick, A; Schmiegel, W | 1 |
| Giessen, C; Haas, M; Heinemann, V; Laubender, RP; Mansmann, U; Modest, DP; Schulz, C; Stintzing, S | 1 |
| Blough, D; Koepl, L; Mummy, D; Ramsey, S; Shankaran, V; Yim, YM; Yu, E | 1 |
| Gibbs, P; Hack, SP; Kerr, A; Price, T; Stokes, L; Todd, C; Tran, G | 1 |
| Abrahámová, J; Bláha, M; Büchler, T; Dušek, L; Kupec, M; Nohejlová Medková, A; Pavlík, T | 1 |
| Abu-Arafeh, A; Campbell, RT; Dalzell, JR | 1 |
| Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M | 1 |
| Aisu, N; Hoshino, S; Miyake, T; Naito, M; Tanimura, S; Yamashita, Y; Yoshida, Y | 1 |
| Maroun, JA | 1 |
| Bogenrieder, T; Landthaler, M; Schölmerich, J; Stolz, W; Weitzel, C | 1 |
| Höffken, K; Kliche, KO; Kubsch, K; Masri-Zada, R; Raida, M | 1 |
| Huber, H; Kornek, GV; Längle, F; Raderer, M; Scheithauer, W; Schmid, K; Schüll, B | 1 |
| Desmoulin, F; Gilard, V; Malet-Martino, M; Martino, R | 1 |
| Brierre, JE; Buller, EJ; Cole, JL; Fontenot, MF; Lormand, NA; Rainey, JM; Rinaldi, DA; Stagg, MP | 1 |
| Needle, MN | 1 |
| Eng, C; Kindler, HL; Schilsky, RL | 1 |
| D'Orazio, AI; Gambill, BD | 1 |
| Gambill, BD | 1 |
| Fishman, AD; Wadler, S | 1 |
| Fisher, MD | 1 |
| Grem, JL; Xu, Y | 1 |
| Pentheroudakis, G; Twelves, C | 1 |
| Aubert, C; Bezulier, K; Ciccolini, J; Cuq, P; Evrard, A; Fina, F; Giacometti, S; Martin, PM; Romain, S; Roussel, M | 1 |
| Chu, E; Copur, S; DeGrendele, HC; Jain, VK; Lee, D; Maung, K; Schilsky, R | 1 |
| Chen, G; Chi, GY; Li, N; Rothmann, M; Temple, R; Tsou, HH | 1 |
| Kerr, D | 1 |
| Rothenberg, ML | 1 |
| Twelves, C | 2 |
| Ayers, GD; Lin, E; Morris, JS | 1 |
| Copeland, EM; Hochwald, SN; Lind, DS; MacKay, SL; Malaty, J; Moldawer, LL | 1 |
| Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL | 1 |
| De Bruijn, EA; Friedel, G; Guetens, G; Hendriks, JM; Pauwels, B; Romijn, S; Van Putte, BP; Van Schil, PE | 1 |
| Depisch, D; Kornek, GV; Kovats, E; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B | 1 |
| Batist, G; Cohen, V; Morin, I; Panet-Raymond, V; Rozen, R; Sabbaghian, N | 1 |
| Hoff, PM | 1 |
| Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U | 1 |
| Porschen, R | 1 |
| Eda, H; Endo, M; Hattori, K; Ishikawa, T; Ishitsuka, H; Miwa, M; Miyazaki-Nose, T; Shimma, N; Tanimura, H; Ura, M; Yamada-Okabe, H | 1 |
| Cunningham, D; Gillbanks, A; Harper-Wynne, C; Hill, M; Norman, AR; Sumpter, K | 1 |
| Barceló, R; Ferreiro, J; López-Vivanco, G; Mañé, JM; Muñoz, A; Rubio, I | 1 |
| Cognetti, F; Ferraresi, V; Gabriele, A; Gamucci, T; Giannarelli, D; Nardoni, C; Pino, MS; Zeuli, M | 1 |
| Achterrath, W; Frings, S; Harstrick, A; Rustum, YM; Schleucher, N; Seeber, S; Tewes, M; Vanhoefer, U; Wilke, HJ | 1 |
| Fuchs, CS | 1 |
| Miwa, K; Nishimura, G | 1 |
| Hosokawa, A | 1 |
| Doi, T; Ohtsu, A | 1 |
| Murakami, M; Naito, M; Ota, T; Shimizu, N; Tsukuda, K | 1 |
| O'Neil, BH | 1 |
| Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S | 1 |
| Heerschap, A; Kamm, YJ; Klomp, DW; Punt, CJ; van Laarhoven, HW | 1 |
| Maung, K | 1 |
| Lewis, NL; Meropol, NJ | 2 |
| Artale, S; Bajetta, E; Beretta, E; Biasco, G; Bonaglia, L; Bonetti, A; Buzzoni, R; Carreca, I; Cassata, A; Cortinovis, D; Di Bartolomeo, M; Ferrario, E; Frustaci, S; Iannelli, A; Lambiase, A; Mariani, L; Marini, G; Pinotti, G | 1 |
| Cats, A | 1 |
| Marshall, JL; Meropol, NJ; Shields, AF; Zalupski, MM | 1 |
| Hahn, P; Jensen, HA; Pfeiffer, P | 1 |
| Lewis, KG; Lewis, MD; Pan, TD; Robinson-Bostom, L | 1 |
| Bukowski, RM; Cunningham, D; Dufour, P; Graeven, U; Harper, P; Hoff, PM; Lokich, J; Madajewicz, S; Maroun, JA; Marshall, JL; Mitchell, EP; Perez-Manga, G; Rougier, P; Schilsky, RL; Schmiegel, W; Schoelmerich, J; Sobrero, A; Van Cutsem, E | 1 |
| Folprecht, G; Köhne, CH | 4 |
| Feng, FY; Fu, Q; Guan, ZZ; Huang, JJ; Liu, DG; Ruan, QL; Shi, D; Sun, SR; Wei, YQ; Wu, G; Wu, WQ; Wu, XD; Xiong, HH; Yang, CY; Yu, BM; Yu, SY; Zhang, P; Zhao, Y; Zheng, S; Zhuang, W; Zou, LQ | 1 |
| Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S | 1 |
| Abbruzzese, A; Caraglia, M; Ceciarini, F; Correale, P; Francini, G; Giorgi, G; Guarnieri, A; Marsili, S; Messinese, S; Micheli, L; Nencini, C; Neri, A; Petrioli, R; Piccolomini, A; Prete, SD; Vuolo, G | 1 |
| Chen, VM; Flower, RL; Jackson, D; Morel-Kopp, MC; Thrift, KM; Ward, CM | 1 |
| Abbruzzese, JL; Carter, S; Hoff, PM; Lassere, Y; Pazdur, R; Polito, D; Samid, D | 1 |
| Brunet, R; Butts, C; Cassidy, J; Conroy, T; Debraud, F; Díaz-Rubio, E; Figer, A; Grossmann, J; Sawada, N; Schöffski, P; Sobrero, A; Tabernero, J; Twelves, C; Van Cutsem, E | 1 |
| Brouwers, JR; Jansman, FG; Postma, MJ; van Hartskamp, D; Willemse, PH | 1 |
| Hoff, PM; Pazdur, R | 1 |
| Goldberg, RM; Penland, SK | 1 |
| O'Connell, MJ | 1 |
| Cunningham, D; Hill, ME; Norman, AR; Oates, J; Price, T; Rao, S; Ross, PJ; Shellito, P; Tebbutt, N | 1 |
| Baek, JH; Bang, SM; Cho, EK; Im, SA; Lee, JH; Oh, JH; Park, SH; Park, YS; Shin, DB | 1 |
| Hoff, P; Lassere, Y | 1 |
| Deery, P; Faithfull, S | 1 |
| Gerbrecht, BM; Kangas, T | 1 |
| Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ | 1 |
| Baker, JH; Huxham, LA; Kyle, AH; Minchinton, AI; Nykilchuk, LK | 1 |
| Scheithauer, W | 1 |
| Blum, J; Scheithauer, W | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Iqbal, S; Lenz, HJ | 1 |
| Gnad-Vogt, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Wein, A | 1 |
| Hitre, E; Láng, I | 1 |
| Berger, MR; Eyol, E; Rodenbach, M; Seelig, MH | 1 |
| Casaretti, R; Comella, P; Farris, A; Gambardella, A; Leo, S; Lorusso, V; Maiorino, L; Massidda, B; Natale, D; Tafuto, S | 1 |
| Bernhard, J; Borner, MM; Brauchli, P; Dietrich, D; Herrmann, R; Honegger, H; Koeberle, D; Lanz, D; Popescu, R; Rauch, D; Roth, AD; Saletti, P; Wernli, M | 1 |
| Mayer, RJ; Meyerhardt, JA | 1 |
| Grothey, A; Hieke, K; Kleeberg, UR; Stauch, M | 2 |
| Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H | 1 |
| Goldberg, RM; O'Neil, BH | 1 |
| Tejpar, S; Van Cutsem, E; Verslype, C | 1 |
| Haller, DG | 1 |
| Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS | 1 |
| Bolaños, M; Casado, E; Escudero, P; Feliu, J; Gómez-Reina, MJ; González-Baron, M; Llosa, F; Lopez, R; Lopez-Gómez, L; Sanz-Lacalle, JJ; Vicent, JM; Yubero, A | 1 |
| Gauthier, AM; Hennessy, BT; Hortobagyi, G; Michaud, LB; Valero, V | 1 |
| Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S | 1 |
| Beretta, GD; Labianca, R; Milesi, L; Mosconi, S; Pessi, MA | 1 |
| Asmar, L; Boehm, KA; Cartwright, T; Encarnacion, C; Lopez, T; Vukelja, SJ | 1 |
| Wu, WQ; Yu, BM | 1 |
| Bakker, JM; Falk, S; Groenewegen, G; Kerr, DJ; Maughan, T; Nortier, JW; Punt, CJ; Rea, DW; Richel, DJ; Semiond, D; Smit, JM; Steven, N; Ten Bokkel Huinink, WW | 1 |
| Aggarwal, S; Chu, E | 1 |
| Cannone, M; Casaretti, R; Comella, P; Farris, A; Gambardella, A; Leo, S; Lorusso, V; Maiorino, L; Massidda, B; Natale, D; Tafuto, S | 1 |
| Coutsouvelis, J; McKendrick, J | 1 |
| Cunningham, D; Ng, M; Norman, AR | 1 |
| Hendriks, JM; Pauwels, B; Romijn, S; Van Putte, BP; Van Schil, PE; Vermorken, JB | 1 |
| Punt, CJ | 2 |
| Leong, LA; Rosales, J | 1 |
| Aquino, A; Bonmassar, E; Correale, P; Cusi, MG; Del Vecchio, MT; Ferrari, F; Francini, G; Giorgi, G; Intrivici, C; Marsili, S; Micheli, L; Nencini, C; Placa, ML; Tsang, KY | 1 |
| Caricato, M; Coppola, R; Di Seri, M; La Cesa, A; Rocci, L; Santini, D; Schiavon, G; Spalletta, B; Tonini, G; Vincenzi, B | 1 |
| Chong, G; Cunningham, D; Dickson, JL; Hill, ME; Norman, AR; Oates, J; Price, TJ; Rao, S; Tebbutt, N | 1 |
| Saif, MW | 1 |
| Braud, Fd; Brunet, R; Butts, CA; Cassidy, J; Conroy, T; Diaz-Rubio, E; Figer, A; Grossmann, J; Schoffski, P; Sobrero, AF; Tabernero, JM; Twelves, CJ; Van Cutsem, EJ | 1 |
| Hochster, HS | 1 |
| Fioravanti, S; Grem, JL; Harold, N; Leonard, GD; Quinn, MG; Schuler, B; Thomas, RR; Wright, MA | 1 |
| Arnold, D | 1 |
| Guichard, SM; Jodrell, DI; Mayer, I | 1 |
| Earle, M; Evans, T; Ferri, W; Friedland, D; Jacobs, SA; Matin, K; Pinkerton, R; Ramanathan, RK; Richards, T; Troetschel, M; Volkin, R; Wieand, S; Wong, MK | 1 |
| Hoeffding, LD; Jakobsen, A; Lindebjerg, J; Nielsen, JN | 1 |
| Chuang, JC; Jones, PA; Kwan, JM; Li, TW; Liang, G; Yang, AS; Yoo, CB | 1 |
| Fung, A; Viale, PH; Zitella, L | 1 |
| Baltesgard, L; Ehrsson, H; Fokstuen, T; Glimelius, B; Mortensen, JP; Pfeiffer, P; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, KM; Wallin, I; Øgreid, D | 1 |
| Hurwitz, H; Kabbinavar, F | 1 |
| Morse, MA | 1 |
| Gollins, S; Grieve, R; Samuel, L; Twelves, C | 1 |
| Reddy, GK | 1 |
| Gill, S; Ho, C; Ng, K; O'Reilly, S | 1 |
| Blanquicett, C; Buchsbaum, DJ; Carpenter, MD; Chhieng, DC; Diasio, RB; Eloubeidi, M; Johnson, MR; Russo, S; Saif, MW; Sellers, JC; Vickers, SM | 1 |
| Ouchi, KF; Sekiguchi, F; Tanaka, Y; Yanagisawa, M | 1 |
| Babaoglu, MO; Guler, N; Kurt, M; Shorbagi, A; Yasar, U | 1 |
| Hoff, PM; Varadhachary, GR | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B | 1 |
| Jensen, SA; Lønborg, JT; Sørensen, JB | 1 |
| Goyle, S; Maraveyas, A | 1 |
| Cheng, YC; Lam, W; Leung, CH; Park, SY | 1 |
| Alliot, C | 1 |
| Gasparro, S; La Cesa, A; Santini, D; Schiavon, G; Tonini, G; Vincenzi, A; Vincenzi, B | 1 |
| Parker, WB; Someya, H; Thottassery, JV; Westbrook, L | 1 |
| De Greef, K; Hendriks, JM; Romijn, S; Van Putte, BP; Van Schil, PE | 1 |
| Beale, P; Clarke, SJ; Horvath, L; Ong, S; Rivory, L; Sharma, R | 1 |
| Bolaños, M; Casado, E; De Castro, J; de Mon, MA; Escudero, P; Feliu, J; Galán, A; González-Barón, M; Lopez-Gómez, L; Losa, F; Salud, A; Vicent, JM; Yubero, A | 1 |
| Du, W; Posner, M; Schmidt, H; Shafaee, Z; Weichselbaum, R | 1 |
| Cassidy, J; O'Neill, VJ | 1 |
| Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX | 1 |
| Abad, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Tabernero, J | 1 |
| Alvarez, JV; Arcediano, A; Cassinello, J; Castro, IG; Colmenarejo, A; Filipovich, E; López, MJ; Marcos, F; Pujol, E; Segovia, F | 1 |
| Abdalla, EK; Eng, C; Madary, A; Vauthey, JN | 1 |
| Boukovinas, I; Christofillakis, C; Georgoulias, V; Potamianou, A; Syrigos, K; Tselepatiotis, E; Tsousis, S; Varthalitis, I; Ziras, N | 1 |
| Choi, YH; Chung, HC; Jeung, HC; Jung, JJ; Kim, TS; Kwon, WS; Lee, JO; Park, KH; Rha, SY | 1 |
| Gruenberger, B; Gruenberger, T; Scheithauer, W | 1 |
| Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR | 1 |
| Assenat, E; Duffour, J; Ychou, M | 1 |
| Cowan, J; Kaltenthaler, E; Marples, M; Orr, B; Seymour, MT; Ward, SE | 1 |
| Eng, C; Shalan, N | 1 |
| Barzon, L; Cartei, G; Nadai, M; Palù, G; Palumbo, M; Richter, SN; Trestin, A | 1 |
| Clarke, SJ; Hoskins, J; Li, KM; Rivory, LP; Sharma, R | 1 |
| Shimamura, T; Tada, M; Yamaguchi, K | 1 |
| Afchain, P; André, T; de Gramont, A; Segura, C | 1 |
| Akkermans-Vogelaar, JM; Antonini, NF; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Punt, CJ; Rodenburg, CJ; Vreugdenhil, G; Wals, J | 1 |
| Monga, DK; O'Connell, MJ | 1 |
| Berg, DT | 1 |
| McLeod, HL; O'Neil, BH | 1 |
| Andria, M; Dhami, M; Diasio, RB; Godfrey, T; Gold, PJ; Kovatich, AJ; Lund, KA; Meropol, NJ; Mitchell, E; Schwarting, R | 1 |
| Caricato, M; Coppola, R; Di Seri, M; Santini, D; Schiavon, G; Spalletta, B; Tonini, G; Vincenzi, B; Virzí, V | 1 |
| Aabo, K; Bjerregaard, B; Eckhoff, L; Jakobsen, A; Mortensen, JP; Pfeiffer, P; Sandberg, E; Schønnemann, K | 1 |
| Arnold, D; Schmoll, HJ | 1 |
| Amatori, F; Bocci, G; Boldrini, L; Danesi, R; Del Tacca, M; Di Paolo, A; Fontanini, G; Lastella, M; Vannozzi, F | 1 |
| Agelaki, S; Androulakis, N; Chatzidaki, D; Georgoulias, V; Gioulbasanis, J; Kalbakis, K; Kalykaki, A; Kotsakis, AP; Mavroudis, D; Sfakiotaki, G; Souglakos, J; Tsetis, D; Tzardi, M; Vamvakas, L; Vardakis, N | 1 |
| Ballardini, P; Di Fabio, F; Gentile, AL; Giaquinta, S; Lelli, G; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL | 1 |
| Cioppa, T; Civitelli, S; Francini, E; Francini, G; Intrivici, C; Lorenzi, M; Marsili, S; Nettuno, R; Paolelli, L; Petrioli, R; Roviello, F; Tanzini, G | 1 |
| Branch, A; Cassidy, J; MacDonald, L; MacLeod, A; McDonald, A; Mohammed, N | 1 |
| García-Foncillas, J; Gil, C; Monreal, I; Rodríguez, J; Salgado, J; Zabalegui, N | 1 |
| Doyle, DP; Engelking, C | 1 |
| DeSimone, P; Sapp, CM | 1 |
| Lahans, T | 1 |
| Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ | 1 |
| El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM | 1 |
| Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S | 1 |
| Almond, J; Ralston, S | 1 |
| Ahmad, R; Al-Obaidi, MJ; Dawson, C; Hughes, G; O'Reilly, E; Ramesh, S; Riddle, P; Sekhar, M; Shapiro, S; Smith, J | 1 |
| Danenberg, KD; Danenberg, PV; Jakobsen, A; Jensen, LH | 1 |
| Arkenau, HT; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T | 1 |
| Abad, A; Aparicio, J; Aranda, E; Carrato, A; Chaves, M; Díaz-Rubio, E; Gómez-España, A; González-Flores, E; Losa, F; Massutí, B; Maurel, J; Queralt, B; Reina, JJ; Rivera, F; Sastre, J; Tabernero, J | 1 |
| Cassidy, J; Kelly, C | 1 |
| Danenberg, KD; Danenberg, PV; Jakobsen, A; Kuramochi, H; Lindebjerg, J; Nielsen, JN; Shimizu, D; Vallböhmer, D; Yang, DY | 1 |
| Sargent, D; Schmoll, HJ | 1 |
| Antonini, NF; Creemers, GM; Dalesio, O; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Loosveld, OJ; Mol, L; Punt, CJ; Rodenburg, CJ; Sinnige, HA; Slee, PHTJ; Tesselaar, ME; van Bochove, A; Vreugdenhil, G; Wals, J; Werter, MJ | 1 |
| Liem, AH; Planting, AS; van Halteren, HK | 1 |
| Kallistratos, MS; Karabelis, A; Kopterides, P; Kosmas, C; Mylonakis, N; Skopelitis, H; Syrios, J; Tsavaris, N | 1 |
| Cognetti, F; Di Costanzo, F; Ferraresi, V; Gabriele, A; Gamucci, T; Gasperoni, S; Gelibter, AJ; Giannarelli, D; Nuzzo, C; Pollera, CF; Signorelli, C; Zeuli, M | 1 |
| Kibble, A | 1 |
| Bexon, A; Diamandidis, D; Eckhardt, SG; Javle, M; Justice, GR; Keiser, W; Lee, FC; Liebmann, JE; Lin, E; Patt, YZ; Salvatore, JR | 1 |
| Kondoh, K; Mori, K; Sawada, N | 1 |
| Astrup Jensen, S; Mård, D; Sørensen, JB; Thomsen Lønborg, J; Vilmar, A | 1 |
| Bajetta, E; Bajetta, R; Celio, L; Colombo, A; Denaro, A; Di Bartolomeo, M; Dotti, K; Ferrario, E; Mancin, M; Pusceddu, S | 1 |
| André, T; Blanchard, P; Huguet, F | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Er, O; Kaya, AO; Ozturk, B; Polat, M; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Brandsma, D; De Jong, FA; Hamberg, P; Sleijfer, S; Verweij, J | 1 |
| Bauer, RW; Eichler, K; Selby, JB; Vogl, TJ; Zangos, S | 1 |
| Gel-Moreno, B; Hernández-Borlan, R; Ibeas-Rollan, R; Martínez-Ródenas, F; Monzó-Planella, M; Moreno-Solórzano, I; Moreno-Solórzano, J; Navarro-Vigo, M; Ortigosa-Rodríguez, S; Pou-Sanchis, E | 1 |
| Chang, AY; Fong, FK; Hsin, KW; Lim, R; Lopes, G; Wong, J | 1 |
| Barrueco, J; Fuchs, CS; Ganju, V; Jeffery, M; Marshall, J; Mitchell, E; Richards, D; Schulz, J; Soufi-Mahjoubi, R; Wang, B; Wierzbicki, R | 1 |
| Buechele, T | 1 |
| Beale, P; Brennscheidt, U; Bugat, R; Clarke, S; Delord, JP; Fettner, SH; Feyereislova, A; Rakhit, A; Van Cutsem, E; Verslype, C | 1 |
| Audisio, RA; Bruce, C; Köhne, CH | 1 |
| Battistelli, S; Civitelli, S; Fiaschi, AI; Francini, E; Francini, G; Lorenzi, M; Marsili, S; Pascucci, A; Petrioli, R; Roviello, F; Tanzini, G | 1 |
| Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ | 1 |
| Geboes, K; Van Cutsem, E | 1 |
| Au, GK; Chan, RT; Choi, CK; Ho, JW; Law, WL; Lui, L; Siu, S; Tung, SY | 1 |
| B, DY; Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Er, O; Kaya, AO; Oguz, M; Ozkan, M; Uner, A; Yaman, E; Yildiz, R | 1 |
| Artells, R; Gel, B; Hernandez, R; Ibeas, R; Martinez, F; Monzo, M; Moreno, I; Moreno, J; Navarro, A; Navarro-Vigo, M | 1 |
| Alonso, V; Bovio, H; Colomer, R; Cortés-Funes, H; Escudero, P; García-Carbonero, R; Grávalos, C; Jimeno, A; Juez, I; Sevilla, I; Vega-Villegas, ME | 1 |
| Barrueco, J; Fuchs, CS; Marshall, J | 1 |
| Clarke, SJ; Hoskins, JM; Liddle, C; London, R; Rivory, LP; Sharma, R; Zucknick, M | 1 |
| Gruenberger, B; Gruenberger, T; Hacker, S; Kandutsch, S; Klinger, M; Wrba, F | 1 |
| Antonini, NF; Cats, A; Creemers, GJ; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Rodenburg, CJ; Schrama, JG; Tol, J; Vos, AH | 1 |
| Carrato, A; Gallego-Plazas, J; Guillén-Ponce, C | 1 |
| Arkenau, HT; Englisch-Fritz, C; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T | 1 |
| Balteskard, L; Berglund, A; Fokstuen, T; Ogreid, D; Pfeiffer, P; Ploen, J; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, K; Yilmaz, M | 1 |
| Clark, JW; Zuckerman, DS | 1 |
| Cohen, DJ; Hochster, HS | 1 |
| Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C | 1 |
| Katirtzoglou, NA; Saif, MW; Syrigos, KN | 1 |
| Cassidy, J; Clarke, S; Couture, F; Díaz-Rubio, E; Figer, A; Koski, S; Lichinitser, M; Rivera, F; Saltz, L; Scheithauer, W; Sirzén, F; Wong, R; Yang, TS | 1 |
| Cassidy, J; Clarke, S; Couture, F; Díaz-Rubio, E; Figer, A; Koski, S; Lichinitser, M; Rivera, F; Saltz, LB; Scheithauer, W; Sirzén, F; Wong, R; Yang, TS | 1 |
| Gruenberger, B; Gruenberger, T; Punzengruber, R; Scheithauer, W; Tamandl, D; Zielinski, C | 1 |
| Arnheim, KE | 1 |
| Allegra, C; Bertino, JR; Cassidy, J; Clarke, SJ; Cunningham, D; Douillard, JY; Gilberg, F; Gustavsson, BG; Haller, DG; Hoff, PM; Milano, G; O'Connell, M; Rothenberg, ML; Rustum, Y; Saltz, LB; Schmoll, HJ; Sirzén, F; Tabernero, J; Twelves, C; Van Cutsem, E | 1 |
| Cartwright, TH; Chu, E | 1 |
| Cassidy, J; Schmoll, HJ; Van Cutsem, E | 1 |
| Abad, A; Aparicio, J; Aranda, E; Díaz-Rubio, E; García, T; Ginés, A; Gómez-España, A; Guino, E; Maestu, I; Manzano, JL; Martinez-Balibrea, E; Martínez-Cardús, A; Sastre, J | 1 |
| Folprecht, G; Goldberg, RM; Köhne, CH; Mitry, E; Rougier, P | 1 |
| Avallone, A; Casaretti, R; Comella, P; Franco, L; Sandomenico, C | 1 |
| Alba, E; Carabantes, F; Dueñas, R; González, E; López-Siles, J; Márquez, A; Ribelles, N; Sánchez, A; Sánchez, MJ; Sánchez-Rovira, P; Sevilla, I | 1 |
| Argon, A; Aykan, NF; Basaran, M; Gumus, M; Guney, N; Saglam, S; Sakar, B; Tenekeci, AN; Ustaoglu, MA; Ustuner, Z | 1 |
| Antonini, N; Koopman, M; Mol, L; Punt, C; Simkens, L; Tol, J; van Krieken, H | 1 |
| Heinemann, V; Moosmann, N | 1 |
| Cabral, S; Federico, MH; Filho, Ude P; Franke, FA; Gampel, O; Perdicaris, MR; Ribeiro, Rde A; Segalla, JG; Skare, NG; Van Eyll, B | 1 |
| Csoka, K; Larsson, R; Liliemark, J; Nygren, P | 1 |
| Chang, E; Hahn, TM; Hertel, LW; Lawrence, TS; Shewach, DS | 1 |
| Fukuoka, M; Furuse, K; Hasegawa, K; Hirabayashi, K; Nakajima, H; Niitani, H; Noda, K; Ogura, T; Taguchi, T | 1 |
| Allman, D; Banken, L; Cassidy, J; Dirix, L; Osterwalder, B; Reigner, B; Roos, B; Twelves, C; Utoh, M; Verweij, J; Weidekamm, E | 1 |
| Meropol, NJ | 1 |
| Saeki, T; Takashima, S | 1 |
| Banken, L; Cassidy, J; Glynne-Jones, R; Goggin, T; Reigner, B; Roos, B; Schüller, J; Twelves, C; Utoh, M; Weidekamm, E | 1 |
| Brito, RA; Hoff, PM; Medgyesy, D; Pazdur, R; Ravandi-Kashani, F; Royce, ME; Zukowski, TH | 1 |
| Adjei, AA | 1 |
| Cao, S; Rustum, YM | 1 |
| Brito, R; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, M | 1 |
| Bekradda, M; Cvitkovic, E | 1 |
| Allman, D; Burger, HU; Cassidy, J; Dalley, D; Dirix, L; Findlay, M; Kocha, W; Osterwalder, B; Pazdur, R; Schölmerich, J; Seitz, JF; Twelves, C; Van Cutsem, E; Verweij, J | 1 |
| Banken, L; Cassidy, J; Dumont, E; Durston, S; Mori, K; Reigner, B; Roos, B; Schüller, J; Utoh, M; Weidekamm, E | 1 |
| Bartsch, H; Nair, J; Schmid, K; Velic, I; Winde, G | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N; Matsui, K; Myobudani, H; Nakagawa, K; Negoro, S; Nemoto, S; Nihira, S; Nogami, T; Ogawa, K; Okuda, T; Takeda, K; Takifuji, N; Yamada, M; Yamamoto, N | 1 |
| Damjanov, N; Meropol, NJ | 1 |
| Di Costanzo, F; Gasperoni, S; Sdrobolini, A | 1 |
| Grie, P; Koronkiewicz, M; Skierski, JS | 1 |
| Schilsky, RL | 1 |
| Beger, HG; Blatter, J; Butzer, U; Kornmann, M; Link, KH | 1 |
| Hoff, PM; Pazdur, R; Royce, ME | 1 |
| Peeters, M; Van Cutsem, E | 1 |
| Harstrick, A | 1 |
| Anthoney, A; Twelves, C | 1 |
| Harboe, K; Lind, A; Ogreid, D; Todnem, K; Zotova, L | 1 |
| Maeda, Y; Sasaki, T | 1 |
| Brindley, CJ; Devlin, AJ; Friberg, LE; Karlsson, MO | 1 |
| Donehower, RC | 1 |
| Dwivedy, S; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, ME; Zukowski, TH | 1 |
| Bregman, D; Manalo, J; Mani, S | 1 |
| Blesch, K; Reigner, B; Weidekamm, E | 1 |
| Barker, C; Boyer, M; Cassidy, J; Findlay, M; Hieke, K; Jamieson, C; Osterwalder, B; Twelves, C; Weitzel, C | 1 |
| Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R | 1 |
| Cunningham, D; James, RD | 1 |
| Moiseenko, VM; Orlova, RV; Semenova, AI | 1 |
| Carpini, RD; Fedier, A; Fink, D; Haller, U; Schwarz, VA; Walt, H | 1 |
| Copeland, EM; Hebig, P; Hochwald, SN; Lind, DS; Mackay, S; Malaty, J; Mishra, G; Moldawer, LL; Rekkas, S | 1 |
| Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ | 1 |
| Coleman, R; Cunningham, D | 1 |
| Coudray, AM; Faivre, S; Gespach, C; Louvet, C; Raymond, E | 1 |
| Cunningham, D; Hoff, PM; Maroun, J; Van Cutsem, E | 1 |
| Cassidy, J; Hoff, PM; Schmoll, HJ | 1 |
| Borner, M; Maroun, J; Scheithauer, W; Twelves, C; Wilke, H | 1 |
| Cunningham, D; Maroun, J; Van Cutsem, E; Vanhoefer, U | 1 |
| Cassidy, J; Schmoll, HJ | 1 |
| Johnston, PG; Kaye, S | 1 |
| Allman, D; Bajetta, E; Boyer, M; Bugat, R; Cassidy, J; Findlay, M; Frings, S; Harper, P; Jahn, M; McKendrick, J; Osterwalder, B; Perez-Manga, G; Rosso, R; Rougier, P; Schmiegel, WH; Seitz, JF; Thompson, P; Twelves, C; Van Cutsem, E; Vieitez, JM; Weitzel, C | 1 |
| Reimer, P; Rückle-Lanz, H | 1 |
| Goa, KL; McGavin, JK | 1 |
| Alvarez, E; Bergman, AM; Eriksson, S; Kroep, JR; Loves, WJ; Peters, GJ; Pinedo, HM; Talianidis, I; van der Wilt, CL; van Groeningen, CJ | 1 |
| Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
| Venturini, M | 1 |
| Carpi, A; Cherubini, R; Cognetti, F; Di Costanzo, E; Gasperoni, S; Moscetti, L; Paoloni, FP; Sdrobolini, A; Zeuli, M | 1 |
| Abushullaih, S; Hoff, PM; Munsell, M; Saad, ED | 1 |
| Boige, V; Ducreux, M; Taïeb, J | 1 |
| Adlard, JW; Quirke, P; Richman, SD; Seymour, MT | 1 |
| Hargreaves, D; Ng, T; Nguyen-Van-Tam, J; Twelves, C | 1 |
| Borner, MM; Brauchli, P; Castiglione-Gertsch, M; Dietrich, D; Goldhirsch, A; Hanselmann, S; Herrmann, R; Honegger, H; Morant, R; Müller, S; Pestalozzi, BC; Roth, AD; Saletti, P; Stupp, R; Wernli, M | 1 |
| Kerr, DJ | 1 |
| Groshen, S; Lenz, HJ; Park, DJ; Stoehlmacher, J; Tsao-Wei, D; Zhang, W | 1 |
| Hwang, JJ; Marshall, JL | 1 |
| Bajetta, E; Boyer, M; Bugat, R; Burger, U; Cassidy, J; Garin, A; Graeven, U; Hoff, P; Maroun, J; Marshall, J; McKendric, J; Osterwalder, B; Pérez-Manga, G; Rosso, R; Rougier, P; Schilsky, RL; Twelves, C; Van Cutsem, E | 1 |
| Cassidy, J; Twelves, CJ | 1 |
| Croockewit, AJ; de Boer, JE; Koopmans, PP; van Loenhout, JW | 1 |
| Aabo, K; Adimi, P; Hansen, F; Jakobsen, A; Keldsen, N; Kjaer, M; Pfeiffer, P; Sandberg, E | 1 |
| Abbruzzese, JL; Daugherty, K; Moore, DF; Pazdur, R; Tarassoff, P | 1 |
174 review(s) available for deoxycytidine and Colorectal Neoplasms
| Article | Year |
|---|---|
A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2018 |
FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Proportional Hazards Models; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Retrospective Studies | 2018 |
[Oxaliplatin in colorectal carcinoma: from palliation to cure].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Treatment Outcome | 2004 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Options for metastatic colorectal cancer beyond the second line of treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Cetuximab; Chemoembolization, Therapeutic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Pyridines | 2014 |
Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Cardiomyopathies; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leukoencephalopathies; Male; Middle Aged; Shock, Cardiogenic | 2013 |
Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Survival Rate; Treatment Outcome | 2014 |
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Genetic Markers; Humans; Polymorphism, Genetic; Predictive Value of Tests; Thymidylate Synthase | 2014 |
How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy.
Topics: Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Folic Acid; Folic Acid Antagonists; Folic Acid Deficiency; Genetic Heterogeneity; Genetic Pleiotropy; Genetic Variation; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Mutation; Thymidylate Synthase | 2015 |
Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaloacetates; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Randomized Controlled Trials as Topic; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retreatment; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Hypertriglyceridemia and hyperglycemia induced by capecitabine: a report of two cases and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hyperglycemia; Hypertriglyceridemia; Male; Middle Aged; Oxaloacetates; Triglycerides | 2015 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Use of microRNAs in directing therapy and evaluating treatment response in colorectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Chemoradiotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; MicroRNAs; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Resveratrol; Stilbenes | 2014 |
Oxaliplatin-induced Lhermitte sign. A case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Prognosis; Withholding Treatment | 2014 |
Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Publication Bias | 2015 |
Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaloacetates | 2015 |
Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Japan; Leucovorin; Lymph Node Excision; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates | 2016 |
XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Odds Ratio; Organoplatinum Compounds; Oxaloacetates; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2016 |
Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis; Randomized Controlled Trials as Topic; Risk Factors | 2008 |
Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
[Molecular targets for colon cancer. VEGF, EGFR - and what else?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capecitabine; Cetuximab; Colonoscopy; Colorectal Neoplasms; Deoxycytidine; DNA Mutational Analysis; Drug Delivery Systems; ErbB Receptors; Fluorouracil; Genotype; Humans; Mass Screening; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2008 |
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate; Thrombocytopenia; Vitamin B Complex | 2008 |
First-line therapeutic strategies in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Celecoxib; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vitamin B Complex | 2008 |
Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2010 |
Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Delivery Systems; Female; Fluorouracil; Humans; Neoplasm Metastasis; Prodrugs | 2009 |
Microsatellite instability: a predictive marker in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Databases, Bibliographic; Deoxycytidine; DNA Mutational Analysis; Fluorouracil; Humans; Microsatellite Instability; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Treatment Outcome | 2009 |
Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Genetic prognostic and predictive markers in colorectal cancer.
Topics: beta Catenin; Biomarkers, Tumor; Camptothecin; Capecitabine; Chromosomes, Human, Pair 18; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression Profiling; Genes, APC; Genes, p53; Genomic Instability; Humans; Irinotecan; Microsatellite Instability; Mutation; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
[Chemotherapy of elderly patients with colorectal cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Comorbidity; Cooperative Behavior; Decision Making; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Life Expectancy; Organoplatinum Compounds; Oxaliplatin; Patient Care Team | 2009 |
Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Maximum Tolerated Dose; Palliative Care; Treatment Outcome | 2009 |
Chemotherapy, which drugs and when.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
[The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Topics: Administration, Oral; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Precision Medicine; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2009 |
Evolution of capecitabine dosing in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Practice Guidelines as Topic; Radiotherapy | 2010 |
Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview.
Topics: Adenoma; Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Curcumin; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Oxaloacetates; Prodrugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost Savings; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Health Care Costs; Humans; Neoplasm Metastasis; Prodrugs | 2010 |
Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report.
Topics: Adenocarcinoma; Age Factors; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fatal Outcome; Female; Fluorouracil; Humans; Neurotoxicity Syndromes; Patient Selection; Risk Assessment; Risk Factors | 2011 |
Capecitabine-based chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2011 |
Update on capecitabine alone and in combination regimens in colorectal cancer patients.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Prodrugs; Radiotherapy, Adjuvant | 2010 |
XELOX in colorectal cancer: a convenient option for the future?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Humans; Oxaloacetates; Treatment Outcome | 2011 |
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Multivariate Analysis; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome | 2011 |
5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Biomarker-based selection of therapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; RNA, Messenger; Sequence Analysis, DNA | 2011 |
Common side effects and interactions of colorectal cancer therapeutic agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Complementary Therapies; Deoxycytidine; Drug Interactions; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab | 2011 |
Unilateral hand-foot syndrome: does it take sides? Case report and literature review.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Review Literature as Topic | 2012 |
DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; DNA Copy Number Variations; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; Humans; Leucovorin; Pemetrexed; Treatment Outcome | 2011 |
Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycin; Mutation; Organoplatinum Compounds; Oxaloacetates; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Vascular Endothelial Growth Factor A | 2012 |
Oxaliplatin: a review of approved uses.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin | 2012 |
Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis.
Topics: Capecitabine; Colorectal Neoplasms; Databases, Genetic; Deoxycytidine; Fluorouracil; Folic Acid; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Variation; Genotype; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Tetrahydrofolate Dehydrogenase; Thymidylate Synthase | 2012 |
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2012 |
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Codon; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Mutation; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; ras Proteins; Treatment Outcome | 2012 |
Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cardiovascular Agents; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Heart Diseases; Humans | 2013 |
[Colorectal carcinoma: what's new?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colonoscopy; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Endosonography; Fluorouracil; Humans; Liver Neoplasms; Mass Screening; Metastasectomy; Multimodal Imaging; Neoplasm Staging; Occult Blood; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Positron-Emission Tomography; Practice Guidelines as Topic; Pyridines; Salvage Therapy; Tomography, X-Ray Computed | 2012 |
Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Drug Hypersensitivity; Drug Interactions; Gemcitabine; Head and Neck Neoplasms; Humans; Irinotecan; Pancreatic Neoplasms | 2002 |
Oral fluoropyrimidine treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Patient Compliance; Prodrugs; Pyridines; Tegafur; Treatment Outcome | 2001 |
Advances in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cancer Vaccines; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Uracil | 2001 |
Capecitabine (Xeloda): from the laboratory to the patient's home.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Design; Fluorouracil; Humans; Kidney; Liver | 2002 |
Current status of capecitabine in the treatment of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Risk Factors; Stomatitis; Survival; Treatment Outcome | 2002 |
Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Hospitalization; Humans; Leucovorin; Multicenter Studies as Topic; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prodrugs | 2002 |
The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2003 |
Practical considerations in the use of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 2003 |
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 2; Deoxycytidine; Drug Administration Schedule; Enzyme Inhibitors; Flavonoids; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Isoenzymes; Leucovorin; Membrane Proteins; Organoplatinum Compounds; Oxaliplatin; Piperidines; Prostaglandin-Endoperoxide Synthases; Quinazolines; Thiophenes; Treatment Outcome | 2003 |
[Oral fluoropyrimidines in the treatment of colorectal carcinoma].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Prodrugs; Tegafur; Uracil | 2003 |
Current and ongoing trials with irinotecan in the United States.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Pyrazoles; Sulfonamides | 2003 |
[Doxifluridine for treatment of colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Floxuridine; Fluorouracil; Humans; Pentosyltransferases; Prodrugs; Prognosis; Pyrimidine Phosphorylases; Thymidine Phosphorylase | 2003 |
[Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Oxonic Acid; Prognosis; Pyridines; Tegafur; Thymidylate Synthase; Uracil | 2003 |
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Pyridines; Tegafur; United States; Uracil | 2003 |
[Adjuvant chemotherapy for colorectal carcinoma after curative resection].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colectomy; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Evidence-Based Medicine; Fluorouracil; Humans; Leucovorin; Levamisole; Pharmacogenetics; Polymorphism, Genetic; Prognosis | 2003 |
Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Immunotherapy; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2003 |
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm Metastasis; Tegafur; United Kingdom; Uracil | 2003 |
Integrating oxaliplatin and capecitabine in adjuvant therapy of high-risk colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin | 2003 |
Development of new agents for the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2003 |
New developments in systemic chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2003 |
The role of new agents in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2004 |
Progress in the development of novel treatments for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2004 |
Current strategies in previously untreated advanced colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2004 |
Current status of adjuvant therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Europe; Fluorouracil; Humans; Leucovorin; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; United States | 2004 |
[New therapy options in colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Treatment Outcome | 2004 |
Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
Topics: Activities of Daily Living; Algorithms; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Decision Trees; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Monitoring; Fluorouracil; Foot; Hand; Humans; Nurse's Role; Nursing Assessment; Oncology Nursing; Paresthesia; Patient Education as Topic; Primary Prevention; Severity of Illness Index; Skin Care; Syndrome | 2004 |
Implementation of capecitabine (Xeloda) into a cancer centre: UK experience.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Cancer Care Facilities; Capecitabine; Colorectal Neoplasms; Cost Savings; Critical Pathways; Deoxycytidine; Fluorouracil; Home Care Services; Humans; Medical Oncology; Nurse's Role; Oncology Nursing; Organizational Innovation; Patient Education as Topic; Program Development; State Medicine; Time Factors; United Kingdom | 2004 |
Implications of capecitabine (Xeloda) for cancer nursing practice.
Topics: Administration, Oral; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Communication; Deoxycytidine; Documentation; Drug Monitoring; Fluorouracil; Home Care Services; Humans; Nurse's Role; Nursing Records; Oncology Nursing; Patient Acceptance of Health Care; Patient Care Team; Patient Education as Topic; Professional Autonomy; Time Factors | 2004 |
[Advances in palliative and adjuvant chemotherapy of colon cancer].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Levamisole; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Tegafur; Uracil | 2004 |
Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Erythema; Female; Fluorouracil; Foot; Hand; Humans; Male; Patient Education as Topic; Syndrome | 2004 |
Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans | 2004 |
[Recent results of irinotecan therapy in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Survival Analysis; Treatment Outcome | 2004 |
Systemic therapy for colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Prodrugs; Pyridines | 2005 |
Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Epothilones; Fluorouracil; Glutamates; Guanine; Humans; Indoles; Organoplatinum Compounds; Oxaliplatin; Pemetrexed | 2005 |
Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Prodrugs | 2005 |
Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Esophageal Neoplasms; Gastrointestinal Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum Compounds; Stomach Neoplasms | 2004 |
Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Prodrugs | 2005 |
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Erythema; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Retrospective Studies; Skin Diseases; Treatment Outcome | 2005 |
The development of clinical research in CRC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasm Staging; Palliative Care; Prodrugs; Prognosis; Quality of Life; Sentinel Lymph Node Biopsy; Survival Rate | 2005 |
Current therapies for advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin | 2005 |
Capecitabine: effective oral fluoropyrimidine chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Contraindications; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Prodrugs; Randomized Controlled Trials as Topic | 2005 |
The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Myocardial Ischemia; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Risk Factors; Thromboembolism | 2005 |
[Chemotherapy of patients with colorectal carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Incidence; Irinotecan; Leucovorin; Neoplasm Staging; Netherlands; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis | 2005 |
Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Quality of Life; Retrospective Studies; Treatment Outcome | 2005 |
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cause of Death; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Costs; Drug Hypersensitivity; Drug Industry; Female; Fluorouracil; Humans; Irinotecan; Male; Medical Assistance; Nausea; Neoplasm Staging; Nurse's Role; Oncology Nursing; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Patient Education as Topic; Treatment Outcome; United States; Vomiting | 2005 |
Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Vitamin B Complex | 2005 |
Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Pyrimidines; Treatment Outcome | 2005 |
Capecitabine/Oxaliplatin combinations in advanced colorectal cancer: summary of recent randomized studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2005 |
Chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tegafur; Uracil; Vitamin B Complex | 2005 |
Capecitabine in the treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Forecasting; Humans; Prodrugs | 2005 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Lung Neoplasms; Lymphoma, Non-Hodgkin; Mucositis; Neoplasms; Prednisone; Radiotherapy; Severity of Illness Index; Stomatitis; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2006 |
[Irinotecan for the treatment of metastatic colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Folic Acid; Humans; Irinotecan; Maximum Tolerated Dose; Multicenter Studies as Topic; Pharmacogenetics | 2006 |
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; State Medicine; Tegafur; Treatment Outcome; United Kingdom; Uracil | 2006 |
Biological agents versus chemotherapy in the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2006 |
[Capecitabine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Neoplasms; Survival Rate | 2006 |
[Adjuvant treatment of colorectal cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Tegafur; Uracil | 2006 |
Surgical adjuvant therapy for colorectal cancer: current approaches and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant | 2006 |
Capecitabine: a new adjuvant option for colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Cause of Death; Colorectal Neoplasms; Continuity of Patient Care; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Interactions; Fluorouracil; Humans; Infusions, Intravenous; Life Style; Multivariate Analysis; Nausea; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Care Planning; Risk Factors; Safety Management; Stomatitis; United States; Vomiting | 2006 |
Update on capecitabine in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans | 2006 |
Oral capecitabine (Xeloda) in cancer treatment.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Fetus; Fluorouracil; Humans; Nurse's Role; Patient Education as Topic; Treatment Outcome | 2007 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Sample Size; Survival Analysis | 2008 |
Capecitabine in the treatment of colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans | 2007 |
[Gemcitabine and digestive carcinomas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Cisplatin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Digestive System Neoplasms; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Stomach Neoplasms | 2007 |
Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.
Topics: Adult; Antiemetics; Antineoplastic Agents, Phytogenic; Ataxia; Camptothecin; Capecitabine; Central Nervous System; Colorectal Neoplasms; Cytotoxins; Deoxycytidine; Dexamethasone; Dysarthria; Female; Fluorouracil; Granisetron; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Sarcoma, Small Cell; Serotonin Antagonists; Topoisomerase I Inhibitors | 2008 |
Treatment of advanced colorectal cancer in the elderly.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colectomy; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Stents | 2007 |
The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Death; Cell Survival; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Tegafur; Treatment Outcome; Uracil; Vascular Endothelial Growth Factor A | 2007 |
Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Pyridines; Survival Analysis | 2008 |
Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Vascular Endothelial Growth Factor A | 2007 |
Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biological Therapy; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Protein-Tyrosine Kinases; Signal Transduction; Vascular Endothelial Growth Factor A | 2007 |
Capecitabine: an overview of the side effects and their management.
Topics: Administration, Oral; Age Factors; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Humans; Male; Patient Education as Topic; Prodrugs | 2008 |
Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans | 2008 |
Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Fluorouracil; Humans; Neoplasm Staging; Netherlands; Organoplatinum Compounds; Oxaliplatin; Receptors, Vascular Endothelial Growth Factor | 2008 |
Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2008 |
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil | 1998 |
Oral fluoropyrimidines in the treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Humans; Oxidoreductases; Pyridines; Tegafur; Uracil | 1998 |
[Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Mice; Mice, Nude; Stomach Neoplasms | 1999 |
Fluoropyrimidines: a critical evaluation.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Leucovorin; Oxonic Acid; Pyridines; Tegafur; Uracil | 1999 |
Potential of Xeloda in colorectal cancer and other solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasms | 1999 |
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Glutamates; Guanine; Humans; Pemetrexed; Platinum Compounds; Pyridines; Quinazolines; Tegafur; Thiophenes; Uracil | 1999 |
New drugs in therapy of colorectal cancer: preclinical studies.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Humans; Oxidoreductases; Prodrugs; Quinazolines; Tegafur; Thiophenes; Thymidine Phosphorylase; Thymidylate Synthase; Uracil | 1999 |
Oral fluoropoyrimidines.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Humans; Leucovorin; Oxidoreductases; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 1999 |
Oxaliplatin: a new therapeutic option in colorectal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Synergism; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 1999 |
Oral therapy for colorectal cancer: how to choose.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Availability; Capecitabine; Colorectal Neoplasms; Decision Making; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Humans; Leucovorin; Tegafur; Uracil | 2000 |
Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Prodrugs; Treatment Outcome | 2000 |
Pharmacology and clinical status of capecitabine.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Fluorouracil; Humans | 2000 |
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?
Topics: Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunotherapy; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes | 2000 |
Oral fluoropyrimidines in colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Leucovorin; Oxonic Acid; Pyridines; Tegafur; Uracil | 2000 |
Rational development of capecitabine.
Topics: Animals; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Evaluation, Preclinical; Fluorouracil; Humans | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pyridines; Stomach Neoplasms; Tegafur; Uracil | 2000 |
[Fluorinated pyrimidines in oral treatment of advanced colorectal cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Humans; Leucovorin; Oxidoreductases; Prodrugs; Pyrimidines; Tegafur; Uracil | 2000 |
[Progress in chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxonic Acid; Pyridines; Tegafur | 2000 |
Role of oral chemotherapy in colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin | 2000 |
Colorectal cancer: chemotherapy treatment overview.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome; Uracil | 2000 |
Novel combinations with oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes | 2000 |
Capecitabine in colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Meta-Analysis as Topic; Middle Aged; Radiation, Ionizing; Survival Rate | 2001 |
Clinical pharmacokinetics of capecitabine.
Topics: Antacids; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Fluorouracil; Food; Humans; Intestinal Absorption; Leucovorin; Liver Diseases; Paclitaxel; Protein Binding; Taxoids | 2001 |
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Pyrimidines; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms | 2001 |
New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Humans; Outpatients; Tegafur; Uracil | 2001 |
[Preclinical studies of oxaliplatin in combination chemotherapy].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Mice; Models, Biological; Organoplatinum Compounds; Oxaliplatin; Tumor Cells, Cultured | 2001 |
The evolution of fluoropyrimidine therapy: from intravenous to oral.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Neoplasm Staging; Randomized Controlled Trials as Topic; Retrospective Studies | 2001 |
Answering patients' needs: oral alternatives to intravenous therapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Patient Satisfaction; Quality of Life; Tegafur; Uracil | 2001 |
Optimizing the use of irinotecan in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Quality of Life; Retrospective Studies; Survival Analysis; Treatment Outcome | 2001 |
Integrating oxaliplatin into the management of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin | 2001 |
Capecitabine: a novel agent for the treatment of solid tumors.
Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Prodrugs | 2001 |
Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Prodrugs; Randomized Controlled Trials as Topic | 2001 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer.
Topics: Absorption; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Interactions; Enzyme Induction; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Survival Analysis; Up-Regulation | 2001 |
Rational development of capecitabine.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Mice; Mice, Nude; Prodrugs; Randomized Controlled Trials as Topic; Survival Analysis | 2002 |
[The new chemotherapy of colorectal cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Postoperative Care; Prodrugs; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes; Time Factors | 2002 |
Prediction of the response of colorectal cancer to systemic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Survival Rate; Treatment Outcome | 2002 |
Capecitabine/irinotecan combination regimens in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan | 2002 |
Capecitabine: fulfilling the promise of oral chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms; Prodrugs | 2002 |
Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Pyrimidines; Research Design; Safety | 2002 |
[Oral fluoropyrimidines registered for the treatment of metastatic colorectal carcinoma: a possible gain].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Pyrimidines; Tegafur; Uracil | 2002 |
295 trial(s) available for deoxycytidine and Colorectal Neoplasms
| Article | Year |
|---|---|
A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Tapering; Fluorouracil; Humans; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Treatment Outcome | 2022 |
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Frontotemporal Dementia; Gemcitabine; Humans; Irinotecan; Prospective Studies; Trifluridine | 2023 |
Fast-track multidisciplinary treatment versus conventional treatment for colorectal cancer: a multicenter, open-label randomized controlled study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Costs and Cost Analysis; Deoxycytidine; Female; Fluorouracil; Humans; Laparoscopy; Length of Stay; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Quality of Life; Treatment Outcome | 2019 |
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxaliplatin; Treatment Outcome | 2020 |
Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Sorafenib; Treatment Outcome | 2021 |
Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Deoxycytidine; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Leucovorin; Male; Middle Aged; Prognosis; Progression-Free Survival; Topoisomerase I Inhibitors; Treatment Outcome; Young Adult | 2021 |
Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Cytokines; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Prospective Studies; Treatment Outcome | 2019 |
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Folic Acid; Humans; Irinotecan; Leucovorin; Male | 2019 |
A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Prognosis; Simvastatin; Survival Analysis; Treatment Outcome | 2019 |
Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; CD8-Positive T-Lymphocytes; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hydrogen; Japan; Lymphocyte Activation; Male; Masks; Middle Aged; Neoplasm Staging; Oxaloacetates; Prognosis; Programmed Cell Death 1 Receptor; Progression-Free Survival; Respiratory Therapy; Treatment Outcome | 2019 |
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; Cholangiocarcinoma; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoplasm Staging; Niacinamide; Protein Kinase Inhibitors; Ramucirumab; Squamous Cell Carcinoma of Head and Neck | 2019 |
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Indazoles; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2013 |
An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Inflammation; Leucovorin; Lymphocytes; Male; Neutrophils; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prognosis; Proportional Hazards Models; Prospective Studies; Pyrimidines; Reproducibility of Results | 2013 |
Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Netherlands; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Treatment Outcome | 2013 |
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Republic of Korea; Young Adult | 2013 |
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Prognosis; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Indoles; Irinotecan; Maximum Tolerated Dose; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think!
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Digestive System Surgical Procedures; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate | 2013 |
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Cecum; Colon, Descending; Colon, Sigmoid; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Rectum; Sigmoid Neoplasms; Survival; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2013 |
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Calcium-Binding Proteins; Camptothecin; Capecitabine; Colorectal Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; EGF Family of Proteins; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Leucovorin; Male; MicroRNAs; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaloacetates; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Sweden; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; DNA Copy Number Variations; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Prognosis; PTEN Phosphohydrolase; ras Proteins | 2013 |
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Piperazines; Prospective Studies; Pyrimidines; Treatment Outcome | 2013 |
Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Oxaloacetates; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030).
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Glomerular Filtration Rate; Humans; Male; Metabolic Clearance Rate; Middle Aged; Sex Factors | 2013 |
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Survival Rate | 2013 |
Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Comorbidity; Creatinine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Oxaloacetates | 2013 |
Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Prognosis; Treatment Outcome | 2013 |
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.
Topics: Adult; Aged; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; EGF Family of Proteins; Erlotinib Hydrochloride; Female; Fluorouracil; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Mutation; Neoplasm Metastasis; Oxaloacetates; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Transforming Growth Factor alpha | 2013 |
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Proteins; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Organoplatinum Compounds; Oxaloacetates; Placebos; Predictive Value of Tests; Prognosis; Quinazolines; Survival Analysis | 2013 |
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Dasatinib; Deoxycytidine; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Vascular Endothelial Growth Factor A | 2014 |
The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Australia; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Mitomycin; Quality of Life; Treatment Outcome | 2014 |
Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates | 2013 |
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Leucovorin; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2014 |
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Middle Aged; Treatment Outcome | 2013 |
Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Analysis; Tomography, X-Ray Computed | 2014 |
A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Treatment Outcome | 2013 |
Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Translational Research, Biomedical | 2014 |
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Delayed-Action Preparations; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Loperamide; Male; Middle Aged; Octreotide; Quality of Life; Severity of Illness Index; Young Adult | 2014 |
Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheterization, Central Venous; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Vascular Access Devices | 2014 |
Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Isotope Labeling; Male; Middle Aged; Neoplasm Metastasis; Patient Selection; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed | 2014 |
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Treatment Outcome | 2014 |
Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research G
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2014 |
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Treatment Outcome | 2013 |
Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male | 2014 |
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Organoplatinum Compounds; Oxaliplatin | 2014 |
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Republic of Korea; Salvage Therapy; Tegafur; Treatment Outcome; Uracil | 2014 |
Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; California; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Frail Elderly; Geriatric Assessment; Health Status; Humans; Male; Middle Aged; Prospective Studies; Quality of Life; Surveys and Questionnaires | 2014 |
Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cytokine-Induced Killer Cells; Deoxycytidine; Female; Fluorouracil; Humans; Immunotherapy, Adoptive; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Retrospective Studies | 2014 |
Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2014 |
A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Treatment Outcome; Young Adult | 2014 |
Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Evidence-Based Medicine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Practice Patterns, Physicians'; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; United Kingdom | 2015 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2014 |
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Retreatment; Treatment Outcome | 2014 |
Oxaliplatin and ototoxicity: is it really safe for hearing?
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Hearing Loss; Hearing Tests; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2014 |
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2015 |
Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Oxaloacetates; Predictive Value of Tests; Treatment Outcome | 2015 |
A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2015 |
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2015 |
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Deoxycytidine; DNA, Neoplasm; Female; Fluorouracil; Genes, ras; Humans; Male; Mitomycin; Mutation; Phosphatidylinositol 3-Kinases; Prognosis | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2015 |
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Morpholines; Nausea; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Vomiting | 2015 |
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Drugs, Chinese Herbal; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Quality of Life; Stomatitis; Young Adult | 2015 |
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Female; Fluorouracil; Humans; Intention to Treat Analysis; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Oxaloacetates; Prospective Studies; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Quality of Life; Risk Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2015 |
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Mitomycin; Neoplasm Metastasis; Vascular Endothelial Growth Factor D | 2015 |
The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Japan; Male; Middle Aged; Pyridoxine; Risk Factors; Time Factors; Treatment Failure; Young Adult | 2014 |
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Humans; Japan; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prospective Studies | 2016 |
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2015 |
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retreatment; Survival Rate | 2016 |
Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Sulfonamides | 2016 |
Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; CpG Islands; Deoxycytidine; Disease-Free Survival; DNA Methylation; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Phenotype; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Treatment Outcome | 2016 |
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; China; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2016 |
Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Prospective Studies; Time Factors; Treatment Outcome | 2016 |
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Analysis | 2008 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2008 |
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Fever; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin | 2008 |
Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Cross-Over Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Leucovorin; Male; Middle Aged; Neoplasm Staging; Probability; Prospective Studies; Reference Values; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome | 2008 |
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2008 |
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Rectal Neoplasms; Survival Analysis; Time Factors | 2009 |
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminoquinolines; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged | 2008 |
GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genotype; Glutathione S-Transferase pi; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Genetic | 2008 |
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pain Measurement; Survival Analysis; Treatment Outcome | 2008 |
Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2008 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines | 2009 |
Preoperative chemoradiation for locally advanced rectal cancer with capecitabine 2,000 mg/m2/day.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Preoperative Care; Vitamin B Complex; Young Adult | 2008 |
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Quality of Life; Statistics, Nonparametric; Treatment Outcome | 2008 |
A dynamic model of hand-and-foot syndrome in patients receiving capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Models, Biological; Reproducibility of Results; Syndrome; Young Adult | 2009 |
A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2009 |
Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Codon; Colorectal Neoplasms; Deoxycytidine; Epidemiologic Methods; Female; Fluorouracil; Genetic Predisposition to Disease; Genotype; Glutathione S-Transferase pi; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Treatment Outcome | 2009 |
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); DNA-Binding Proteins; Drug Administration Schedule; Drug Resistance, Neoplasm; Endonucleases; Female; Fluorouracil; Gene Expression; Humans; Male; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; RNA, Messenger; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Failure | 2008 |
Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Patient Compliance; Patient Selection; Radiotherapy, High-Energy; Survival Analysis; Treatment Outcome | 2009 |
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Organoplatinum Compounds; Oxaliplatin | 2009 |
DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gene Dosage; Humans; Irinotecan; Male; Middle Aged; Predictive Value of Tests; Prognosis | 2009 |
Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Tolerance; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies | 2009 |
Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prognosis; Survival Rate; Treatment Outcome; United Kingdom | 2009 |
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Adenosquamous; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; DNA Methylation; DNA Mismatch Repair; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Incidence; Irinotecan; Male; Microsatellite Instability; Middle Aged; MutL Protein Homolog 1; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Prognosis; Promoter Regions, Genetic; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2009 |
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; ras Proteins; Treatment Failure; Vascular Endothelial Growth Factor A | 2009 |
Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2009 |
XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2009 |
Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Pyrazoles; Sulfonamides; Survival Rate | 2009 |
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neutropenia; Prospective Studies; Survival Analysis; Treatment Outcome | 2009 |
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Young Adult | 2009 |
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2009 |
Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Folic Acid; Health Care Costs; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Retrospective Studies; Treatment Outcome | 2009 |
Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Capecitabine; Cell Cycle Proteins; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Endonucleases; Fluorouracil; Humans; Irinotecan; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Transcription Factors; Tumor Suppressor Proteins | 2009 |
[Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Chronotherapy; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates | 2010 |
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival Analysis; Treatment Outcome | 2010 |
Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Tegafur | 2009 |
Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 2009 |
A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged | 2010 |
Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates | 2010 |
Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Case-Control Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Home Care Services; Humans; Male; Middle Aged; Palliative Care; Quality of Life | 2009 |
Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Patient Satisfaction; Prospective Studies; Quality of Life; Surveys and Questionnaires | 2010 |
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Thymidine Phosphorylase; Thymidylate Synthase | 2010 |
Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheter Ablation; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cryosurgery; Deoxycytidine; Dexamethasone; Drug Administration Schedule; Feasibility Studies; Female; Floxuridine; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Risk Assessment; Time Factors; Treatment Outcome; United States | 2010 |
Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Treatment Outcome | 2010 |
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Capecitabine; Colorectal Neoplasms; Demography; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Proportional Hazards Models; Protein Kinase Inhibitors; Treatment Failure | 2011 |
Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Glutathione S-Transferase pi; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Survival Analysis | 2010 |
[Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Foot Dermatoses; Hand Dermatoses; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Syndrome; Thrombocytopenia | 2010 |
[Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Endostatins; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Recombinant Proteins | 2010 |
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male | 2010 |
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Japan; Male; Middle Aged; Nausea; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Sensation Disorders; Treatment Outcome | 2010 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Treatment Outcome; Young Adult | 2011 |
Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Colorectal Neoplasms; Cross-Over Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Humans; Male; Middle Aged | 2011 |
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Australasia; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Hypotension; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Quality of Life; Thrombocytopenia; Treatment Outcome | 2010 |
Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2010 |
A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2010 |
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quality of Life | 2011 |
Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaloacetates; Patient Selection; Treatment Outcome | 2011 |
Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Recombinant Fusion Proteins; Salvage Therapy; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
[Efficacy and safety of bevacizumab plus capecitabine for metastatic colorectal cancer].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Treatment Outcome | 2010 |
Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Erythema; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Pyridoxine; Vitamin B Complex | 2010 |
A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Recurrence; Treatment Outcome | 2010 |
Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Enhancer Elements, Genetic; Fluorouracil; Genetic Association Studies; Genotype; Humans; Kaplan-Meier Estimate; Multifactor Dimensionality Reduction; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Proportional Hazards Models; Thymidylate Synthase; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis | 2011 |
The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Calcium; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Magnesium; Male; Middle Aged; Neuroprotective Agents; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2011 |
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Neoplasm Staging; Prospective Studies | 2011 |
Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Gluconate; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Magnesium Sulfate; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Retrospective Studies; Treatment Outcome; Young Adult | 2010 |
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Time Factors; Treatment Outcome; United States | 2012 |
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cinnamates; Colorectal Neoplasms; Cyclohexanes; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epoxy Compounds; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Models, Statistical; Oxaloacetates; Republic of Korea; Sesquiterpenes; Survival Analysis; Treatment Failure | 2012 |
Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Blotting, Western; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Genetic; Retrospective Studies; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2011 |
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; DNA, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Phosphatidylinositol 3-Kinases; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate; Treatment Outcome | 2011 |
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Risk Factors | 2011 |
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Germany; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost of Illness; Costs and Cost Analysis; Deoxycytidine; Female; Fluorouracil; Health Care Costs; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2011 |
[Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates | 2011 |
Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; DNA, Neoplasm; Fluorouracil; Humans; Mutation; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate; Tumor Suppressor Protein p53 | 2011 |
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Frail Elderly; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quality of Life; United Kingdom | 2011 |
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Survival Rate; Thrombocytopenia | 2012 |
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Fluorouracil; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Quinazolines | 2011 |
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate | 2011 |
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA Mutational Analysis; Female; Fluorouracil; Genes, ras; Humans; Male; Middle Aged; Mitomycin; Mutation; Proto-Oncogene Proteins B-raf; ras Proteins; Treatment Outcome | 2011 |
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaloacetates; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Incidence; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Skin Diseases; Treatment Outcome | 2011 |
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Molecular Targeted Therapy; Obesity; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
[Results of adjuvant chemotherapy (XELOX) of advanced colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Tract; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxaloacetates; Papillon-Lefevre Disease; Prospective Studies; Retrospective Studies; Treatment Outcome; Vascular Neoplasms | 2011 |
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cell Count; Colorectal Neoplasms; Deoxycytidine; Endothelial Cells; Endothelium, Vascular; Female; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2011 |
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome; Young Adult | 2011 |
A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2011 |
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Neoplasm Metastasis; Quality of Life | 2011 |
Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
Topics: Adenocarcinoma; Aged; Algorithms; Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Pyrazoles; Sulfonamides | 2012 |
Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Phosphorylcholine | 2011 |
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Liver Neoplasms; Logistic Models; Lung Neoplasms; Male; Proportional Hazards Models; Treatment Outcome | 2012 |
Fast track multi-discipline treatment (FTMDT trial) versus conventional treatment in colorectal cancer--the design of a prospective randomized controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Protocols; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Laparoscopy; Length of Stay; Leucovorin; Oxaloacetates; Prospective Studies | 2011 |
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Treatment Outcome | 2012 |
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Greece; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Treatment Outcome | 2012 |
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2012 |
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Survival Rate; Treatment Outcome | 2012 |
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2012 |
First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2012 |
Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable fo
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Hypertension; Kaplan-Meier Estimate; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2012 |
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Case-Control Studies; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Dendritic Cells; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Gemcitabine; Humans; Immunomodulation; Immunotherapy; Interleukin-2; Irinotecan; Killer Cells, Natural; Male; Middle Aged; Recombinant Proteins; T-Lymphocyte Subsets | 2012 |
A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2012 |
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Analysis; Treatment Outcome | 2012 |
Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Irinotecan; Male; Mutation; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Prognosis; Retrospective Studies; Signal Transduction; Skin; Treatment Outcome | 2013 |
Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Vomiting | 2012 |
Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Colorectal Neoplasms; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Conformal | 2012 |
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Osteopontin; Treatment Outcome | 2012 |
Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Treatment Outcome | 2013 |
A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Placebos; Pyridoxine | 2012 |
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Incidence; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prospective Studies | 2012 |
Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group CO06-01.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Quality of Life; Treatment Outcome | 2013 |
Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Tract; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2012 |
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brazil; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Proportional Hazards Models; Pyridines; Quinazolines; Survival Analysis | 2012 |
Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Rectal Neoplasms; Treatment Outcome | 2012 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Republic of Korea; Tegafur | 2012 |
Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Cross-Over Studies; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Tablets; Therapeutic Equivalency | 2013 |
XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; Humans; Male; Oxaloacetates; Survival Rate; Treatment Outcome | 2013 |
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prospective Studies; Republic of Korea; Thrombocytopenia; Treatment Outcome | 2014 |
Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Postoperative Complications; Preoperative Care; Prognosis; Prospective Studies; Survival Rate | 2013 |
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Genes, ras; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2012 |
[Effects of qisheng mixture on chemotherapy induced myelosuppression in patients with colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drugs, Chinese Herbal; Erythrocyte Count; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hemoglobins; Humans; Leucovorin; Leukocyte Count; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Platelet Count | 2012 |
Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome; Tumor Burden | 2013 |
Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Randomized Controlled Trials as Topic | 2013 |
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Quality of Life; Time Factors; Treatment Outcome; Venous Thrombosis | 2013 |
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Folic Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2002 |
Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Treatment Outcome | 2002 |
Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine.
Topics: Animals; Antimetabolites, Antineoplastic; Bile; Biotransformation; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Hydroxylation; In Vitro Techniques; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Prodrugs; Rats; Tissue Distribution | 2002 |
Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Urologic Neoplasms | 2002 |
Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta-Alanine; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Leucovorin; Male; Middle Aged | 2003 |
Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2003 |
Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2003 |
Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged | 2003 |
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis | 2004 |
Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma; Colorectal Neoplasms; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Probability; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Injections, Intravenous; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Survival Analysis; Treatment Outcome | 2004 |
A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Fluorouracil; Foot Dermatoses; Guideline Adherence; Hand Dermatoses; Humans; Hyperbilirubinemia; Japan; Lymphopenia; Middle Aged; Patient Selection; Survival Rate; Syndrome; Time Factors; Treatment Outcome | 2004 |
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2004 |
Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Survival Rate; United States | 2004 |
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Safety; Survival Rate | 2004 |
Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Survival Analysis; Treatment Outcome | 2004 |
First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Survival Rate | 2004 |
Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Treatment Outcome | 2004 |
Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Failure; Treatment Outcome | 2005 |
A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Italy; Male; Maximum Tolerated Dose; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Quality of Life; Treatment Outcome | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gene Frequency; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Linkage Disequilibrium; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Polymorphism, Genetic; Prognosis; Prospective Studies; Treatment Outcome; UDP-Glucuronosyltransferase 1A9 | 2005 |
Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Mitomycin; Survival Analysis; Treatment Outcome | 2005 |
Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male | 2005 |
Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Italy; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms | 2005 |
Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Analysis | 2005 |
[Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2005 |
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged | 2005 |
Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Italy; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2005 |
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Neoplasms; Colorectal Neoplasms; Cytotoxicity, Immunologic; Deoxycytidine; Disease Progression; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Infusions, Intravenous; Interleukin-2; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; T-Lymphocytes, Regulatory; Thymidylate Synthase; Treatment Outcome | 2005 |
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paresthesia; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2005 |
A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Trimetrexate | 2005 |
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Failure | 2006 |
A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cross-Over Studies; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Patient Satisfaction; Surveys and Questionnaires | 2006 |
The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Thalidomide; Treatment Outcome | 2006 |
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Time Factors | 2006 |
A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Fatigue; Female; Fluorouracil; Folic Acid; Homocysteine; Humans; Male; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Survival Analysis | 2006 |
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Creatinine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2006 |
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis | 2006 |
Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2006 |
Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2006 |
Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Pain; Peripheral Nervous System Diseases; Pyrazoles; Retrospective Studies; Sulfonamides; Survival Analysis; Treatment Outcome | 2006 |
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Netherlands; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2006 |
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Feasibility Studies; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Logistic Models; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2006 |
Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prodrugs; Sample Size; Survival Analysis; Treatment Outcome | 2007 |
Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cross-Over Studies; Deoxycytidine; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Patient Satisfaction | 2006 |
Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Salvage Therapy; Survival Rate; Time Factors | 2007 |
Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Fluorouracil; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2006 |
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Incidence; Leucovorin; Male; Middle Aged; Neoplasm Staging; Nervous System; Nervous System Diseases; Organoplatinum Compounds; Severity of Illness Index; Treatment Outcome | 2006 |
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Failure | 2008 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Sample Size; Survival Analysis | 2008 |
Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA Mismatch Repair; Female; Fluorouracil; Gene Expression; Humans; Male; Microsatellite Instability; Middle Aged; MutS Homolog 2 Protein; Prodrugs; Prognosis; Survival Analysis; Treatment Outcome | 2007 |
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2007 |
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Tri
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Spain; Treatment Outcome | 2007 |
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2007 |
A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Rate | 2007 |
Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome | 2007 |
Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Capecitabine; Colorectal Neoplasms; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Irinotecan; Liver Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Risk Assessment; Survival Analysis; Treatment Outcome | 2007 |
Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Survival Analysis; Treatment Outcome | 2007 |
Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Survival Analysis | 2007 |
Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Survival Rate; Treatment Outcome | 2007 |
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Diarrhea; Double-Blind Method; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Pulmonary Embolism; Pyrazoles; Shock, Septic; Sulfonamides; Survival Analysis | 2008 |
Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Rate | 2008 |
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines | 2008 |
Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fatty Liver; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Leucovorin; Liver; Liver Neoplasms; Male; Middle Aged; Morbidity; Organoplatinum Compounds; Oxaloacetates; Prognosis; Retrospective Studies; Risk Factors | 2008 |
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Eruptions; Female; Fluorouracil; Humans; Incidence; Male; Middle Aged; Netherlands; Organoplatinum Compounds; Oxaliplatin; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2008 |
Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2008 |
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chronotherapy; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxaloacetates; Treatment Failure; Treatment Outcome | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Infusions, Intravenous; Liver Neoplasms; Liver Regeneration; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Survival Rate | 2008 |
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Placebos | 2008 |
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prospective Studies; Treatment Outcome | 2008 |
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Patient Selection; Polymorphism, Genetic; Prospective Studies; Treatment Outcome | 2008 |
[An early phase II study of gemcitabine hydrochloride (LY 188011). Gemcitabine Cooperative Study Group for Early Phase II].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms | 1996 |
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Capecitabine; Colorectal Neoplasms; Cross-Over Studies; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Food-Drug Interactions; Humans; Male; Middle Aged | 1998 |
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Analysis | 2000 |
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressure Liquid; Colon; Colorectal Neoplasms; Cytidine Deaminase; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Liver; Male; Middle Aged; Oxidoreductases; Prodrugs; Rectum; Spectrophotometry, Ultraviolet; Thymidine Phosphorylase | 2000 |
Phase I trial of oral 2'-deoxy-2'-methylidenecytidine: on a daily x 14-day schedule.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; Deoxyuridine; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Time Factors | 2000 |
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hospitals; Humans; Leucovorin; Male; Middle Aged; Patient Acceptance of Health Care; Prospective Studies | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Injections, Intravenous; Leucovorin; Male; Middle Aged; Nausea; Stomatitis; Survival Analysis; Treatment Outcome | 2001 |
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Prodrugs; Prospective Studies; Survival Analysis | 2001 |
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Stomatitis; Treatment Outcome | 2002 |
Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Evaluation; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Safety; Survival Rate | 2001 |
Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Incidence; Keratoderma, Palmoplantar; Male; Middle Aged; Prodrugs; Risk Factors; Severity of Illness Index; Syndrome; Time Factors; Treatment Outcome | 2002 |
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2002 |
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Injections, Intravenous; Leucovorin; Male; Middle Aged; Survival Analysis | 2002 |
Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Drug Combinations; Fluorouracil; Humans; Leucovorin; Nausea; Survival Rate; Tegafur; Time Factors; Uracil | 2002 |
Phase II study of gemcitabine in advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged | 1992 |
380 other study(ies) available for deoxycytidine and Colorectal Neoplasms
| Article | Year |
|---|---|
Self-Delivery Janus-Prodrug for Precise Immuno-Chemotherapy of Colitis-Associated Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Budesonide; Cell Line; Colitis-Associated Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Materials Testing; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Molecular Structure; Prodrugs | 2022 |
Clinical Efficacy of Bevacizumab Plus XELOX Chemotherapy in Colorectal Cancer and Application Value of Mindfulness-Based Stress Reduction Intervention.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Mindfulness; Oxaloacetates; Quality of Life; Treatment Outcome | 2022 |
Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Hospitals; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rectal Neoplasms; Retrospective Studies | 2022 |
Co-delivery of gemcitabine and salinomycin in PEGylated liposomes for enhanced anticancer efficacy against colorectal cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Humans; Liposomes; Polyethylene Glycols | 2023 |
Targeting SREBP1 chemosensitizes colorectal cancer cells to gemcitabine by caspase-7 upregulation.
Topics: Adult; Aged; Antineoplastic Agents; Caspase 7; Cell Line, Tumor; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Sterol Regulatory Element Binding Protein 1; Up-Regulation; Young Adult | 2019 |
LncRNA AGAP2-AS1 augments cell viability and mobility, and confers gemcitabine resistance by inhibiting miR-497 in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Oncogenes; Prognosis; RNA, Long Noncoding; Up-Regulation | 2020 |
Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; China; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Quality-Adjusted Life Years | 2020 |
Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2021 |
Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
Topics: Aged; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Dexamethasone; Drug Hypersensitivity; Female; Fluorouracil; Humans; Incidence; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Risk Factors | 2017 |
Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Male; Middle Aged; Oxaloacetates; T-Lymphocyte Subsets; Treatment Outcome | 2017 |
Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Medication Adherence; Middle Aged; Oxaloacetates; Retrospective Studies; Self Report | 2017 |
Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Health Services Accessibility; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Registries; Retrospective Studies; Saskatchewan; Survival Rate; Travel | 2017 |
Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Ethiodized Oil; Female; Gemcitabine; Humans; Hyperthermia, Induced; Irinotecan; Laser Therapy; Liver Neoplasms; Male; Microwaves; Middle Aged; Mitomycin; Neoadjuvant Therapy; Palliative Care; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2018 |
Safety evaluation of simultaneous resection of colorectal primary tumor and liver metastasis after neoadjuvant therapy: A propensity score matching analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Patient Safety; Proctectomy; Propensity Score; Retrospective Studies; Treatment Outcome | 2019 |
A molecular basis for the synergy between 17‑allylamino‑17‑demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Camptothecin; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gene Expression; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Irinotecan; Lactams, Macrocyclic; Matrix Metalloproteinase 9; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A | 2019 |
Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Cell Line, Tumor; Colorectal Neoplasms; Cyclophosphamide; Dendritic Cells; Deoxycytidine; Gastrointestinal Neoplasms; Gemcitabine; Immunotherapy; Mice; Myeloid-Derived Suppressor Cells; Neoplastic Syndromes, Hereditary; Spleen; T-Lymphocytes, Regulatory | 2019 |
Values of applying white blood cell counts in the prognostic evaluation of resectable colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Basophils; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Eosinophils; Female; Fluorouracil; Humans; Leucovorin; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Organoplatinum Compounds; Oxaloacetates; Prognosis | 2019 |
Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Cycle Proteins; Clofarabine; Colorectal Neoplasms; Deoxycytidine; DNA Damage; DNA Repair; Gemcitabine; HCT116 Cells; Histones; HT29 Cells; Humans; Mice; Mice, Nude; Nuclear Proteins; Rad51 Recombinase; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Emotions; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2019 |
Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Cell Proliferation; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; Drug Interactions; Female; Floxuridine; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 2019 |
Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adjuvant; Colon; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Microsatellite Instability; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Prognosis; Rectum; Signal Transduction; Survival Analysis; Transforming Growth Factor beta | 2019 |
Prognostic Factors for Colorectal Cancer Patients Treated With Combination of Immune-cell Therapy and First-line Chemotherapy: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cell- and Tissue-Based Therapy; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis | 2019 |
MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
Topics: Aged; Biomarkers, Pharmacological; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genetic Association Studies; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic | 2013 |
Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Hepatic Veins; Hepatic Veno-Occlusive Disease; Humans; Hyaluronic Acid; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Portal Vein; Predictive Value of Tests; Prospective Studies; Radial Artery; Severity of Illness Index | 2013 |
High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Line, Tumor; Cohort Studies; Colon; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Rectum; Up-Regulation | 2013 |
Isolated lung perfusion as an adjuvant treatment of colorectal cancer lung metastases: a preclinical study in a pig model.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Hemodynamics; Humans; Lung Neoplasms; Perfusion; Swine; Treatment Outcome; Vasoconstriction | 2013 |
Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Analysis of Variance; Antimetabolites, Antineoplastic; Capecitabine; Clinical Audit; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Home Care Services; Humans; Longitudinal Studies; Male; Middle Aged; Practice Patterns, Nurses'; Prospective Studies; Standard of Care; Telemedicine; Telephone; United Kingdom | 2013 |
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Female; Fluorouracil; Germany; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Practice Guidelines as Topic; Prospective Studies; Vomiting; Young Adult | 2013 |
[Changes of lymphocyte subsets before and after chemotherapy in colorectal carcinoma patients].
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Lymphocyte Subsets; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2013 |
XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colectomy; Colorectal Neoplasms; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tegafur; Treatment Outcome | 2013 |
Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2013 |
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Metastasectomy; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2013 |
On 5-fluorouracil therapy of colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Prospective Studies; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Visualising and quantifying angiogenesis in metastatic colorectal cancer : A comparison of methods and their predictive value for chemotherapy response.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunohistochemistry; In Situ Hybridization; Male; MicroRNAs; Microvessels; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Oxaloacetates; Prognosis; Young Adult | 2013 |
Financial incentives in cancer care and impact on prescribing practice.
Topics: Aged; Antineoplastic Agents; Australia; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Prescriptions; Fluorouracil; Hospitals, Private; Hospitals, Public; Humans | 2013 |
CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Base Sequence; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms; Deoxycytidine; DNA Methylation; DNA Primers; Docetaxel; Female; Gemcitabine; Gene Silencing; Humans; Mice; Microsatellite Instability; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Taxoids; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2014 |
Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Feasibility Studies; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Tegafur | 2013 |
Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies | 2013 |
Gastrointestinal cancer: AVEX: opportunities in elderly patients with mCRC.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Fluorouracil; Humans; Prognosis | 2013 |
Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Oxaloacetates; Retrospective Studies; Survival Analysis | 2013 |
Oxaliplatin-based chemotherapy in patients aged 75 years or older with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Treatment Outcome | 2013 |
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; ROC Curve; Survival Analysis; Treatment Outcome | 2013 |
Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Cell Line, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; CpG Islands; Deoxycytidine; Disease-Free Survival; DNA Methylation; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; RNA, Small Interfering; Transfection | 2014 |
Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
Topics: Adult; Aged; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Health Services Needs and Demand; Health Status; Humans; Longitudinal Studies; Middle Aged; Pancreatic Neoplasms; Quality of Life; Response Evaluation Criteria in Solid Tumors | 2015 |
Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Substitution; Fluorouracil; Heart Diseases; Humans; Irinotecan; Middle Aged; Quinazolines; Thiophenes | 2014 |
Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genotype; Humans; Leucovorin; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Proteins; Organoplatinum Compounds; Oxaloacetates; Pharmacogenetics; Polymorphism, Single Nucleotide; Recurrence; Retrospective Studies | 2014 |
[Efficacy and tolerance of maintenance therapy in patients with incurable advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2013 |
Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hong Kong; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaloacetates; Prognosis; Survival Rate; Time Factors | 2014 |
[Neoadjuvant chemotherapy with capecitabine plus oxaliplatin and bevacizumab for the treatment of patients with resectable metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates | 2013 |
Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Peritoneal Neoplasms; Prognosis; Survival Rate; Tegafur | 2014 |
Design, synthesis and ex-vivo release studies of colon-specific polyphosphazene-anticancer drug conjugates.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colon; Colorectal Neoplasms; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Design; Gemcitabine; HT29 Cells; Humans; Methotrexate; Organophosphorus Compounds; Polymers; Rats | 2014 |
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2014 |
A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoembryonic Antigen; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Pilot Projects; Prognosis; Prospective Studies; Treatment Outcome | 2014 |
Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Erythrocyte Indices; Female; Fluorouracil; Humans; Male; Mean Platelet Volume; Middle Aged; Oxaloacetates; Platelet Count; Retrospective Studies; Treatment Outcome | 2014 |
Genetic biomarkers for Fluorouracil toxicity prediction: the long road to clinical utility.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Thymidylate Synthase | 2014 |
Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.
Topics: Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Genome-Wide Association Study; Genomics; Hand-Foot Syndrome; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide | 2014 |
Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Treatment Outcome | 2014 |
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genetic Association Studies; Humans; Hydro-Lyases; Male; Middle Aged; Polymorphism, Genetic; Proteins; Thymidylate Synthase; Young Adult | 2015 |
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry.
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Czech Republic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Hypertension; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Proportional Hazards Models; Registries; Retrospective Studies; Thromboembolism | 2014 |
Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Rectum; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; DNA Damage; DNA Repair; Female; Fluorouracil; HCT116 Cells; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Radiation-Sensitizing Agents; Radiation, Ionizing; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2014 |
[Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hand-Foot Syndrome; Humans; Stomach Neoplasms | 2013 |
A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2014 |
A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cell Phone; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Monitoring, Physiologic; Pilot Projects | 2014 |
MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine.
Topics: Animals; Antibodies; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Deoxycytidine; Doxycycline; Drug Therapy; Enediynes; ErbB Receptors; Female; Gemcitabine; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Neoplasms, Experimental; Recombinant Fusion Proteins; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Catheterization, Peripheral; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Pain; Retrospective Studies; Vascular Access Devices | 2015 |
First-line mono-chemotherapy in frail elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Frail Elderly; Humans; Male; Retrospective Studies; Treatment Outcome | 2014 |
RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genotype; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); rac1 GTP-Binding Protein; ras Proteins | 2014 |
Maintenance therapy for colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Maintenance Chemotherapy; Organoplatinum Compounds; Oxaliplatin | 2014 |
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Czech Republic; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Proportional Hazards Models; Registries; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Floxuridine; Fluorouracil; Humans; Pantoprazole; Proton Pump Inhibitors | 2014 |
Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorouracil; Humans; Male; Middle Aged | 2014 |
Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cold Temperature; Colorectal Neoplasms; Denmark; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Liver Neoplasms; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Prognosis; Retrospective Studies | 2014 |
The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autonomic Nervous System; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates | 2014 |
Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Metastasectomy; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prospective Studies; Survival Rate | 2014 |
Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Community Health Services; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Genotype; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; United States; Young Adult | 2014 |
A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Cyclobutanes; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis | 2014 |
Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Health Status; Humans; Leucovorin; Male; Middle Aged; Prospective Studies; Quality of Life; Surveys and Questionnaires | 2015 |
Capecitabine: toxic epidermal necrolysis and Stevens-Johnson syndrome.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Risk Assessment; Risk Factors; Stevens-Johnson Syndrome; Time Factors; United Kingdom | 2014 |
[Retrospective analysis of the bevacizumab and CapeOX combination in untreated metastatic/recurrent colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Recurrence; Retrospective Studies; Treatment Outcome | 2014 |
[Tolerability of XELOX in postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Drug Tolerance; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Retrospective Studies | 2014 |
Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Aspirin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans; Markov Chains; Models, Economic; Neoplasm Recurrence, Local; Neoplasm Staging; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Remission Induction; Reproducibility of Results; Secondary Prevention | 2014 |
Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; MicroRNAs; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Tissue Array Analysis; Treatment Outcome | 2014 |
Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy-Induced Febrile Neutropenia; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutrophils; Oxaloacetates; Predictive Value of Tests; Risk Factors | 2015 |
Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA Mutational Analysis; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies | 2014 |
A 21-year-old patient with a HER2-positive colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Molecular Imaging; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Predictive Value of Tests; Radioisotopes; Radiopharmaceuticals; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Young Adult; Zirconium | 2015 |
Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Carriers; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Irinotecan; Liver; Liver Neoplasms; Male; Microspheres; Middle Aged | 2014 |
Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases; Prospective Studies; Recovery of Function | 2014 |
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Hypertension; Male; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Proteinuria; Retrospective Studies; Treatment Outcome | 2015 |
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Down-Regulation; Female; Fluorouracil; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Proportional Hazards Models; Retrospective Studies; Risk Factors; Smad4 Protein; Time Factors; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
[A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for Japanese patients with advanced colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2015 |
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2015 |
[Epinephros metastasis of colorectal cancer complicated by tumor thrombosis of inferior vena cava].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Agents; Capecitabine; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Thrombectomy; Thrombosis; Treatment Outcome; Vena Cava, Inferior | 2015 |
Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Uracil | 2015 |
The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Digestive System Surgical Procedures; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome | 2015 |
[Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Treatment Outcome | 2015 |
A Study on Drug Interaction between Warfarin and Capecitabine with Special Reference to the Co-Administered Term or the Discontinuation Term of Capecitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Retrospective Studies; Treatment Outcome; Warfarin | 2015 |
[Prognostic Factors of Stage 3 Colorectal Cancer in 433 Patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Lymph Nodes; Neoplasm Staging; Oxaloacetates; Prognosis; Retrospective Studies; Survival Rate | 2015 |
Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hypercalciuria; Iran; Leucovorin; Male; Middle Aged; Nephrocalcinosis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Peripheral Nervous System Diseases; Renal Tubular Transport, Inborn Errors; Risk Factors | 2015 |
The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Cell Line; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; HCT116 Cells; HEK293 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Middle Aged; NFI Transcription Factors; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates | 2016 |
Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Central Venous Catheters; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Retrospective Studies | 2016 |
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbazoles; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Phthalimides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2016 |
CEST theranostics: label-free MR imaging of anticancer drugs.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Contrast Media; Deoxycytidine; Drug Delivery Systems; Female; Fluorescence; Gemcitabine; Humans; Image Interpretation, Computer-Assisted; Immunoenzyme Techniques; Liposomes; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Theranostic Nanomedicine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Impact of novel histopathological factors on the outcomes of liver surgery for colorectal cancer metastases.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma; Cetuximab; Colorectal Neoplasms; Databases, Factual; Deoxycytidine; Fibrosis; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver; Liver Neoplasms; Metastasectomy; Mitotic Index; Multivariate Analysis; Necrosis; Neoadjuvant Therapy; Neoplasm Grading; Organoplatinum Compounds; Oxaloacetates; Panitumumab; Prognosis; Retrospective Studies; Tumor Burden | 2016 |
GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Genotype; Humans; Leucovorin; Male; Middle Aged; N-Acetylgalactosaminyltransferases; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Analysis | 2016 |
Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaloacetates | 2016 |
Reply to 'Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients' by C. Cremolini et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaloacetates | 2016 |
Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunotherapy, Adoptive; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Retrospective Studies; T-Lymphocyte Subsets; Treatment Outcome | 2016 |
Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Case-Control Studies; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gamma Rays; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Prospective Studies; Quality of Life; Stents; Survival Analysis | 2016 |
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Organoplatinum Compounds; Oxaloacetates; Platelet Count; Prognosis; Retrospective Studies; Treatment Outcome | 2016 |
Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; CD3 Complex; CD56 Antigen; CD8 Antigens; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Inflammation; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2017 |
Accurate, Direct, and High-Throughput Analyses of a Broad Spectrum of Endogenously Generated DNA Base Modifications with Isotope-Dilution Two-Dimensional Ultraperformance Liquid Chromatography with Tandem Mass Spectrometry: Possible Clinical Implication.
Topics: 5-Methylcytosine; Animals; Biomarkers; Brain; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; DNA; Humans; Isotope Labeling; Mixed Function Oxygenases; Nucleotidases; Reproducibility of Results; Swine; Tandem Mass Spectrometry; Thymus Gland | 2016 |
Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates | 2008 |
Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.
Topics: Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Cytidine Deaminase; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Humans; Metabolic Networks and Pathways; Prodrugs; Tetrahydrouridine | 2008 |
Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Therapy; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; ErbB Receptors; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Survival Analysis; Treatment Outcome | 2008 |
Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, erbB-1; Genes, ras; Humans; Leucovorin; Mutation; Organoplatinum Compounds; Oxaliplatin; Prognosis; Research Design; Treatment Outcome | 2008 |
Management of colorectal liver metastases after complete response to neoadjuvant chemotherapy. A case of computertomography-guided wire marking of the liver tumor.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colectomy; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Oxaloacetates; Preoperative Care; Radiography, Interventional; Tomography, X-Ray Computed | 2009 |
[The prevention of diarrhea while under capecitabine therapy].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Fluorouracil; Humans; Lactase; Lactose | 2008 |
The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Costs; Female; Fluorouracil; Humans; Infusions, Intravenous; Italy; Leucovorin; Male; Middle Aged; Retrospective Studies; Young Adult | 2008 |
Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2008 |
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pleural Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chest Pain; Colorectal Neoplasms; Coronary Vasospasm; Deoxycytidine; Diagnosis, Differential; Electrocardiography; Fluorouracil; Humans; Male; Middle Aged; Myocardial Infarction; Risk Factors; Treatment Outcome | 2008 |
Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines.
Topics: Animals; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Breast Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Colorectal Neoplasms; Cytarabine; Deoxycytidine; Drug Carriers; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; Humans; Mice; Nanogels; Nucleosides; Polyethylene Glycols; Polyethyleneimine; Polymers; Polyphosphates | 2008 |
Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Morbidity; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Preoperative Care; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 2008 |
Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Palliative Care; Prospective Studies; Survival Rate; Tomography, Spiral Computed | 2009 |
In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capecitabine; Cell Line, Tumor; Colorectal Neoplasms; Deoxycytidine; Drug Tolerance; Fluorouracil; Humans; Immunotherapy; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Xenograft Model Antitumor Assays | 2009 |
To widen the setting of cancer patients who could benefit from metronomic capecitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Rectal Neoplasms; Stomach Neoplasms; Treatment Outcome | 2009 |
Fatal drug-drug interaction of brivudine and capecitabine.
Topics: Adverse Drug Reaction Reporting Systems; Aged, 80 and over; Antimetabolites, Antineoplastic; Antiviral Agents; Bromodeoxyuridine; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fatal Outcome; Female; Fluorouracil; Herpes Zoster; Humans; Switzerland | 2009 |
Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer.
Topics: Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fees, Pharmaceutical; Female; Fluorouracil; Health Expenditures; Humans; Male; Middle Aged; Retrospective Studies | 2009 |
Targeted therapy for advanced colorectal cancer--more is not always better.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Treatment Failure; Vascular Endothelial Growth Factor A | 2009 |
Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chi-Square Distribution; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hepatic Veno-Occlusive Disease; Humans; Leucovorin; Liver Neoplasms; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaloacetates; Regression Analysis; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome | 2009 |
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, Transgenic, Suicide; Genotype; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Prognosis; Survival Analysis | 2009 |
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxaloacetates | 2009 |
Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2009 |
Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2009 |
Chemotherapy and immunotherapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Monitoring; Fluorouracil; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
Chemotherapy and immunotherapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2009 |
Chemotherapy and immunotherapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Sex Distribution | 2009 |
Subacute cutaneous lupus erythematosus induced by capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Facial Dermatoses; Female; Fluorouracil; Humans; Lupus Erythematosus, Cutaneous | 2009 |
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Irinotecan; Orotate Phosphoribosyltransferase; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Thymidine Phosphorylase; Thymidylate Synthase; Treatment Outcome | 2009 |
Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Genetic Variation; Hematologic Neoplasms; Humans; Immunoenzyme Techniques; Male; Middle Aged; Mutation; Neoplasm Staging; Open Reading Frames; Polymerase Chain Reaction; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
[Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Palliative Care | 2009 |
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gene Frequency; Genetic Variation; Haplotypes; Humans; Introns; Male; Middle Aged; Mutation; Neoplasms; Polymorphism, Genetic; Sequence Analysis, DNA; Severity of Illness Index; Stomach Neoplasms; White People | 2009 |
Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Organoplatinum Compounds; Oxaliplatin; Thymidine Phosphorylase; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Current role of bevacizumab in colorectal cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Curcumin; Cyclin D1; Cyclooxygenase 2; Deoxycytidine; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 9; Mice; Neoplasm Metastasis; NF-kappa B; Receptors, CXCR4; Vascular Endothelial Growth Factor A | 2009 |
[Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Sex Factors; Tegafur | 2009 |
Health utility scores of colorectal cancer based on societal preference in Japan.
Topics: Adaptation, Psychological; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Health Knowledge, Attitudes, Practice; Health Status Indicators; Health Surveys; Humans; Japan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Patient Satisfaction; Quality of Life; Sex Factors; Social Perception; Statistics as Topic; Stress, Psychological; Surveys and Questionnaires | 2009 |
A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cause of Death; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Monitoring; Fluorouracil; Humans; Irinotecan; Middle Aged; Multicenter Studies as Topic; Netherlands; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2010 |
Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Computer Simulation; Decision Support Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Humans; Models, Biological; Randomized Controlled Trials as Topic; Reproducibility of Results; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Metastatic colorectal cancer: is surgery necessary?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Research Design; Retrospective Studies; SEER Program; Unnecessary Procedures | 2009 |
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neutropenia; Odds Ratio; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Socioeconomic Factors; Treatment Outcome; United Kingdom | 2010 |
Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Health Care Costs; Humans; Male; Middle Aged; Retrospective Studies | 2009 |
Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Hot Temperature; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Time Factors; Treatment Outcome | 2010 |
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Humans; Liver Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Thymidylate Synthase; Treatment Outcome | 2009 |
The impact of new treatment options for advanced colorectal cancer on routine care: results of a retrospective analysis of 206 consecutive patients treated in a community-based oncology group practice in Germany.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Germany; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Outcome Assessment, Health Care; Oxaliplatin; Retrospective Studies; Survival Analysis; Vitamin B Complex | 2010 |
Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cerebellar Diseases; Colorectal Neoplasms; Deoxycytidine; Drug Monitoring; Female; Fluorouracil; Humans; Liver Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prodrugs | 2010 |
EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Epidermal Growth Factor; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Survival Rate; Thymidylate Synthase; Treatment Outcome | 2010 |
Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA Mismatch Repair; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Infusions, Intravenous; Leucovorin; Male; Microsatellite Instability; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Prognosis; Survival Rate; Young Adult | 2010 |
Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deoxycytidine; Diffusion of Innovation; Drug Approval; Drug Utilization; Gemcitabine; Humans; Models, Statistical; Pancreatic Neoplasms; Quality of Health Care; SEER Program; United States; United States Food and Drug Administration | 2010 |
[Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Anaphylaxis; Anti-Allergic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Child; Colorectal Neoplasms; Deoxycytidine; Drug Hypersensitivity; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Sex Factors; Young Adult | 2010 |
[Cardiotoxicity induced by 5-fluorouracil or capecitabine].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Heart; Heart Diseases; Humans; Isosorbide Dinitrate; Nitroglycerin; Prodrugs; Risk Factors; Vasodilator Agents | 2010 |
[Validation study of KRAS mutation in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Genes, ras; Genetic Predisposition to Disease; Genetic Testing; Humans; Leucovorin; Male; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Pathology, Molecular; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2009 |
MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
Topics: Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chromosome Mapping; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prognosis; Rectal Neoplasms; Tumor Suppressor Proteins | 2010 |
The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Haplotypes; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Polymorphism, Single Nucleotide; Predictive Value of Tests; Vascular Endothelial Growth Factor A | 2011 |
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Cost Sharing; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Costs; Financing, Personal; Fluorouracil; Humans; Japan; Multicenter Studies as Topic; Oxaloacetates; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors; Treatment Outcome | 2010 |
Chemotherapy-associated peripheral sensory neuropathy assessed using in vivo corneal confocal microscopy.
Topics: Aged; Capecitabine; Carcinoma; Colorectal Neoplasms; Cornea; Deoxycytidine; Fluorouracil; Humans; Male; Microscopy, Confocal; Paresthesia | 2010 |
[Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Fluorouracil; Humans; Intensive Care Units; Male | 2010 |
Steroids, cancer and vertebral fractures: a dreaded combination.
Topics: Adrenal Cortex Hormones; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Female; Fluorouracil; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Organoplatinum Compounds; Osteoporosis; Oxaliplatin; Palliative Care; Quality of Life; Risk Factors; Spinal Fractures; Time Factors; Treatment Outcome; Vertebroplasty | 2011 |
Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hypertriglyceridemia; Male; Middle Aged; Neoplasms; Risk Factors; Stomach Neoplasms | 2010 |
Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients.
Topics: Age Factors; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Health Expenditures; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Sex Factors | 2010 |
Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2010 |
Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Confidence Intervals; Deoxycytidine; Female; Fluorouracil; Germany; Health Knowledge, Attitudes, Practice; Humans; Male; Medication Adherence; Middle Aged; Patient Care Team; Statistics as Topic; Statistics, Nonparametric | 2011 |
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Bisoprolol; Bone Neoplasms; Capecitabine; Colic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Heptanoic Acids; Humans; Hypercholesterolemia; Ileus; Leucovorin; Lymphatic Metastasis; Middle Aged; Nausea; Pyrroles; Ventricular Premature Complexes; Vomiting | 2011 |
High frequency of hand foot syndrome with capecitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cross-Sectional Studies; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Syndrome | 2010 |
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxaloacetates; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2011 |
Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins.
Topics: Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Capecitabine; Carboplatin; Case-Control Studies; Chromatography, Affinity; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Female; Fluorouracil; Glutathione S-Transferase pi; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neurophysiology; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Phenotype; Survival Rate; Treatment Outcome | 2010 |
Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Motor Neuron Disease; Neoplasm Staging; Neurophysiology; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
[Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer--countermeasures against hand-foot syndrome].
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Erythema; Female; Fluorouracil; Foot; Hand; Humans; Male; Middle Aged | 2010 |
Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Hepatic Veno-Occlusive Disease; Humans; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Randomized Controlled Trials as Topic; Survival Rate | 2010 |
Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Health Care Costs; Humans; Linear Models; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models | 2010 |
Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Genotype; Humans; Irinotecan; Neoplasm Metastasis; Pharmacogenetics; Survival Analysis; Time Factors; Vascular Endothelial Growth Factor A | 2010 |
Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Blood Cell Count; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Creatinine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Hemoglobins; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Patient Selection | 2010 |
Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Bevacizumab-based therapy and complication risk after colonic stent placement: is it time for a warning?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Diseases; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Intestinal Obstruction; Intestinal Perforation; Organoplatinum Compounds; Oxaliplatin; Rupture, Spontaneous; Stents | 2010 |
ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA; Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Retrospective Studies | 2010 |
Comment on 'capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer'.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Treatment Outcome | 2011 |
A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Calibration; Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; Drug Monitoring; Drug Stability; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin | 2010 |
Changing management and survival in patients with stage IV colorectal cancer.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Antineoplastic Agents; Australia; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Colostomy; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Proportional Hazards Models; Pyrimidines; Radiotherapy, Adjuvant; Survival Rate | 2011 |
The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Fluorouracil; Humans; Liver Function Tests; Oxaloacetates; Retrospective Studies; S-Adenosylmethionine | 2012 |
Analysis of tumor burden versus progression-free survival for Phase II decision making.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Decision Making; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Trastuzumab; Tumor Burden | 2011 |
Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Alveolitis, Extrinsic Allergic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Japan; Leucovorin; Lung Diseases, Interstitial; Male; Medical Records Systems, Computerized; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Pulmonary Fibrosis; Retrospective Studies; Severity of Illness Index; Smoking; Tomography, X-Ray Computed | 2011 |
Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Coronary Vasospasm; Defibrillators, Implantable; Deoxycytidine; Fluorouracil; Humans; Male; Ventricular Fibrillation | 2012 |
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Colorectal Neoplasms; Cytidine Deaminase; Deoxycytidine; E2F Transcription Factors; Erythema; Female; Fluorouracil; Foot Dermatoses; Genetic Association Studies; Genetic Predisposition to Disease; Hand Dermatoses; Haplotypes; Humans; Logistic Models; Male; Middle Aged; Pain; Polymorphism, Single Nucleotide; Prodrugs; Promoter Regions, Genetic; Sequence Analysis, DNA; Syndrome; Transcription, Genetic | 2011 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Capecitabine; Child; Child, Preschool; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infant; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy after early failure of adjuvant systemic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Hyperthermia, Induced; Infusions, Parenteral; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prospective Studies; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Metabolome; Metabolomics; Middle Aged; Neoplasm Metastasis; Nuclear Magnetic Resonance, Biomolecular; Prognosis; Salvage Therapy | 2011 |
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Biomarkers, Tumor; Capecitabine; Carcinoma; Case-Control Studies; Clinical Trials, Phase III as Topic; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Haplotypes; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2011 |
PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Predictive Value of Tests; Promyelocytic Leukemia Protein; Retrospective Studies; Survival Rate; Transcription Factors; Tumor Suppressor Proteins | 2012 |
[A case of toxicity caused by drug interaction between capecitabine and phenytoin in patient with colorectal cancer].
Topics: Adult; Anticonvulsants; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Interactions; Epilepsy; Female; Fluorouracil; Humans; Phenytoin | 2011 |
Do we need oncology trials tailored for the elderly or frail?
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Frail Elderly; Health Services Needs and Demand; Humans; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Salvage Therapy; Treatment Outcome | 2011 |
Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Genes, Tumor Suppressor; Humans; Immunohistochemistry; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Smad4 Protein; Statistics as Topic; Statistics, Nonparametric | 2011 |
Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data.
Topics: Antineoplastic Agents; Bayes Theorem; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Empirical Research; Fluorouracil; Hand-Foot Syndrome; Humans; Markov Chains | 2011 |
Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
First-line treatment of advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2011 |
Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Costs and Cost Analysis; Decision Making; Deoxycytidine; Drug Costs; Female; Fluorouracil; Health Care Costs; Hong Kong; Hospitalization; Humans; Insurance, Health, Reimbursement; Length of Stay; Leucovorin; Male; Middle Aged; Office Visits; Organoplatinum Compounds; Oxaloacetates; Travel | 2011 |
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemokines; Colorectal Neoplasms; Cytokines; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genetic Variation; Genotype; Humans; Leucovorin; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Pharmacogenetics; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Vascular Endothelial Growth Factor A | 2011 |
Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation.
Topics: Adaptation, Physiological; Algorithms; Antimetabolites, Antineoplastic; Bayes Theorem; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Fluorouracil; Hand-Foot Syndrome; Humans; Markov Chains; Metabolic Clearance Rate; Models, Biological; Prodrugs; Prognosis; Treatment Outcome | 2012 |
[End results of combined treatment in metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Pelvic Exenteration; Positron-Emission Tomography; Proctocolectomy, Restorative; Quality of Life; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Salvage Therapy | 2011 |
Chemotherapy for older patients with colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cardiovascular Diseases; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Frail Elderly; Humans; Prodrugs | 2011 |
SNPs and haplotypes in DPYD and outcome of capecitabine--Letter.
Topics: Carcinoma; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Polymorphism, Single Nucleotide | 2011 |
SNPs and Haplotypes in DPYD and Outcome of Capecitabine-Letter.
Topics: Carcinoma; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Polymorphism, Single Nucleotide | 2011 |
Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Blotting, Western; Camptothecin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Death, Sudden; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged | 2012 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Down-Regulation; Doxorubicin; Etoposide; Floxuridine; Fluorescent Antibody Technique; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomic Instability; Humans; Irinotecan; Metaphase; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Protein Array Analysis; Reproducibility of Results; Tegafur; Tissue Array Analysis; Tumor Cells, Cultured; Up-Regulation; Uracil | 2012 |
[Our experience of the treatment with XELOX±Bevacizumab for unresectable advanced colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates | 2011 |
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2011 |
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis | 2012 |
Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Tomography, X-Ray Computed | 2012 |
Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Health Services Needs and Demand; Hospitals, Teaching; Humans; Male; Medication Adherence; Middle Aged; Patient Education as Topic; Patient Satisfaction; Surveys and Questionnaires; United Kingdom | 2012 |
The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Young Adult | 2012 |
The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; G(M1) Ganglioside; Humans; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Severity of Illness Index; Survival Rate; Treatment Outcome | 2012 |
A valid formulation of the analysis of noninferiority trials under random effects meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Computer Simulation; Data Interpretation, Statistical; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Meta-Analysis as Topic; Models, Statistical | 2012 |
Dose-modified XELIRI chemotherapy for metastatic colorectal cancer--a retrospective study of 78 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Neoplasm Metastasis; Retrospective Studies | 2012 |
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Drug Evaluation, Preclinical; Fluorouracil; Humans; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines; Randomized Controlled Trials as Topic | 2012 |
X-ACT: an important step on an unfinished journey.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoembryonic Antigen; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Capecitabine; Carcinoembryonic Antigen; Catheter Ablation; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chi-Square Distribution; Colorectal Neoplasms; Cryosurgery; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Hepatectomy; Humans; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaloacetates; Proportional Hazards Models; Retrospective Studies; Tumor Burden; Young Adult | 2012 |
Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer.
Topics: Angiogenesis Inducing Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; E-Selectin; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; Female; Fibroblast Growth Factor 2; Fluorouracil; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Oxaloacetates; Platelet-Derived Growth Factor; Prognosis; Vascular Endothelial Growth Factor A | 2012 |
[Side effect analyses in consideration of renal functions for capecitabine-administered patients].
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Kidney Diseases; Male; Middle Aged | 2012 |
Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Retrospective Studies; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factors | 2012 |
Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiomyopathies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neuromuscular Diseases; Organoplatinum Compounds; Oxaliplatin | 2012 |
Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Xenograft Model Antitumor Assays | 2012 |
Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome.
Topics: 2-Propanol; Acetates; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Camphor; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dermatologic Agents; Drug Combinations; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Plant Extracts; Treatment Outcome | 2010 |
Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Netherlands; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Retrospective Studies; Treatment Outcome | 2012 |
Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Capecitabine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fluorouracil; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; Neoplasm Metastasis; NF-kappa B; Platelet Endothelial Cell Adhesion Molecule-1; Signal Transduction; STAT3 Transcription Factor; Triterpenes; Tumor Suppressor Proteins; Ursolic Acid; Xenograft Model Antitumor Assays | 2012 |
Effectiveness of oxaliplatin desensitization protocols.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Desensitization, Immunologic; Drug Hypersensitivity; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Skin Tests | 2013 |
New strategy in hepatic metastatic colorectal cancer: tomotherapy and capecitabine followed by hepatic surgical resection.
Topics: Antineoplastic Agents; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Intensity-Modulated | 2012 |
Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Female; Fluorouracil; Hospitalization; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Office Visits; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Palliative Care; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Retrospective Studies; Scandinavian and Nordic Countries; Sweden | 2012 |
Capecitabine-induced chest pain relieved by diltiazem.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Calcium Channel Blockers; Capecitabine; Carcinoma, Squamous Cell; Chest Pain; Colorectal Neoplasms; Coronary Vasospasm; Deoxycytidine; Diltiazem; Electrocardiography; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Prodrugs; Secondary Prevention; Treatment Outcome | 2012 |
Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models.
Topics: Animals; Antigen Presentation; Antimetabolites, Antineoplastic; Chlorocebus aethiops; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Herpes Simplex; Injections, Intralesional; Interferon-gamma; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Simplexvirus; Spleen; T-Lymphocytes; Vero Cells | 2013 |
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Hypoxia; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Vorinostat | 2012 |
Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Perioperative Care; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate | 2013 |
S-1 in colorectal cancer: a new standard of care?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur | 2012 |
Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans; Induction Chemotherapy; Leucovorin; Maintenance Chemotherapy; Neoplasm Metastasis; Organoplatinum Compounds; Oxaloacetates | 2012 |
Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Case-Control Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Safety; Survival Rate | 2013 |
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deglutition Disorders; Deoxycytidine; Drug Administration Schedule; Dyspnea; Female; Fluorouracil; Humans; Incidence; Leucovorin; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Paresthesia; Prospective Studies; Spasm | 2012 |
Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Male; Medication Adherence; Medication Errors; Middle Aged; Patient Compliance; Pilot Projects; Prognosis; Prospective Studies; Quinazolines | 2013 |
Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; SEER Program; Survival Rate | 2013 |
Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; SEER Program | 2013 |
[Cost analysis of XELOX and FOLFOX-4 chemotherapy regimens for colorectal carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Costs and Cost Analysis; Czech Republic; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates | 2012 |
Cardiotoxicity with 5-fluorouracil based agents: rechallenge cannot currently be safely advised.
Topics: Chest Pain; Colorectal Neoplasms; Deoxycytidine; Diltiazem; Female; Fluorouracil; Humans; Male | 2013 |
Pilot study of the early start of chemotherapy after resection of primary colorectal cancer with distant metastases (Pearl Star 01).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Colon, Sigmoid; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxaloacetates; Pilot Projects; Postoperative Care; Prognosis; Survival Rate; Time Factors | 2013 |
New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pyrazoles; Sulfonamides | 2002 |
Capecitabine in the management of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans | 2001 |
Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Fluorouracil; Humans; Hutchinson's Melanotic Freckle; Male; Melanoma; Middle Aged; Neoplasms, Second Primary; Nevus, Pigmented; Prodrugs; Skin; Skin Neoplasms | 2002 |
25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2001 |
First-line capecitabine is as effective as 5-fluorouracil/leucovorin in treating advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Prodrugs; Randomized Controlled Trials as Topic | 2001 |
Capecitabine combinations in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin | 2001 |
Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Spectrometry, Mass, Electrospray Ionization | 2003 |
Clinical colorectal cancer: oral chemotherapy comes of age.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Prodrugs | 2001 |
Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bystander Effect; Capecitabine; Cell Division; Cell Membrane; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Fas Ligand Protein; fas Receptor; Fluorouracil; Humans; Membrane Glycoproteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidylate Synthase; Time Factors; Transfection; Tumor Cells, Cultured | 2002 |
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2002 |
Design and analysis of non-inferiority mortality trials in oncology.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Confidence Intervals; Controlled Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Research Design; Statistics as Topic | 2003 |
Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Europe; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2002 |
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Female; Fluorouracil; Humans; Hypoxia; Isoenzymes; Male; Membrane Proteins; Middle Aged; Neovascularization, Pathologic; Peripheral Nervous System Diseases; Prodrugs; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Retrospective Studies; Sulfonamides; Syndrome | 2002 |
[Chemotherapy improves prognosis in colorectal carcinoma. Soon oral therapy at home?].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Home Care Services; Humans; Organoplatinum Compounds; Oxaliplatin | 2002 |
Antineoplastic therapy in colorectal cancer through proteasome inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Colorectal Neoplasms; Cysteine Endopeptidases; Deoxycytidine; DNA, Neoplasm; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Enzyme Precursors; Gemcitabine; Gene Transfer Techniques; Humans; Leupeptins; Luciferases; Multienzyme Complexes; NF-kappa B; Proteasome Endopeptidase Complex; Rats; Transcriptional Activation; Tumor Cells, Cultured; Up-Regulation | 2003 |
Isolated lung perfusion with gemcitabine in a rat: pharmacokinetics and survival.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Survival; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Infusions, Intravenous; Lung Neoplasms; Male; Models, Animal; Rats; Survival Analysis; Tumor Cells, Cultured | 2003 |
Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Alleles; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA, Neoplasm; Female; Fluorouracil; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Predictive Value of Tests | 2003 |
Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Capecitabine; Cell Division; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); DNA Primers; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oxidoreductases; Polymerase Chain Reaction; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome | 2003 |
Onycholysis associated with capecitabine in combination with irinotecan in two patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Nail Diseases; Nails | 2003 |
Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Survival Analysis | 2003 |
Capecitabine in colorectal, breast, and other solid tumors: novel therapeutic approaches. Selected abstracts from ASCO 2003.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Prodrugs | 2003 |
In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Fluorine; Fluorouracil; Humans; Liver; Liver Neoplasms; Magnetic Resonance Spectroscopy; Male; Middle Aged; Prodrugs | 2003 |
Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Retrospective Studies | 2003 |
Inflammation of actinic keratoses during capecitabine therapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diagnosis, Differential; Facial Dermatoses; Female; Fluorouracil; Humans; Keratosis | 2004 |
[First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Rate | 2004 |
An immediate hemolytic reaction induced by repeated administration of oxaliplatin.
Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antibody Specificity; Antigens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Grouping and Crossmatching; Blood Transfusion; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Disease Progression; Fatal Outcome; Female; Fluorouracil; Humans; Immunoglobulin G; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2004 |
Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Humans; Injections, Intravenous; Leucovorin; Netherlands; Palliative Care; Prodrugs; Retrospective Studies | 2004 |
Microregional effects of gemcitabine in HCT-116 xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; HCT116 Cells; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therapy; Death; Deoxycytidine; Disease Models, Animal; Gemcitabine; Glutamates; Guanine; Liver Neoplasms; Male; Neoplasm Metastasis; Pemetrexed; Rats; Rats, Inbred Strains | 2005 |
Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheters, Indwelling; Colorectal Neoplasms; Cost Savings; Deoxycytidine; Drug Costs; Fee Schedules; Fluorouracil; Germany; Health Care Costs; Hospitals, Municipal; Hospitals, University; Humans; National Health Programs; Patient Admission | 2005 |
Costs of treatment of colorectal cancer in different settings in Germany.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Costs and Cost Analysis; Deoxycytidine; Fluorouracil; Germany; Hospitals, Municipal; Hospitals, University; Humans; Inpatients; Leucovorin; Outpatients; Time Factors | 2004 |
Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; In Vitro Techniques; Inhibitory Concentration 50; Lung Neoplasms; Male; Melphalan; Rats; Rats, Inbred Strains; Tumor Cells, Cultured | 2005 |
Chemotherapy for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin | 2005 |
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chronotherapy; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
Topics: Administration, Oral; Adult; Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Safety; Survival Rate | 2005 |
Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Con: Pumpin' FU (or, avoiding that oral fixation).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2005 |
[Healing for more patients].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasm Staging | 2005 |
Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies.
Topics: Animals; Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; Drug Stability; Floxuridine; Fluorouracil; Humans; Liver; Mice; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2005 |
Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunohistochemistry; Thymidylate Synthase; Treatment Outcome | 2005 |
Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Carcinoma, Transitional Cell; Catechin; Cell Line, Tumor; Colorectal Neoplasms; Cytidine; Decitabine; Deoxycytidine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Female; Gene Silencing; HT29 Cells; Humans; Hydralazine; Male; Procainamide; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Neoplasm Metastasis; Phthalazines; Pyridines; Vascular Endothelial Growth Factor A | 2005 |
Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2005 |
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Colorectal Neoplasms; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Immunohistochemistry; Intestinal Mucosa; Ki-67 Antigen; Lead; Mice; Mice, Nude; Neoplasm Transplantation; Pancreas; Pancreatic Neoplasms; Pyrazoles; RNA, Messenger; Sulfonamides; Xenograft Model Antitumor Assays | 2005 |
Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Thymidine Phosphorylase; Xenograft Model Antitumor Assays | 2006 |
Capecitabine-induced severe hypertriglyceridemia: report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Hypertriglyceridemia; Male; Middle Aged; Triglycerides | 2006 |
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Tegafur; Thiophenes; Treatment Outcome; Uracil | 2005 |
On prejudice and facts and choices.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Health Services Accessibility; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Patient Satisfaction; Randomized Controlled Trials as Topic | 2006 |
Benefits and risks of palliative capecitabine based therapy to elderly patients with advanced colorectal cancer: Danish single centre experiences.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Denmark; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Palliative Care; Prodrugs; Prospective Studies; Risk Assessment; Risk Factors; Survival Analysis | 2006 |
Apurinic/apyrimidinic endonuclease-1 protein level is associated with the cytotoxicity of L-configuration deoxycytidine analogs (troxacitabine and beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine) but not D-configuration deoxycytidine analogs (gemcit
Topics: Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Cytosine; Deoxycytidine; Dioxolanes; DNA-(Apurinic or Apyrimidinic Site) Lyase; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; RNA, Small Interfering; Transfection | 2006 |
Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Mitomycin; Neoplasm Metastasis; Patient Selection; Prognosis; Reproducibility of Results; Treatment Outcome | 2006 |
c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-beta-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells.
Topics: Apoptosis; Arabinonucleosides; Carcinoma; Caspase 3; Caspases; Colorectal Neoplasms; Deoxycytidine; DNA-Binding Proteins; Gemcitabine; Gene Deletion; Genes, Tumor Suppressor; Humans; Nuclear Proteins; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-abl; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Up-Regulation | 2006 |
Toxicity and efficacy of isolated lung perfusion with gemcitabine in a rat model of pulmonary metastases.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Lung; Lung Neoplasms; Male; Random Allocation; Rats; Ribonucleotide Reductases; Treatment Outcome | 2006 |
Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; HCT116 Cells; Hedgehog Proteins; Humans; Paclitaxel; Pancreatic Neoplasms; Radiation, Ionizing; Time Factors; Veratrum Alkaloids | 2006 |
Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).
Topics: Adenocarcinoma; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Risk Assessment; Tegafur; Uracil | 2006 |
Southwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capecitabine; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Liver Neoplasms; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Southwestern United States | 2006 |
In response to: 'On prejudice and facts and choices', an editorial by Kohne and Folprecht.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Choice Behavior; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Prejudice | 2006 |
Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; In Vitro Techniques; Inhibitory Concentration 50; Lung Neoplasms; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Stomach Neoplasms; Tumor Suppressor Proteins | 2006 |
Neoadjuvant therapy with bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Liver Neoplasms; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Treatment Outcome | 2006 |
In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Deoxycytidine; DNA Topoisomerases; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Topoisomerase Inhibitors; Treatment Outcome | 2006 |
Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Deoxyuridine; Female; Fluorouracil; Humans; Male; Thymidine | 2007 |
Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Multicenter Studies as Topic; Predictive Value of Tests; Prospective Studies; Thymidine Phosphorylase; Thymidylate Synthase | 2006 |
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Caco-2 Cells; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gene Expression; HT29 Cells; Humans; Inhibitory Concentration 50; Intestinal Mucosa; Male; Middle Aged; Polymorphism, Genetic; Thymidine Phosphorylase; Thymidylate Synthase; Tumor Cells, Cultured | 2006 |
A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cancer Care Facilities; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Monitoring; Female; Fluorouracil; Home Care Services, Hospital-Based; Humans; Leadership; Male; Middle Aged; Nurse's Role; Nursing Audit; Nursing Evaluation Research; Outpatient Clinics, Hospital; Patient Satisfaction; Pharmacy Service, Hospital; Program Evaluation; Prospective Studies; Retrospective Studies; Scotland; Surveys and Questionnaires | 2007 |
Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Fluorouracil; Gene Deletion; Genotype; Heterozygote; Humans; Models, Statistical; Mutation; Polymorphism, Genetic; Quinazolines; Sequence Analysis, DNA; Thiophenes; Thymidylate Synthase; Treatment Outcome | 2007 |
Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Erythema; Fluorouracil; Humans; Male; Middle Aged; Penis; Scrotum | 2007 |
Integrating Chinese and conventional medicine in colorectal cancer treatment.
Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drugs, Chinese Herbal; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Medicine, Chinese Traditional; Middle Aged | 2007 |
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Tegafur; United Kingdom; Uracil | 2007 |
Acute myeloid leukaemia secondary to treatment with capecitabine for metastatic colorectal cancer.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Leukemia, Myeloid | 2007 |
DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
Topics: Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; RNA, Messenger; Treatment Outcome | 2007 |
Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2007 |
[Myocardial ischaemia as a result of treatment with capecitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Myocardial Ischemia | 2007 |
Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Electrocardiography; Female; Fluorouracil; Head and Neck Neoplasms; Heart; Heart Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Prospective Studies | 2008 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Routes; Economics, Medical; Fluorouracil; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome | 2007 |
Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Thymidine Phosphorylase; Xenograft Model Antitumor Assays | 2007 |
Prognosis of small bowel adenocarcinoma treated with Mayo or Xelox regimen: a matched case-control study from a database of 581 patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Intestine, Small; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Palliative Care; Treatment Outcome | 2008 |
Comments on final report of the AIO Colorectal Cancer Group Study: fluorouracil/oxaliplatin versus capecitabine/oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Research Design | 2007 |
Capecitabine plus oxaliplatin in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin | 2007 |
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Stomach Neoplasms | 2008 |
Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Oxaloacetates; Retrospective Studies; Survival Analysis | 2008 |
Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Humans; Male; Middle Aged; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Survival Analysis; Transcription Factors; Xeroderma Pigmentosum Group A Protein; Xeroderma Pigmentosum Group D Protein | 2007 |
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Randomized Controlled Trials as Topic; Survival Rate | 2008 |
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; DNA, Neoplasm; Enhancer Elements, Genetic; Female; Fluorouracil; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Thymidylate Synthase | 2008 |
Systemic therapy for metastatic colorectal cancer: current questions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms | 2008 |
Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dehydration; Deoxycytidine; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Randomized Controlled Trials as Topic; Vomiting | 2008 |
[Therapy of colorectal carcinoma. To combine saves lives].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Folic Acid; Humans; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Randomized Controlled Trials as Topic; Time Factors; Vitamin B Complex | 2004 |
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Europe; Fluorouracil; Gastrointestinal Diseases; Humans; Leucovorin; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Residence Characteristics; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; United States; Vitamin B Complex; Withholding Treatment | 2008 |
Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Economics, Pharmaceutical; Fluorouracil; Hospital Costs; Humans; Models, Economic; Neoplasm Metastasis; Patient Selection; Research Design; Treatment Outcome | 2008 |
Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Economics, Pharmaceutical; Fluorouracil; Hospital Costs; Humans; Infusions, Parenteral; Leucovorin; Models, Economic; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Research Design; Treatment Outcome; Vitamin B Complex | 2008 |
Chemotherapy in elderly patients with colorectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Geriatric Assessment; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2008 |
A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carboxylesterase; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Progression; DNA, Neoplasm; Female; Fluorouracil; Genotype; Humans; Multivariate Analysis; Pilot Projects; Polymorphism, Genetic; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Thymidylate Synthase | 2008 |
XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; L-Lactate Dehydrogenase; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxaloacetates; Pilot Projects; Randomized Controlled Trials as Topic | 2007 |
Evaluation of quality of life in patients with metastatic colorectal cancer treated with capecitabine.
Topics: Antimetabolites, Antineoplastic; Brazil; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Health Status; Health Status Indicators; Humans; Least-Squares Analysis; Leucovorin; Male; Middle Aged; Prospective Studies; Psychological Tests; Quality of Life; Sex Factors; Surveys and Questionnaires; Vitamin B Complex | 2008 |
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cladribine; Colorectal Neoplasms; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; In Vitro Techniques; Leukemia; Lung Neoplasms; Lymphoma; Ribonucleotide Reductases; Tumor Cells, Cultured; Urogenital Neoplasms | 1995 |
Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deoxycytidine; Deoxyribonucleotides; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1994 |
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis | 1999 |
Increased levels of promutagenic etheno-DNA adducts in colonic polyps of FAP patients.
Topics: Adenoma; Adenomatous Polyposis Coli; Adult; Aged; Aged, 80 and over; Colon; Colonic Polyps; Colorectal Neoplasms; Deoxyadenosines; Deoxycytidine; DNA Adducts; Female; Humans; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress | 2000 |
Cytostatic and cytotoxic effects of (E)-2'-deoxy-2'-(fluoromethylene)-cytidine on a solid tumor and a leukemia cell line.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Tumor Cells, Cultured | 2000 |
Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Kinetics; Liver Neoplasms; Male; Middle Aged; Neoplastic Stem Cells; Pancreatic Neoplasms; Tumor Cells, Cultured | 2000 |
Future treatment options with capecitabine.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Forecasting; Humans | 2000 |
Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC).
Topics: Antineoplastic Agents; Blood Platelets; Body Fluid Compartments; Carcinoma, Non-Small-Cell Lung; Cell Survival; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Hematologic Diseases; Humans; Leukocyte Count; Leukocytes; Lung Neoplasms; Models, Biological; Neutropenia; Neutrophils; Platelet Count | 2000 |
[The potential of capecitabine (Xeloda) in the treatment of disseminated solid tumors].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Neoplasms; Survival Analysis; Treatment Outcome | 2001 |
[Oral cytostatic drug in colorectal carcinoma. Selective tumor therapy at home].
Topics: Administration, Oral; Ambulatory Care; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans | 2001 |
Xeloda in colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Male; Prodrugs; Treatment Outcome | 2001 |
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Base Pair Mismatch; Breast Neoplasms; Carrier Proteins; Colorectal Neoplasms; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Epirubicin; Female; Gemcitabine; Humans; Intercalating Agents; Mitoxantrone; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Nuclear factor-kappa B is upregulated in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Caspase 3; Caspases; Colon; Colorectal Neoplasms; Cysteine Proteinase Inhibitors; Deoxycytidine; DNA; Gemcitabine; Humans; Intestinal Mucosa; Leupeptins; NF-kappa B; Protein Binding; Rectum; Tumor Cells, Cultured | 2001 |
Thymidine phosphorylase (TP) activation: convenience through innovation.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Enzyme Activation; Fluorouracil; Humans; Thymidine Phosphorylase | 2001 |
The role of deoxycytidine kinase in gemcitabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Colorectal Neoplasms; Deoxycytidine; Deoxycytidine Kinase; Dexamethasone; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression; Glucocorticoids; HL-60 Cells; Humans; Protein Kinase C; Ribonucleotide Reductases; RNA, Messenger; Staurosporine; Tumor Cells, Cultured; U937 Cells | 2000 |
Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2002 |
Capecitabine monotherapy in metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Neoplasm Metastasis | 2001 |
Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Approval; European Union; Humans; Leucovorin; Neoplasm Staging; Tegafur; Uracil | 2002 |
Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Genotype; Humans; Male; Polymorphism, Genetic; Thymidylate Synthase | 2002 |